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SUMMARY
In this thesis, the development o f an immunoassay system for glycosylated 
albumin is described. The technique that was used consisted of a ffin ity  separation 
o f glycosylated from non-glycosylated albumin, followed by an enzyme-linked 
immunosorbent assay (ELISA) fo r albumin. The assay sensitivity was*2mg/l and was 
suffic iently sensitive to measure the glycosylated albumin concentration in the 
urine and plasma o f both diabetic and non-diabetic subjects.
An overnight timed urine sample and blood sample were collected from  85 
diabetic subjects (56 IDDM, 29 NIDDM) and 39 age and sex matched non-diabetic 
control subjects. Plasma and urinary glycosylated albumin, urinary a^- 
microglobulin, glycosylated haemoglobin, plasma and urinary creatinine were 
measured. Duration o f diabetes, body weight and presence o f retinopathy were 
noted.
The diabetic subjects were grouped according to their albumin excretion rate 
(AER) and a relationship was found between urinary glycosylated albumin and 
albumin excretion rate. An association was found between increasing albumin 
excretion rate and elevated protein giycosylation and an enhanced excretion of 
glycosylated albumin was demonstrated.
A ff in ity  chromatography was used to measure glycosylated haemoglobin as 
part o f the Islington Diabetes Survey. Some of the screening samples and almost 
all o f the follow-up samples were measured. Three glycosylated haemoglobin 
methods were compared as screening tests for diabetes mellitus, the other methods 
were carried out at the Whittington Hospital. A ff in ity  chromatography was found 
to have the highest specific ity and predictive value (positive) tests of the three 
methods, and was shown to be potentially useful as a screening test.
The recognition that protein glycosylation is increased in the diabetic state 
has resulted in investigation of its  usefulness as a screening tool and o f its 
involvement in the pathogenesis of diabetic complications. Glycosylated proteins 
may have a role in population screening for diabetes, and may be involved in, and 
indicative of, the development o f the sequelae of diabetes mellitus.
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CHAPTER 1 
INTRODUCTION
1:1 General Introduction
When this study was planned, there were no direct assays available fo r the 
measurement o f glycosylated albumin (Gly-Alb), and so i t  was decided to develop a 
sensitive immunoassay for G ly-Alb, and to use this assay in an investigation of the 
relationship between glycosylated proteins and microalbuminuria in diabetes 
mellitus. We also carried out glycosylated haemoglobin (GHb) measurements as 
part o f the Islington Diabetes Survey.
This introductory Chapter, therefore, begins w ith a b rie f description of the 
classification and diagnosis o f diabetes mellitus and then reviews the lite ra tu re  on 
GHb, its discovery, chemical nature, and methods for its measurement. The 
applications of GHb measurement are then reviewed, followed by glycosylation of 
other proteins and their roles in the development of diabetic complications, w ith 
emphasis on the renal changes that are common in diabetes mellitus.
1:2 Diabetes M ellitus
Diabetes mellitus is a universal health problem, which affects societies all 
over the world. A t least 30 m illion people are thought to be involved throughout 
the world (WHO 1985) and the numbers of reported cases are increasing rapidly. 
This increase may be due to a number o f factors, including ageing of populations, 
changes in lifestyles and improvement in diagnosis. Although i t  may appear to be a 
more obvious problem in affluent societies, i t  is in fac t found in all societies. In 
developing countries, diagnosis and m orta lity  data are more d if f ic u lt to obtain.
Obesity is strongly associated with diabetes in some societies, whereas in 
others, m alnutrition may be an important determinant. Infection and food toxins 
are also thought to play a part; environmental factors in teract w ith varying 
degrees and types o f inherited susceptibility. Research is ongoing into the causes 
of diabetes, its aetiology and the prevention o f the complications which can 
develop, improvements in treatment and assessment o f the efficacy o f treatm ent.
1:3 D efinition, Classification and Diagnosis of Diabetes
1:3:1 Defin ition
Diabetes mellitus is a state of chronic hypergiycaemia, resulting from 
genetic and environmental factors. This state is brought about by the inab ility  of 
the beta cells o f the Islets o f Langerhans to produce suffic ient insulin, or by an 
excess o f factors opposing its action, resulting in poor control o f blood glucose 
concentration (Newsholme & Leech 1983). This imbalance leads to abnormalities 
o f carbohydrate, lipid and protein metabolism. Characteristic symptoms include 
ketoacidosis, th irs t, increased urine volume and raised blood glucose concentration. 
As the condition progresses complications frequently develop. These include 
damage to peripheral nerves, capillaries of the kidneys and retina and excessive 
arteriosclerosis.
1:3:2 Classification
A classification of diabetes and other categories of glucose intolerance has 
been developed and recommended by the National Diabetes Data Group (National 
Diabetes Data Group 1979), and by the Expert Committee on Diabetes o f the World 
Health Organisation (WHO 1980). There has been general acceptance of this 
classification, but more recently, m alnutrition-related diabetes m ellitus has been 
included as a major clin ica l sub-class, ranking w ith insulin-dependent diabetes 
mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) (WHO 1985). 
Table 1:1 shows the revised classification system described by the WHO Study 
Group in 1985.
Table 1:1
Classification o f Diabetes Mellitus and Other 
Categories o f Glucose Tolerance
Class Name Characteristic
Diabetes Mellitus
Insulin-dependent diabetes Insulin required to prevent ketosis and
m ellitus (IDDM) preserve life
Non-insulin requiring or ketosis prone, but may 
use insulin at times. Serum insulin may be 
normal, elevated or depressed. In obese 
subjects, weight loss may improve glucose 
tolerance
Severe hypergiycaemia present, requiring 
insulin for control, not usually ketosis prone. 
Some residual insulin production
Other types o f diabetes asso- DM present in addition to (i) pancreatic
ciated w ith certain conditions disease; (ii) disease of hormonal etiology; ( iii)
and syndromes drug or chemical-induced conditions; (iv)
abnormalities of insulin or receptors; (v) 
genetic syndromes; (vi) other.
Impaired glucose tolerance (i)
Non-obese, (ii) Obese, (iii) Non-diagnostic fasting BG and glucose
associated with other syndromes tolerance between normal and DM
Gestational diabetes Glucose intolerance, onset or recognition
during pregnancy. Reclassification needed 
post partum
Statistical Risk Classes
Previous abnormality of glucose Normal glucose tolerance but substantially
tolerance increased risk of developing DM
Non-insulin-dependent diabetes 
mellitus (NIDDM) (i) Non-obese 
(ii) Obese
M alnutrition-related diabetes 
mellitus (MRDM)
Potential abnormality of glucose Normal glucose tolerance but previous
tolerance abnormal glucose tolerance found
1:3:3 Diagnosis
The diagnosis of diabetes is usually based on characteristic signs and 
symptoms, such as increased th irs t and urine volume, glycosuria, unexplained 
weight loss and, in severe cases, drowsiness and coma (WHO 1985). Unequivocally 
raised blood glucose levels may establish diagnosis, and may also do so when 
symptoms are less severe. In cases where the signs are less clear and blood glucose 
levels less clearly raised, measurements made under standard conditions may be 
needed to assist the confirmation of diagnosis. The oral glucose tolerance test 
(OGTT) has become widely accepted as a diagnostic tool, but differences in the 
execution of the test and interpretation o f the results s till remain. The situation is 
fu rther complicated by day-to-day variations in individuals and the knowledge that 
results are affected by many factors including previous diet, emotion, trauma, 
other diseases, drugs and tim e o f day (Modan e ta l. 1984).
Three expert committees have published standard c rite ria  fo r diagnosis o f 
diabetes mellitus (Keen et al. 1979; National Diabetes Data Group 1979; WHO 
1980), which are in overall agreement. The National Diabetes Data Group (NDDG) 
and WHO crite ria  fo r diabetes, as shown in Table 1:2 are v irtua lly  identica l. Both 
perm it a diagnosis based on the presence of the classic diabetic symptoms and 
random plasma glucose values o f ll. lm m o l/1  or greater; both also perm it a 
diagnosis o f diabetes based on a fasting plasma glucose concentration of 7.8 mmol/1 
or greater. In persons without unequivocal symptoms and in those w ith  lower 
random or fasting plasma glucose levels, both require a glucose tolerance test in 
which blood glucose concentration is measured 2 hours a fte r a 75g oral glucose 
challenge. The NDDG and WHO both require that, for diagnosis of diabetes, this 2- 
hour value be equal to, or greater than, ll. lm m o l/1 ; the NDDG also requires tha t a 
m id-test blood sample be taken and that the glucose concentration of this sample
Table 1:2 C rite ria  for Diagnosis of Diabetes M ellitus and
Impaired Glucose Tolerance: Recommendations of the WHO (1985)
Diabetes Mellitus
Fasting value
2-hours a fte r 75g glucose 
load
Impaired glucose tolerance
Fasting value
2-hours a fte r 75g glucose 
load
Glucose Concentration
Whole Blood 
Venous Capillary
>6.7 >6.7
>10.0 >11.1
<6.7 <6.7
6.7-10.0 7.8-11.1
mmol/1
Plasma 
Venous Capillary
>7.8 >7.8
>11.1 12.2
<7.8 <7.8
7.8-11.1 8.9-12.2
also be equal to or greater than ll. lm m o l/1 ."  This requirement fo r a m id-test value 
by NDDG makes only a slight difference (Harris 1985); 91% o f individuals in a 
sample survey of the United States population whose 2-hour value exceeded 11.1 
mmol/1 also had 1-hour values exceeding 11.1 mmol/1.
Impaired glucose tolerance (IGT) describes individuals whose fasting plasma 
glucose concentration is lower than that required for a diagnosis of diabetes and 
whose plasma glucose level 2 hours a fter a 75g oral glucose challenge is between 
7.8 and ll. lm m o l/1 .
Long-term results of follow-up studies of diabetes such as the Bedford Survey 
(Sharp et al. 1964) and the Whitehall Study (Reid et al. 1974) have shown the 
predictive ab ility  o f a blood glucose measurement, made 2 hours a fte r an oral 
glucose load, fo r increased incidence of atherosclerotic disease and risk o f 
cardiovascular death over a ten-year period. The groups were defined by a 2-hour 
post load blood glucose c rite ria  described in Table 1:2. Both diabetic and IGT 
subjects showed an increase in development of vascular disease but only the new 
diabetics carried an increased risk o f developing retinopathy. These findings 
contributed to the setting-up of the WHO diagnostic c rite ria  and are evidence of 
the relevance o f the OGTT as a diagnostic test fo r diabetes.
As these studies used only the 2-hour blood glucose measurement, other 
c rite ria  cannot be assessed from these results. The new crite ria  include fasting 
blood glucose levels, but this value is more d iff ic u lt to standardise experimentally.
An effective  method o f population screening should be sensitive enough to 
identify most, i f  not all, o f the diseased population, and be re la tive ly cheap, quick 
and easy to perform. I t  must also have a reasonable positive predictive value so 
that subsequent, more specific, and costlier fina l diagnostic tests w ill have a high 
yield. A t present this diagnosis rests on ’abnormally1 increased blood glucose levels 
in both the fasting state and following an oral glucose load.
The classification system based on the OGTT has gained wide acceptance in 
studies of diabetes. However, the test is time-consuming, unpleasant fo r the 
patients and problematic in large-scale population screening. Two-stage screening,
i.e., the measurement o f fasting blood glucose levels in the population followed by 
OTGGs fo r individuals w ith abnormally high values, has been found to be 
unsatisfactory. This is due to the fa ilure to detect some individuals w ith  glucose 
intolerance (National Diabetes Data Group 1979). In order to ease the task of 
screening a large population, some workers have simplified the OGTT by taking 
only one blood sample, usually 2 hours following the oral glucose load. The re lative 
usefulness of these much reduced tests have yet to be established (Modan el al. 
1984).
1:4 Glycosylated Haemoglobin -  Discovery and Chemical Nature
1:4:1 Discovery
U ntil the mid-1950's, i t  was assumed that haemoglobin was homogeneous, as 
careful crysta llization techniques had confirmed. However, in 1958 Allen et al. 
carried out ion exchange chromatography on crystallized haemoglobin and found a 
minor component which was not an a rtifa c t o f preparation or chromatography. Nor 
could i t  be removed by crystallization under the most exacting conditions. Over 
90% o f the soluble protein w ithin normal adult human red cells is haemoglobin A, 
consisting o f two alpha chains and two beta chains (a^, In addition, they
found several minor haemoglobin components which they designated HbA^a, H b A ^  
and HbA^c in the order o f the ir elution from the chromatography column, the last 
of which is the most abundant.
Holmquist & Schroeder (1966) showed that HbA^c is structura lly identical to 
HbA except that an N-term inal amino group o f a 0 chain is attached to a carbonyl 
group of an aldehyde or ketone by a Schiff base. Bookchin & Gallop (1968) 
confirmed that there was a Schiff base linkage on both beta chains, and showed 
that the N-term inal valine residues of both beta chains were linked to a hexose. 
These techniques could not, however, distinguish between various hexose isomers.
Interest in HbA^c was enhanced by the demonstration by Rahbar (1968) tha t 
this component was increased about 2-fold in patients w ith diabetes mellitus. 
Starch gel electrophoresis was used to separate the HbA^c component and 
illus tra te  the difference between diabetic and non-diabetic haemolysates.
1:4:2 The Chemical Nature of Glycosylated Haemoglobin
T rive lli et al. (1971) c larified  the increase of the glycosylated haemoglobins 
in diabetic subjects using ion exchange chromatography. They found that one or
more hexoses were bound to the beta chains, and that 75-80% o f the 'fast1 fraction  
of the haemoglobin was accounted for by HbA^c» No relationship was found in this 
early study between the level o f glycosylation and age, duration, therapy or 
complications in the diabetic subjects.
Bunn et al. (1975) investigated the nature and mode o f linkage of the 
carbohydrate moiety in HbA^c from normal and diabetic individuals. Glucose and 
mannose were both found following hydrolysis o f the molecule. They found tha t 
the hexose was bound to the alpha amino term inal position of the beta chain 
(valine) o f the haemoglobin in a Schiff base linkage. This aldimine linkage could 
rearrange in a reversible manner to form a ketoamine linkage (Figure 1:1) which 
was stable to acid hydrolysis. Several minor haemoglobin components were found, 
of which HbA^c was the major constituent.
ii
Fluckiger & W interhalter (1976) carried out in v itro  synthesis of HbA^c to 
determine its structure and synthetic pathway. They incubated whole blood w ith  
radioactive-labelled glucose and analysed the products compared w ith  native 
HbAic . Tryptic peptide mapping techniques and the th iobarbituric acid (TBA) 
assay were used. In this test, acid hydrolysis releases the ketoamine-linked sugar 
as 5-hydroxymethyl fu rfu ra l which then forms a colour complex w ith TBA. They 
showed that the product formed was indistinguishable from native HbA^c. 
Between 2-2.4 moles o f labelled glucose bound to each haemoglobin te tram er, w ith  
ten times more bound to the beta chains than to the alpha chains. Over 90% o f the 
labelled glucose was found to be attached to the N -term inal peptides. The overall 
reaction was summed up as a nucleophilic attack on the carbohydrate by the 
unprotonated amino group o f the haemoglobin molecule. Their work was one o f the 
firs t major contributions to our understanding of the structure of GHb and led the 
way fo r many groups of workers to investigate this material.
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Bunn and co-workers also carried out extensive work in this area. Their 
investigation of the formation of HbA^c showed that i t  was formed slowly 
throughout the life-span o f the red cell (Bunn et al. 1976). Red cells w ith reduced 
life-spans due to haemolysis, had lower levels o f HbA^c. They described three 
negatively charged minor components o f haemoglobin, HbA-^a, H b A ^ , and HbA^c, 
comprising 1.6, 0.8 and 4% of haemoglobin respectively in normal individuals.
Koenig et al. (1977) investigated the nature and linkage of the carbohydrate
moiety, by studying the enzymatic digests of borohydride reduced beta HbA^c
chains separated by ion exhange chromatography. They suggested that the
carbohydrate was glucose-6-phosphate, but this was contradicted by McDonald et
al. (1978) who showed that phosphate was present in HbA^a and H b A .^  but not in
HbA.., or HbA, . lb  1c
Dolhofer & Wieland (1978) showed that HbA^c was formed post-ribosomally 
by the attachment o f glucose to the N -term inal valine via covalent bonds. They 
confirmed that glucose-6-phosphate was the carbohydrate moiety in HbA^g and 
HbAib but not in HbA^c . Further studies o f the minor haemoglobin components 
(Bunn et al. 1979) showed that there were four components which were separable 
by ion exchange chromatography from the main haemoglobin constituent, 
designated HbAQ. The glucosyl ketoamine linkage in HbA^c was detected 
co lorim etrica lly using the TBA test. On the ion exchange column, HbAQ eluted 
a fte r HbA^c and the leading edge of HbAQ, as well as H b A ^ , contained 
carbohydrate. Both glycosylated components were increased in diabetic 
individuals. Synthetic HbA^c and glycosylated HbAQ both underwent an Amadori 
rearrangement to the more stable ketoamine linkage. 8-10% of the HbAQ in
normal individuals was found to be glycosylated. Several sites on the alpha and 
beta chains of HbAQ were glycosylated, where glucose had linked to the epsilon- 
amino group of the lysine residues on the alpha and beta sub-units as well as at the 
amino term inal valine of the alpha chain. Even though glucose binds covalently to 
a number of d iffe rent amino groups on both haemoglobin chains, only one 
modification, that o f the addition of glucose to the beta chain amino terminus, 
resulted in the chromatographically d iffe rent component of HbA^c.
The synthesis of HbA^c in v itro  has been extensively studied, and the effects 
o f time, glucose concentration and incubation temperature investigated. Spicer et 
al. (1979) reported that the level o f HbA^c in in tact erythrocytes increased with 
time, glucose concentrations (from 5 to 500mM) and incubation temperature (4- 
37°C). Higgins et al. (1982) showed that glycosylation was determined not only by 
the mean blood glucose level, but also by the red cell life  span and red cell 
permeability. They indicated that i t  was important to consider the c lin ica l status 
of the patient, as many diseases decrease the red blood cell life-span. The rate of 
synthesis of HbA^c is affected by the presence of 2,3 diphosphoglycerate (2,3 DPG) 
and carbon dioxide, both o f which normally in teract w ith the amino terminus o f the 
beta chain, and by saturation and intracellu lar pH. K inetic  analysis of the 
formation of HbA^c (Higgins & Bunn 1981) yielded rate constants fo r the three 
processes involved; (a) condensation of glucose and haemoglobin to form  the Schiff 
base intermediate (pre-A^c) (b) dissociation of glucose from haemoglobin and (c) 
rearrangement o f the Schiff base to the stable ketoamine form . Their studies 
showed that during the incubation o f haemoglobin w ith glucose, the labile aldimine 
increased to reach an equilibrium plateau w ithin a few hours. During this tim e only 
a minute amount o f ketoamine was formed since the rate of rearrangement was 
only 1/60 that of the rate of dissociation back to Hb
and glucose. More than one active site was shown in the Hb molecule; although the 
beta chain amino terminus is favoured, other sites are also glycosylated, but more 
slowly. They calculated that at a blood glucose level o f 5mmol/l, approximately
0.5% o f the to ta l Hb would be pre- A lc  or approximately 10% of the to ta l HbA^c in 
normal red cells.
These studies, and those of other workers (Acharya & Manning 1980; Garel et 
al. 1979; Shapiro e ta l.  1980) confirmed that the non-enzymatic glycosylation o f Hb 
involved the in itia l formation o f a reversible aldimine precursor.
By simultaneous determination of HbA^c and the labile fraction (or H bA j^) 
and the corresponding blood glucose level i t  has been ascertained that the HbA^c 
level remains constant, whereas the H b A ^  fraction varies in parallel w ith the 
blood glucose level (Stickland et al. 1982). Further detailed studies of the kinetics 
of HbA^c formation from pre-HbA^c or HbA^d have shown that the process is 
more readily reversible than was previously thought (Mortensen 1985). The firs t 
step, formation o f the Schiff base is rapid and rearrangement to the stable form is 
much slower. This second reaction is also reversible, however, and this must be 
taken into account when HbA^d is eliminated by saline incubation. Not only is the 
labile component removed by this incubation, but also the concentration of H b A ^  
is significantly lowered. This means that when pre-treatm ent o f samples has been 
carried out using an incubation step to remove the Schiff base, the concentration 
o f the stable adduct w ill also be a rtific ia lly  lowered.
Investigation of the carbohydrate moieties involved in the glycosylation of Hb 
showed that the minor Hb components contained d iffe rent sugars (Bunn 1981a). 
Sugars that have been found to be precursors of GHb are readily transported into
the erythrocyte. The formation o f  the ketoamine adduct was influenced not only 
by the concentration of the sugar but also by the equilibrium between the open and 
ring formations of the sugar. The chain structure was found to be more reactive 
than the ring structure. Sugar molecules that combined with the protein molecule 
were in the open (chain) formation, and subsequent rearrangement of the glucose 
molecule takes place, to the ring structure.
Glucose-6-phosphate was found to react faster w ith Hb and to have a less 
stable ring structure than glucose. More glucose-6-phosphate molecules than 
glucose were in the active aldehyde form.
The carbohydrate components of the minor Hb's have been shown to be 
fructose-1,6-diphosphate, glucose-6-phosphate and glucose incorporated into 
H bA ia, A ^a2 aRd A^c respectively (McDonald e t'a l. 1978; Abraham et al. 1983). I t  
has been suggested (Krishmanoorthy a t al. 1977) that H b A ^  is non-glycosylated 
and is a deamidation product o f HbAQ (Monnier & Cerami 1982a). However, 
Garrick et al.(1980) showed that HbA^g^ and H b A ^ ^  contained sugar phosphates, 
but HbA^^ and HbA^c contained non-phosphorylated sugars.
Further kinetic studies o f the formation o f GHb have shown that the stable 
H b A ^  formed in 24 hours was equal to, on average, 0.006% of the to ta l Hb per 
mmol o f glucose (Svendsen e ta l.  1981). They also showed that an increase o f blood 
glucose level o f 1 mmol/1 increased the level o f HbA^c by 0.058% o f the to ta l Hb 
concentration in 24 hours.
Detailed investigation of the sites o f incorporation o f glucose in the Hb 
molecule (Foldi et al. 1982) showed that 65% o f the incorporated glucose was bound
to five peptides in the alpha chain. The major sites o f glycosylation in the beta 
chain were described by Mortensen & Christophersen (1982). Garlick et al. (1983) 
showed that 88% of the glucose in HbA^c was attached to the beta chain amino 
term inal valine, and that the remaining 12% was probably linked to the same lysine 
and valine groups as in HbAQ. The relative stabilities o f the sites of incorporation 
have been studied and the ketoamine linkages o f aldotriose at the alpha amino 
groups are almost irreversible. The higher stab ility  of ketoamine linkages o f Val-1 
($) suggests that some o f the structura l features of the protein around the alpha 
amino groups of the beta chain confer a degree of s tab ility  to the ketoamine 
adducts there (Acharya and Sussman 1984).
1:5 Other Monosaccharides Which Combine with Haemoglobin
The non-enzymatic glycosylation reaction is not lim ited to glucose, and a 
variety of sugars and sugar phosphates including ribose, galactose and glucose-6- 
phosphate can covalently attach to proteins (Dolhofer & Wieland 1978). Ribose is 
one of the most effective, whereas glucose is the least e ffective in glycosylation, 
and the rates of reaction o f d iffe rent monosaccharides w ith protein (using 
haemoglobin as the model) can vary over a 300-fold range. Aldohexoses as well as 
ketohexoses, such as fructose and xylulose can condense w ith protein, although in 
general the rate of interaction of the la tte r group is less than that of the former. 
This appears to be due to the fac t that aldehyde carbonyl groups are re la tive ly 
more electrophilic than ketone carbonyl groups, and the reaction proceeds by a 
nucleophilic attack of an unprotonated amino group on the carbonyl group of the 
sugar. The relative reactiv ity  o f individual monosaccharides is strongly influenced 
by the extent to which the compound exists in the open (acyclic) form , which in 
turn depends on the equilibrium between the open and ring configurations.
Although non-enzymatic glycosylation can involve d iffe ren t sugars, glucose is 
the major carbohydrate nutrient in humans. In view of the mounting evidence that 
the reaction exerts deleterious effects on structure-function relationships of 
involved proteins, i t  is o f interest to consider factors that pro tect humans from 
non-enzymatic glycosylation and its potentially injurious consequences. According 
to Bunn & Higgins (1981) this relates to the stab ility  of the ring structure of 
glucose, which under normal circumstances and at physiological concentrations o f 
glucose, lim its  the forward reaction that attaches glucose to proteins. Bunn & 
Higgins proposed that the emergence of glucose rather than other monosaccharides 
as the most important metabolic fuel coincided w ith the stab ility  of its  ring 
structure, which lim its  undesirable side reactions attributable to covalent 
modification of proteins via non-enzymatic glycosylation.
1:6 The E ffec t o f Glycosylation on Haemoglobin Function
In itia lly  i t  was thought that glycosylation o f Hb would a ffec t its function. 
McDonald et al. (1979) studied the functional properties of the minor components 
o f Hb, and showed that they each possessed unique properties which differed from 
HbAQ. They suggested that the glucose moieties attached to the amino terminus of 
the beta chain might in terfere w ith the binding o f 2,3 DPG, a regulator o f Hb 
function and thereby a ffec t oxygen binding capacity. The two most acidic 
components H b A j^  and H b A ^ ^  have lower oxygen a ffin ities  than HbA (Imagawa 
et al. 1982). The slight increase in oxygen a ffin ity  (about 2 mm Hg) o f diabetic 
blood has been attributed to increased levels of HbA^c, which has a raised oxygen 
a ffin ity .
Bunn (1981a) showed that no significant influence on oxygen transport had 
been found. Even in diabetic subjects w ith two or three times the normal level o f 
HbA^c only a very slight change in oxygen unloading was evident. I t  is unlikely 
that this change has any c lin ica l significance since patients w ith mutant Hbs and 
higher oxygen a ffin ities do not show signs of poor oxygenation of the ir peripheral 
tissues (Monnier & Cerami 1982a).
1:7 Methods of Measurement of Glycosylated Haemoglobin
Assay methods fo r the analysis o f GHb that are in routine use can be divided 
into three main categories based on the manner in which glycosylated and non­
glycosylated Hb components are measured (Table 1:3). The firs t group of 
methodologies considered are the techniques which use charge differences as a 
means o f separation, o f which there are three types, followed by a method which is 
based on the reactiv ity  of the carbohydrate group. Finally, a method based on the 
structural characteristics o f the GHb molecule is described.
1:7:1 Cation Exchange Chromatography
This technique has been widely used and adapted and much of the early work 
investigating the chemical nature o f GHb has involved ion exchange 
chromatography. Schnek & Schroeder (1961), Holmquist & Schroeder (1966) and 
T rive lli et al. (1971) developed and adapted a technique using a cation exchange 
resin, Bio-Rex 70 (Bio-Rad Laboratories, Richmond, California, USA). The 
principle o f the method is that most GHb species, including HbA^c, are more 
negatively charged than HbA and bind less well to a resin that a ttracts 
haemoglobin components based on the ir charge. The more negatively charged 
haemoglobin components, H b A ^  H bA j^  and HbA^c elute before the main 
haemoglobin fraction HbAQ and their proportion of the to ta l haemoglobin can be 
determined using a spectrophotometer. McDonald et al. (1978) adapted the 
technique and used a sodium chloride gradient from 0.1M to 1.0M to elute the 
minor components followed by HbAQ. These studies investigated the structure and 
function of GHb and involved the large-scale separation of haemoglobin 
components, w ith the application of up to 6g of haemolysate onto chromatography 
columns up to 5 cm x 40 cm.
Table 1:3
Classification of Glycosylated Haemoglobin Assay 
Methods Used in Routine Clinical Laboratories
1. Methods based on charge differences between glycosylated and non­
glycosylated haemoglobins.
(a) Cation exchange chromatography (including HPLC): glycosylated H bAp 
(H bA ia i, HbAla 2 , HbAlfc), HbAlc  and HbAld ) a ll separated from HbA.
(b) Electroendosmosis: glycosylated HbA^ ( H b A ^ ,  HbA^a2, HbA^b, HbA^c and 
H b A id) a ll separated from HbA.
•(c) Isoelectric focusing: HbA^c separated from remainder of HbA^'and HbA.
2. Methods based on chemical reactiv ity  o f carbohydrate groups on 
haemoglobin.
(a) Hydroxymethylfurfural - th iobarbituric acid (colorim etric) method:
ketohexoses on the N-term inal valine as well as lysine groups on the a and 8 
chains are measured.
3. Methods based on the structural characteristics of the carbohydrate groups 
on haemoglobin.
(a) A ff in ity  chromatography: haemoglobin bound ketohexoses on N -term inal
valine o f 8-chain as well as on non-8 N-term inal loci are separated.
4. Other methods
(a) Radioimmunoassay
(b) Fructosamine
The method has been adapted fo r the measurement of GHb levels in large 
numbers o f samples, eluting HbA^ (HbA^g, HbA^b and HbA^c) separately from 
HbAQ. Kynoch &. Lehman (1977) were the f irs t to develop a rapid smaller scale 
assay using &io-Rex 70, but this took 2^ hours to complete and required large 
quantities of potassium cyanide.
Welch & Boucher (1978) developed a rapid micro-scale method, which 
required only 0.05ml of blood and took fo rty  minutes to complete. This method not 
only reduced the time needed fo r each GHb estimation but also reduced the 
quantity of potassium cyanide used to prevent the conversion of haemoglobin to 
met-haemoglobin, making the technique more suitable for routine hospital 
laboratories.
Other groups have investigated the effects of pH and tried to make the 
method faster to perform. Chou et al. (1978) adapted the method of T rive lli et al. 
(1971) using 10ml resin columns and the same buffer systems as Schnek & 
Schroeder (1961). Clarke &. Canivet (1979) developed a methodology that 
perm ittted up to 30 columns to be run simultaneously, w ith the measurement of 
HbA^c instead o f HbA^ as in the other micro-column methods. In this technique, 
by varying the number of binding sites (i.e., the product o f the height o f the column 
and the diameter), the pH of the resin and the buffers and the osmolarity o f the 
buffers, they were able to increase the d iffe rentia l separation to a point at which 
HbA^g and HbA^h were eluted as a separate peak from H b A ^ . However, the pH 
of the buffers used was found to be c ritica l, as was the temperature making the 
method less suitable fo r routine use, despite its specific ity fo r HbA^c.
Worth et al. (1980) investigated the effects of temperature on the m icro- 
column assay and found that variations in temperature had a major influence on the 
results obtained. When samples from pooled haemolysates were run at room 
temperature on consecutive days, inter-assay coefficients of variation were several 
times greater than those achieved when temperature was maintained at a constant 
level.
These findings were confirmed by Simon & Eissler (1980) who defined 
tolerance lim its  fo r osmolarity and pH o f the buffers and temperature of the 
columns. Within s tr ic tly  set lim its  for these parameters, they were able to obtain 
good reproducibility. However, they pointed out that HbF interfered w ith the
assay, as i t  co-eluted w ith HbA^.
Nikolov &. Damianova (1983) compared a slightly adapted version of the 
micro-scale assay (Welch & Boucher 1978) w ith a method using Am berlite  resin 
(Fluka, Buchs, Switzerland), they found that using the la tte r technique shortened 
the procedure, and that performing i t  at 22°C improved reproducibility.
The next step from rapid, micro-scale methods was to develop an automated 
technique using the Bio-Rex 70 resin. This was described by Blouquit et al. (1983) 
who used a three buffer system to separate HbA^g and H b A ^  and then HbA^c 
from HbAQ. They used an increase in sodium chloride content in the buffers to 
remove HbA^c and HbAQ once the other faster-moving fractions had been eluted. 
The chromatographic system consisted o f a sample injector, peris ta ltic  pump and 
two resin-filled columns, one being equilibrated while the other was running.
Allen (1983) described a thorough investigation of the effects o f haemoglobin 
variants on HbA^c measurement using Bio-Rad columns. HbA^c levels were found 
to be low in patients heterozygous fo r HbS or HbC. However, results from patients 
homozygous fo r HbS or HbC, or w ith high levels of HbF could not be interpreted as 
values were considerably raised. This can lead to d ifficu lties  in using the results as 
prior knowledge o f the existance o f a haemoglobin variant is not usually available.
1:7:2 Electroendosmosis
This is a type of electrophoresis, in which, when a haemolysate is applied to 
an agar gel and an e lectrica l potential is applied across the gel plate, the various 
components can be separated according to charge. The gel contains charged groups 
which in teract w ith the haemoglobin components depending on the ir charge. When 
the e lectrica l current is applied, m igration of HbAQ is retarded more than that of 
the minor components, HbAa, H b A ^ , and HbA^c. The method was developed by 
Menard et al. (1980) and is widely used in routine hospital laboratories, usually w ith 
equipment and reagents made by Corning L im ited (Corning, Halstead, Essex, UK). 
The equipment required is expensive but running costs can be reduced by making 
the agar gel plates instead o f purchasing commercially prepared ones.
The assay measures all o f the more negatively charged minor components of 
haemoglobin HbA^g, H bA j^ and HbA^c (HbA^) as well as the Schiff base and HbF. 
HbC and HbS however, do not interfere (Boucher et al. 1983). The technique allows 
many samples to be run simultaneously, and the whole procedure requires under 2 
hours to be completed. Sample preparation is very stra ight-forward requiring the 
addition of a haemolosying reagent containing saponin.
The technique used by Menard et _al. (1980) is now widely used in conjunction 
w ith the Corning equipment and subsequent workers using the method have made 
few significant alterations to this standard method (Boucher et a l. 1983; Mortensen 
et al. 1983). There are now, however, commerically prepared haemolyzing 
reagents which are used to pre-treat the blood samples, and remove the labile 
fraction. The reagent contains potassium diphthalate, saponin and EDTA and is 
used to incubate the red cells (Nathan et al. 1984; Moore et al. 1986).
1:7:3 Isoelectric Focusing
In this special type of electrophoresis substances such as amino acids and 
peptides are separated in a column along which there is both a pH gradient and a 
voltage gradient. Each compound migrates towards the region in the column where 
the pH corresponds to that o f its isoelectric point and is immobilized (focused) 
there (Williams & Wilson 1976).
Schoos et al. (1978) developed a method suitable fo r routine use, using th in- 
layer polyacrylamide gel. M igration and focusing o f haemoglobin were carried out 
and, a fte r focusing, the proteins were precipitated, and read in a densitometer.
Jeppsson et al. (1978) adapted the polyacrylamide gel, by the addition o f beta 
alanine to the ampholytes and so improved the c ritica l part o f the pH gradient to 
increase specific ity o f the method. Poon A  W hittle (1980) found this method to be 
independent o f ambient temperature and to compare favourably w ith  the ion- 
exchange method.
Mortensen and Marshall (1983) stated that pre-treatm ent o f erythrocytes was 
unnecessary as the HbA^c fraction was well separated from the labile fraction. 
They did, however, study the effects o f saline incubation on the red cell content of 
HbA^c as measured by isoelectric focusing, and found that incubation in isotonic 
saline fo r 6 hours at 37°C significantly decreased the concentration o f HbA^c»
1:7:4 Colorim etric Technique
This method is based on the chemical reactiv ity  of the GHb molecule. The 
technique is widely used, and was originally developed for use in the measurement
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of GHb by Fluckiger & W interhalter (1976). The th iobarbituric acid (TBA) reaction
involves the release of bound glucose from GHb by acid hydrolysis and conversion 
to 5-hydroxymethylfurfural (5HMF). A fte r a lengthy incubation at 100°C the 
haemolysate and oxalic acid m ixture is cooled rapidly to room temperature. This 
drives the Amadori rearrangement, which normally proceeds slowly, and liberates 
5HMF from the protein (W interhalter 1981). The addition o f trich loroacetic acid 
precipitates the haemoglobin, which can then be removed by filtra tio n  or 
centrifugation. The supernatant is then incubated w ith th iobarbituric acid which 
reacts w ith 5HMF to form a compound with an absorption maximum at 443nm.
D iffe ren t incubation times and acid conditions have been investigated by
ti
various groups. In the earliest methods (Fluckiger & W interhalter 1976) the 
hydrolysis was carried out fo r 1 hour w ith 0.3M oxalic acid, but the incubation time 
was la ter increased to 4.5 hours in the presence o f 1M oxalic acid (McFarland et al. 
1979) making i t  a very time consuming process. These modified hydrolysis 
conditions released the maximum amount o f 5HMF from the protein. Gabbay et al. 
(1979) also modified the TBA technique to increase the colour yield and enhance 
reproducibility by increasing the oxalic acid concentration and the duration o f 
heating of the m ixture. Their method involved a 5-hour incubation at 100°C w ith  
1M oxalic acid. Pecoraro et al. (1979) characterized various steps from the method 
o f Gabbay and co-workers that were found to be crucial to precision and compared 
determinations made with the TBA method with corresponding results by the 
traditional chromatographic technique described in Section 1:7:1. The major 
advantages of the colorim etric method, they concluded, included its yield o f stable 
results from samples stored frozen before assay and its ab ility  to determine 
glycosylation o f variant haemoglobins. The method is quantitated using standards 
containing known concentrations of 5HMF or fructose (Percoraro et al. 1979).
The method has been used and adapted for the measurement o f glycosylated 
plasma proteins by various groups who investigated ways of elim inating the 
interference caused by the presence o f glucose. This was achieved by dialysis o f 
the samples against saline prior to hydrolysis (Dolhofer & Wieland 1981). Another 
approach was to precip itate the protein w ith trich loroacetic acid before hydrolysis, 
thus removing free glucose (Ma e ta l.  1981).
Prior to the measurement of GHb on the samples, the haemoglobin 
concentration o f each sample has to be measured and each sample diluted to the 
same haemoglobin concentration so that aliquots of haemolysate containing 
standard concentrations o f haemoglobin can be tested in the assay (Pecoraro et al. 
1979). This extra step, and the problem o f high reagent blanks, makes this 
technique time consuming and cumbersome.
Automated methods have been developed, as the co lorim etric technique in 
common use is laborious. Burrin et al. (1980) modified the method fo r use w ith 
standard autoanalyser apparatus consisting o f  a sampler unit, peris ta ltic  pump, 
heating baths, dialysers and a recording spectrophotometer. The system enabled
the analysis o f 200 samples per day using a modified co lorim etric system based on
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the method of Fluckiger & W interhalter (1976) w ith a reduction in sample size, 
reduction in incubation time w ith oxalic acid and dialysis of the sample instead of 
TCA precipitation. The running time of the system was approximately 2 hours 
from sampling to peak production on the recorder. However, this system did not 
function well and has never been in widespread use. A sim ilar system was 
developed by Ross & Gibson (1979) which required a 2-hour incubation w ith  oxalic 
acid.
By carrying out the hydrolysis stage in an autoclave, Parker e ta l.  (1981) were 
able to reduce the assay time. The method yielded good w ithin and between assay 
coefficients o f variation (2 and 3% respectively) and correlated well w ith an ion- 
exchange method.
The derivatives of phosphorylated sugar give small amounts of coloured 
reaction products; these, however, do not significantly influence the optical density 
reading at 443 nm (W interhalter 1981). The method measures all the non- 
enzymically glycosylated proteins in the haemolysate or whole blood, but the labile 
fraction of GHb contributes very l it t le  to the to ta l measured. Klenk et al. (1982) 
investigated the e ffec t o f incubating the erythrocytes in isotonic saline fo r 5 hours 
prior to the assay and found that the TBA technique showed only a 1.6% decrease.
1:7:5 A ff in ity  Chromatography
A ff in ity  chromatography is a technique for separating large molecules based 
on the ir chemical structure. Shapiro a t al. (1980) f irs t mentioned the ab ility  o f 
amino-1-deoxysorbitols to form a complex w ith borate and suggested its use as a 
potentially powerful tool fo r the purification of non-enzymatically glycosylated 
proteins. Mallia et al. (1981) developed an immobilized boronate ligand on agarose 
which would selectively bind w ith the cis-diol groups of GHb. Aminophenylboronic 
acid in the hemisulphate form, as prepared by the method of Seaman & Johnson 
(1931) was covalently attached to activated agarose gel. The gel was activated 
following the method of Bethell et al. (1979) and then aminophenylboronic acid 
allowed to react w ith it .  Quantities of this a ffin ity  m atrix were washed w ith 
water, loaded into microcolumns to a bed volume of 1ml and equilibrated w ith 
'wash buffer'. This contained ammonium acetate and magnesium chloride at pH 
8.5. Red blood cells were haemolysed and then applied to the gel. Wash buffer was
applied and the unbound (non-glycosylated) haemoglobin collected. Elution buffer 
containing 200 mM sorbitol to compete w ith the cis-diol groups of the GHb, was 
applied and the bound fraction collected separately. The non-bound fraction  was 
diluted, the absorbances o f both fractions measured in a spectrophotometer, and 
the percentage glycosylated haemoglobin calculated from the values (Klenk et al. 
1982).
Bouriotis et al. (1981) developed a method which also used immobilised 
phenylboronic acid to selectively bind diols. Their wash buffer contained 
morpholine-HCl and the elution buffer the same with sorbitol added. They carried 
out the separation at 4°C instead of room temperature. A reasonable correlation 
was found between this method and an ion-exchange method, and the a ffin ity  
technique showed an improved separation of diabetic from non-diabetic samples.
Gould et al. (1982) carried out a detailed study to investigate the effects of 
temperature and pH on the a ffin ity  chromatography method and compared the 
results w ith  those from an electrophoretic method. They found that an increase in 
temperature from 7°C to 37°C caused a decrease in the percentage o f haemoglobin 
that bound to the gel. An increase in pH from 8.1 to 8.9 also resulted in a decrease 
in the bound fraction. They also removed the labile GHb fraction  under a range o f 
conditions. A good correlation was found between the two techniques and a 
running temperature o f 20°C - 1°C and pH of 8.6 - 0.1 were selected as yielding a 
very low coeffic ient o f variation and being convenient to achieve.
Yu et al. (1982b) compared the a ffin ity  chromatography method w ith  ion- 
exchange and TBA methods and found that the former showed the best separation 
between diabetic and non-diabetic samples, correlated best w ith  plasma glucose 
levels and showed the least e ffec t from changes in temperature.
Storage of blood samples at 4°C fo r up to a week was shown to have l it t le  
e ffec t on the results obtained from a ffin ity  chromatography, ion-exchange 
chromatography, or the TBA method (L itt le  a t al. 1983a). The a ffin ity  
chromatography and TBA methods also showed sample stab ility  a fte r storage at 
20°C for a week or more. However, the ion-exchange method showed a marked 
increase in GHb values a fte r only a few days. They also showed that whole blood 
stored at room temperature in sealed capillary tubes for 21 days gave the same 
level o f GHb as fresh samples when measured by a ffin ity  chromatography (L itt le  at 
al. 1983b).
The a ffin ity  chromatography method has been developed fo r routine c lin ica l 
use and a k it  is available which allows a large number o f samples to be measured, 
up to sixty in a working day (Hall e t a l. 1983b). The method can also be used to 
measure glycosylated plasma proteins (Hall et al. 1983a) and glycosylated 
haemoglobin (Talwar et al. 1983) in adult and foetal blood.
There is s till no consensus method fo r the a ffin ity  chromatography technique, 
resulting in poor between-laboratory agreement in an external quality assessment 
scheme (John 1986). A widely used method is that o f Gould et al. (1982), but there 
are many variations in the buffer volumes used, temperature and pH o f the buffers. 
I t  is, however, an inexpensive and rapid technique, which can be carried out at 
room temperature, does not require the removal o f labile GHb and is not subject to 
common interferences (Willey et al. 1984) and so is frequently the method o f 
choice in routine use. I t  is also a flexib le technique that can be adapted fo r the 
measurement o f glycosylated plasma proteins (Gould et al. 1984) and albumin (John 
& Jones 1985).
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Detailed comparison o f ion-exchange and a ffin ity  chromatography (Fluckiger 
et al. 1984) has shown that non-B-N-terminal glycosylation accounts for a 
significant proportion o f the to ta l GHb as measured by a ffin ity  chromatography. 
As ion-exchange chromatography only measures the 3-N -term inal glycosylation, i t  
does not give as complete an estimate of to ta l glycosylation as the a ffin ity  
chromatography method.
1:7:6 Immunoassay
A radioimmunoassay technique has been described by Javid et al. (1978) in 
which a sheep antiserum was raised against NbA^c and the antibodies to the 
common determinants o f HbA^c and HbAQ removed by adsorption. The m ajority of 
the antibodies, however, recognised these common determinants, so that repeated 
adsorption was required to remove the cross-reacting antibodies. The method has 
not yet been developed fo r general use.
Monoclonal antibodies have been generated and characterized that bind 
glycosylated proteins, but do not react w ith normal plasma proteins (Curtiss & 
Witztum 1983). The antibodies recognised glucitollysine, the reduced hexose 
alcohol form o f glucose conjugated to the epsilon amino group of lysine. An 
immunoassay for glycosylated proteins using monoclonal antibodies could o ffe r a 
number of advantages, including sensitivity, specific ity and the ab ility  to handle a 
large number o f samples. However, antibody production is time-consuming and 
costly in itia lly , and so this method has not been widely adopted for routine or 
research purposes.
Two other groups o f workers have recently produced monoclonal antibodies 
w ith specific ity for NbA^c and cross-reactivity studies have shown that the 
antibodies bind only to the haemoglobin fractions with beta-subunits that were 
glycosylated at the N-terminus (Knowles et al. 1986; Kruse et al. 1986).
1:7:7 The Fructosamine Assay
The 'fructosamine' method is a recently developed co lorim etric test which 
measures all glycosylated proteins and lipoproteins and relies on the ab ility  o f 
ketoamines (fructosamines) to act as reducing agents in alkaline solution. A 
manual method was developed by Johnson et al. (1982) that would allow the 
measurement o f up to 40 samples per hour and required only simple equipment.
The procedure adopted was as follows: serum was added to carbonate buffer 
containing nitroblue tetrazolium , the absorbance was measured at 10 and 13 
minutes a fte r mixing and compared w ith that o f standards o f 1-deoxy, 1- 
morpholinofructose plus albumin at 40 g/1 treated identically.
The assay was ideal to be adapted fo r use in a centrifugal analyser as only 
one reagent addition and measurement o f the absorbance change over 5 minutes, 
are required (Lloyd & Marples 1984). The automated method was developed on a 
Cobas Bio analyser (Roche Products Lim ited, Welwyn Garden C ity , UK) and 
enabled the measurement o f 73 samples in an hour.
The technique has been shown to be a viable alternative to the measurement
of GHb. Baker et al. (1984) showed that the fructosamine concentration was more
sensitive to a deterioration in diabetic control than HbA, measurements. Hindlelc
et al. (1983) also used the automated method and showed a good correlation 
between fructosamine concentrations and HbA^ levels.
The method estimates the quantity o f ketoamines in the blood sample and so 
includes all glycosylated proteins and lipoproteins. This is a less specific test than 
the one for GHb, as all glycosylated serum constituents are included, and indeed, 
exactly what is being measured is s till not known. I t  is this uncertainty, w ith the 
enormous cost o f the equipment needed for the automated technique, that has 
prevented widespread adoption of this method.
The albumin concentrationn in the sample may give rise to misleading 
fructosamine results. Plasma albumin levels below 35g/l or above 53g/l were 
shown to cause significant changes in the fructosamine assay that did not re fle c t 
the true degree o f glycaemia, and some form o f albumin correction may therefore 
be necessary in such cases (Lloyd & Marples 1984).
1:8 Criticisms and Comparisons of the Glycosylated Haemoglobin Measurement 
1:8:1 Fast Glycosylation of Haemoglobin
Glycosylation of haemoglobin was thought to be a slow, non-enzymatic
process (Bunn e ta l. 1976) occurring w ithin the erythrocyte and influenced by blood
glucose level. Because the glucose molecule proved so d iff ic u lt to remove from
the haemoglobin i t  was thought that the formation of GHb was irreversible.
Svendsen et al. (1979) suggested that glycosylation might be both rapid and
reversible. They incubated whole blood from diabetic and non-diabetic subjects in
saline w ith or w ithout added glucose and measured HbA^Q and H bA j^  and H b A jc
by ion exchange chromatography. An increase in H b A jc level was found in a ll
samples incubated with glucose, the increase being greater in the samples w ith
lower in itia l HbA-, values (i.e., non-diabetic). A return to pre-incubation levels o f 
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'H b A j ' was noted after 17 hours of incubation in a glucose-free medium.
This evidence for fast glycosylation and dissociation was investigated by 
other groups o f workers who suggested that the rapid increase was due to the 
formation o f the Schiff base, or labile form (Welch 1979; Leslie et _al. 1979). Welch 
made the observation that Svendsen and co-workers presented no evidence that the 
molecule formed during the incubation w ith glucose was stable H bA j ■ and 
suggested that i t  was more like ly to have been the labile form.
This major critic ism  of the .validity-,of HbA^ measurement has since been 
studied and discussed at length. Ploybutr et al. (1982) confirmed that the addition 
o f glucose to normal or diabetic blood increased the level of H bA j in proportion to 
the glucose concentration. However, this rapid glycosylation was detected only by 
the ion-exchange chromatographic method and not by the co lorim etric method.
This had previously been demonstrated in vivo (Svendsen et al. 1980) and Goldstein 
et al. (1980) had suggested that the labile form  m ight be the result o f short-term  
fluctuations in blood glucose concentrations. Sim ilar observations regarding the 
rapid fluctuations o f HbA^ following oral glucose tolerance tests were made by 
Widness et al. (1980), Shenouda e t al. (1982), Scobie et al. (1981), Goebel and Fuessl 
(1982) and Botterman (1981). There were differences o f opinion however, on the 
time scale of the increase; Scobie et al. reported the increase 10 days a fte r the 
oral glucose tolerance test, whereas Goebel and Fuessl reported the increase a fte r 
1 hour. Maquart et al. (1978) showed a slight increase in HbA^c 5 days a fte r the 
glucose load, but reaching a maximum level a fte r 30 days. The studies of Gachon 
et al. (1982) demonstrated that fast deglycosylation was slower than glycosylation, 
and that an oral glucose tolerance test caused an increase o f 10% in HbA^c values 
(K itz is et al. 1982). These findings of raised HbA^c values following an OGTT must 
be due to the presence o f the labile adduct, as one period o f hyperglycaemia 
resulting from the oral glucose load would be unlikely to cause a rise in stable 
H bA ic 30 days later. The labile HbA^c, or pre-HbA^c, created as a result o f an 
OGTT interferes w ith the electroendosmosis and ion-exchange chromatography 
results unless removed before the assay (Forrest etal.- in press b).
The outcome o f these studies and conflicting results has been, in general, an 
agreement that the blood samples should be treated in some way to remove the 
labile HbA^c before using the ion-exchange chromatography and electroendosmosis 
methods. As these rapid variations depend on the synthesis (at high glucose level) 
or dissociation (at low glucose level) o f the labile GHb adduct, the interference 
caused to the fina l HbA^ result is unpredictable. Compagnucci et al. (1981) 
proposed the separate estimation of the to ta l, stable and labile fractions o f Hb. 
The labile fraction was removed by sample incubation in saline at 37°C fo r 6 hours.
Nathan et al. (1981) described a rapid chemical means for removing the labile 
portion, involving a 30 minute incubation of the erythrocytes in 30mM semi- 
carbazide and 12 mM aniline at pH 5.0, 37°C. They found this method to be as 
effective  as a 14-hour incubation in isotonic saline.
The method of Bisse et al. (1982) made use of the instability  of the Schiff 
base adducts in acid conditions. They carried out the haemolysis o f the samples 
w ith a 15-minute incubation in potassium biphthalate buffer, pH 5, at 37°C.
Commercial methods are now available fo r the removal o f labile GHb 
(Nathan et al. 1984) which have been developed by the manufacturers of a m ini- 
column chromatographic k it  and of an electrophoresis method. The firs t involved 
the use of a borate buffer, 0.6M, pH 6.7 to elute the haemoglobin, and the second 
involved haemolysis o f the samples fo r 15 minutes at 38°C in a buffer containing 
potassium diphthalate and saponin at pH 5.0. These methods were compared w ith 
incubation of the erythrocytes in isotonic saline at room temperature fo r 14 hours 
followed by HPLC, using the ion-exchange resin. The chemical methods were as 
effective  as the long incubation, and so are useful alternatives when ion-exchange 
chromatography or electrophoresis methods are used fo r routine assays.
1:8:2 Comparison o f Techniques
Many studies have been carried out to compare the d iffe ren t methods for 
measuring GHb. Early comparisons were made between the co lorim etric  method 
and ion-exchange chromatography (Pecoraro et al. 1979). The advantages of the 
former method were its reproducibility when samples had been stored as 
haemolysates or packed erythrocytes for several months, and its capability to 
estimate GHb levels when variant haemoglobins, including sickle and foeta l 
haemoglobins were present.
Since the development o f the a ffin ity  chromatography technique, 
comparisons have been made between these three methods (Klenk et al. 1982) to 
investigate the effects of common interferences. Results from the a ffin ity  
chromatography technique were shown to be least affected by changes in 
temperature, length o f time over which the samples had been stored and least 
affected by the removal o f the labile GHb fraction of the three techniques. Re- 
chromatography by ion-exchange chromatography and isoelectric focusing analysis 
o f the fractions following an a ffin ity  separation revealed a substantial population 
of glycosylated haemoglobins not measured by the ion-exchange method. Klenk 
and co-workers concluded that the a ffin ity  method offered a rapid, simple and 
precise alternative to the ion-exchange and co lorim etric method already in use 
that was free of many of the common interferences.
Six methods were compared by Mortensen et al. (1983): three ion-exchange 
chromatographic systems, the TBA method, iso-electric focusing and 
electroendosmosis. A ll assays showed a correlation to H b A ^  determined by 
chromatography better than 0.96 and intra-assay variations were about 2%. They 
concluded that the inclusion of HbA^g and H b A ^  in the electroendosmosis 
measurement confused the result, and the HbA^c result from the ion-exchange 
method was related more closely to mean blood glucose. The TBA method was 
shown to be too laborious to be o f routine use.
A collaborative study by Boucher et al. (1983) compared four methods in 
seven laboratories. The measurements were made using small column separation, 
colorim etric analysis, isoelectric focusing and electroendosmosis. As expected, the 
column separation methods gave higher results than the co lorim etric method, due, 
in part, to the presence of the labile component. None o f the methods stood out as
being the most cost-effective and as no inter-laboratory standards could be 
identified, i t  was recommended that each laboratory develop its own 'in-house1 
quality controls and normal range.
The feasib ility  of references and standards were also considered by Peterson 
et al. (1984), who compared ion-exchange, co lorim etric and a ffin ity  techniques. 
The micro-column ion-exchange method proved to be the most discrim inating 
between diabetic and non-diabetic samples, but all methods gave reproducible 
values and correlated well w ith HbA^c by HPLC. Sample storage was also studied 
and the findings o f other groups confirmed, that the colorim etric method was the 
least affected (L itt le  et al. 1983a). I t  was therefore concluded that the 
co lorim etric method would provide a method which could be utilized fo r the 
establishment of stored standards. Peacock (1984) reviewed the widely used 
methods, and agreed that generally acceptable standards fo r all methods were not 
yet available but each laboratory much establish its own.
Electroendosmosis, ion-exchange and a ffin ity  chromatography were compared 
by Kortlandt et al. (1983) to determine the influence of pre-HbA^c, temperature 
and haemoglobin concentration. A ll three methods showed acceptable precision 
and correlated well w ith each other, but only the a ffin ity  chromatography method 
was independent o f the amount o f  pre-A^c present. The electroendosmosis method 
was the only technique that they found to be independent o f temperature. A ll 
three methods were dependent on the haemoglobin concentration and protein 
content of the haemolysate. They concluded that, w ith careful handling, a ll three 
methods were suitable fo r clin ica l use, w ith the a ffin ity  method the easiest and 
fastest to perform.
A thorough study by Moore e t al. (1986) compared isoelectric focusing, 
electroendosmosis, ion-exchange, a ffin ity  and colorim etric methods. Isoelectric 
focusing was used as the reference method, as suggested by Boucher et al. (1983) 
but i t  was too labour-intensive, lengthy and expensive fo r routine use. The other 
four methods correlated well, but as the d iffe ren t methods do not discern identical 
molecular species, i t  is understandable that the correlation values fe ll between 
0.74 and 0.88. Each of the methods has its advantages, and the choice o f a method 
depends on many factors, including number of samples anticipated and the cost of 
establishing a particular method (Goldstein 1986).
1:9 Clinical Application of Glycosylated Haemoglobin Measurement
1:9:1 Glycosylated Haemoglobin in the Diagnosis o f Diabetes
GHb has been suggested as a diagnostic test for glucose intolerance in 
population surveys and in c lin ica l situations (Dods et al. 1979; Boucher et al. 1981; 
Hall et al. 1984). Koenig et al. (1976) reported a good correlation between HbA^c 
levels and the area under the OGTT curve. Santiago et al. (1978) reported a 
correlation between HbA^c and the response to glucose loading at 1-hour and 2- 
hour o f the OGTT. Dods and co-workers, however, showed that between 37% and 
64% of the individuals in their study judged to be diabetic by the OGTT were 
classified as non-diabetic by the HbA^ assay.
HbA^ assay as a diabetes screening technique has the advantage of being 
insensitive to various individual factors that adversely a ffec t the results o f the 
OGTT. Dods et al. (1979) concluded that H bAp used as a screening test fo r 
diabetes, necessitates the use o f conservative c rite ria  in the diagnosis o f  diabetes 
mellitus. Ferre ll at al. (1984) compared GHb measurements w ith blood glucose 
levels taken at 0 hours, 1-hour and 2-hour time points o f an OGTT. They found 
considerable overlap in the distributions of GHb in individuals w ith fasting blood 
glucose levels above and below 7.8mmol/l. Although this suggests a lim ited
usefulness of the GHb measurement fo r diagnosis, the group tested had elevated 
random blood glucose levels, by which they had been selected following a previous 
test. Their results indicate that the measurement o f GHb in an epidemiologic 
survey was useful and that, as a single crite rion , i t  was superior to a random blood 
glucose measurement. They found that fasting blood glucose measurement was 
only slightly more reliable than GHb as a diagnostic tool.
Fasting samples are, however, much more d iff ic u lt to obtain, whereas random 
samples, though easier to obtain, yield a high number o f false positives, 
necessitating a second test fo r those individuals.
Modan at al. (1984) compared five short-cut methods o f population screening 
fo r glucose intolerance. These were to ta l HbA^ measured by ion-exchange 
chromatography, (i.e., labile HbA^ was not removed), fasting plasma glucose, 
combinations of fasting plasma glucose and HbA^, plasma glucose 1 hour post oral 
glucose load and 2 hour post oral glucose load. Their results suggest that fasting 
plasma glucose was more e ffective  than HbA^ in screening fo r IGT and DM. 
Combinations of the two measurements did not improve prediction over fasting 
glucose alone. The most e ffective  single test was a 2-hour post glucose load blood 
glucose level. They concluded, however, that a fu ll OGTT, w ith blood glucose 
measurement made at the 0-hour, 1-hour and 2-hour time-points was the best 
method for screening fo r both IGT and DM.
Hall et al. (1984) measured to ta l and stable GHb and glycosylated plasma 
proteins using the a ffin ity  chromatography method on patients referred fo r an 
OGTT. Significant correlations were found w ith fasting blood glucose or 2-hour 
glucose and the area under the glucose tolerance curve, but no significant 
correlations were found w ith labile (i.e., to ta l minus stable) GHb levels. No 
overlap was found in the GHb levels between non-diabetic, IGT and DM subjects (as 
diagnosed by the WHO criteria).
More recently, Lester et al. (1985) compared the standard WHO 75 g OGTT 
and to ta l GHb in 168 subjects who had been referred for the diagnosis o f DM. 
When divided into normal, impaired and diabetic responses to the OGTT,
considerable overlap was found in the GHb values. A significant correlation was 
found between the to ta l areas under the glucose tolerance test curve and GHb. A 
significant difference was found between the fasting and 2-hour GHb values in 
subjects w ith diabetic response, but as the electrophoretic method had been used, 
this would be expected, as labile material is included in this measurement unless 
removed prior to measurement.
GHb has also been assessed as an alternative marker for diabetes by A lbu tt et 
al. (1985). 535 patients who had been referred fo r diagnosis o f diabetes, were given 
a standard OGTT. They found a significant correlation between HbA^, and fasting 
blood glucose, but also considerable overlap between the HbA^ values in the three 
groups (normal, IGT and DM). The results showed that many patients w ith IGT or 
newly developed DM and HbA^ values w ithin the normal range o f the ir study. They 
concluded that a fu ll OGTT was s till the method of choice for defin ition of glucose 
tolerance, except where the patient has marked chronic hyperglycaemia.
Jovanovic et al. (1981) found that raised HbA^c levels were highly specific 
fo r the detection o f diabetes, but less sensitive than the OGTT. These conclusions 
were confirmed by Mayer & Freedman (1983). Verrillo _et al. (1983) suggested that 
GHb might be a useful test to improve the specific ity o f the OGTT to select and 
follow-up subjects w ith impaired tolerance.
1:9:2 Glycosylated Haemoglobin and the Monitoring of Metabolic Control
As early as 1962 Huisman & Dozy reported the presence of elevated levels o f 
H bA ic in patients w ith diabetes but did not recognize this as a significant finding. 
A fte r the finding of a 'diabetic haemoglobin component1 by Rahbar (1968), T rive lli 
et al. (1971) published the firs t set of figures in diabetic patients. With the ir
macrocolumn technique they found a reference range fo r H bA jc o f 5.0-8.0% and 
values of up to 15% in adult diabetics. High levels of HbA^c in poorly controlled 
diabetic patients decreased a fte r e ffective therapy: 6.8-12.1% before therapy; 4.2- 
7.6% a fte r three months’ intensive treatment (Koenig et al. 1976). These results 
in itia ted many studies regarding the clin ica l application of the measurement o f 
GHb in the management o f diabetes mellitus (Fraser et al. 1979; Turner 1985).
Gabbay et al. (1977) found a good correlation between the actual HbA^c level 
and the urinary glucose measured two months earlier. Subsequently, Casparie & 
Miedema (1977) found very good correlations between HbA^c and c lin ica l 
impression and mean blood glucose level over the previous weeks. However, good 
correlation w ith urinary glucose level could not be confirmed.
These findings have been confirmed in several studies during the last few 
years, where a good correlation between HbA^c and mean blood glucose was 
uniform ly confirmed (Graf et al. 1978; D is tille r & Zail 1979). GHb has been shown 
to remain nearly constant despite transient periods o f hyperglycaemia 
(Compagnucci et al. 1981) and is a more valuable method of assessing overall 
control than random blood glucose measurements (Bunn 1981a).
I t  was in itia lly  thought that GHb reflected overall metabolic control over a 
period o f 3-4 months (Bunn et al. 1976) and that measurements made every 3 
months would be adequate to assess control. A study o f juvenile diabetic subjects 
attending a summer camp, however, appeared to show that HbA^c levels fluctuated 
more acutely (Dunn et al. 1979). Tornqvist a t al. (1983) showed that these short­
term fluctuations in HbA^c levels in children were due to the labile pre-HbA^c and 
found a clear correlation between pre-HbA^c and urinary glucose concentration
during the 12 hours preceding blood sampling. A study of repetitive measurements 
in out-patients, however, showed that HbA^c values were as stable for this 
population as for non-diabetic subjects (Dunn et al. 1981). Svendsen et al. (1982) 
demonstrated a close relationship between HbA^c and blood glucose profiles over a 
5-week period, but the curvilinear relationship suggested that the HbA^c was not a 
very sensitive index o f glycaemic control. Most investigators have confirmed that 
HbA^ is a useful measure of diabetic control, and that i t  has a role in patient 
education and as a care reinforcement tool (Goldstein et al. 1982).
Paisey et al. (1980) compared serial capillary blood glucose measurements 
over 24-hour periods at fo rtn ightly  intervals and compared the values w ith  HbA^ 
levels over three months. Strong correlations found between mean blood glucose 
levels over the three months and GHb measured by both ion-exchange 
chromatography and by the colorim etric method. However, Mehl et al. (1983) 
found a poor correlation between fasting blood glucose and GHb in IDDM and 
NIDDM subjects, which suggest that mean blood glucose levels are more suitable 
fo r comparison w ith GHb.
Further studies have compared GHb w ith other metabolic parameters in 
diabetic subjects. Positive correlations were found between HbA^ and trig lyceride 
levels and mean diurnal blood glucose. A negative correlation was found between 
HbA^ and high density lipoprotein. Several factors are responsible fo r s ignificant 
variations in lip id metabolism: caloric intake, alcohol in the diet, physical a c tiv ity  
and particularly insulin regime, which are also correlated to the quantity o f 
carbohydrate ingested. Optimisation of control in diabetic subjects requires not 
only the normalisation of blood glucose and lipid metabolism, but also the 
maintenance of HDL-cholesterol as a protective factor (Odetti et al. 1983).
The level o f HbA-^ in ambulatory diabetic patients was compared w ith their 
physicians1 ratings of the degree of control and the ir fasting plasma glucose levels 
(Gonen et al. 1977). A close correlation was found between these parameters, and 
in a group of patients in hospital fo r closer study, HbA^ correlated significantly 
w ith mean fasting and mean daily glucose values and w ith maximum daily glucose 
levels.
GHb values were compared w ith practitioners' estimates of glucose control 
over the preceding 10 weeks (Nathan et al. 1984). 24% of the estimates, which
were based on historical and laboratory data collected during a routine c lin ic  v is it, 
differed from the actual mean blood glucose levels calculated from the GHb assay. 
When examined individually or in aggregate, h istorical information, such as 
polyuria, nocturia, or home urine testing for glucose and laboratory information, 
such as fasting or random blood glucose levels, were weak predictors o f actual 
mean concentration o f blood glucose. These workers concluded that the GHb assay 
provided useful information about the long-term glycaemic control o f the patients 
that was otherwise unobtainable from the other information gathered in the c lin ic  
setting.
There is now lit t le  doubt that the periodic monitoring of GHb is useful fo r 
documenting the degree o f glucose control over a period o f several weeks before 
the sample is taken. Evidence supporting the correlation between GHb levels and 
traditional methods of assessing glucose control is abundant (Gabbay et al. 1977; 
Koenig et a l. 1976). GHb levels correlate w ith long-term metabolic control, 
regardless of whether such control is achieved by multiple or single insulin 
injections or insulin pump therapy (Agardh et al. 1985; Dahlquist et al. 1982). Thus, 
periodic measurement of GHb levels provides an objective assessment o f glycaemic 
status that complements and extends information gained from other methods of 
evaluating glucose control and treatment regimens.
There are some circumstances in which the measurement of GHb levels are 
particularly useful, fo r instance, in the management o f insulin-dependent diabetic 
children with poor metabolic control (Miedema & Casparie 1984), or to compare 
the efficacy o f d iffe rent modes of treatm ent (Mecklenburg et al. 1982).
D itzel & Kjaergaard (1978) measured GHb levels in newly diagnosed diabetics 
before and a fte r diet and insulin treatm ent. The average concentration o f HbA^c 
was 11.4% in untreated diabetics as compared w ith 4.3% in healthy controls. With 
prolonged optimal regulation o f blood glucose HbA^c slowly decreased to a mean 
concentration of 5.5%. The concentration of HbA^c correlated significantly w ith 
the fasting blood glucose value.
Koenig et al. (1976) reported on a group of hospitalised diabetic patients 
whose mean HbA^c levels fe ll from 9.8% to 5.8% following a period o f 
improvement in their metabolic control over one to two months.
Tchobroutsky et al. (1980) reported a significant inverse correlation between 
H b A ^  levels and the number of daily insulin injections, but this has since been 
contradicted (Boucher et al. 1980; Agardh & Tallroth 1985). A study by Dahlquist 
e ta l.  (1982) o f 131 IDDM subjects also showed no correlation between insulin dose 
or the number o f insulin injections and HbA^c concentration. However, a low but 
significant positive correlation was found between duration of diabetes and HbA^c 
levels.
A study to investigate the effects o f sulphonylurea therapy in well controlled 
NIDDM subjects, who were given placebo treatm ent until the fasting blood glucose 
values had risen significantly and were then returned to drug treatm ent w ith  diet,
showed changes in HbA^c levels w ith a lag of four to six weeks (Schultz et al.
1981). Newly diagnosed NIDDM subjects were treated w ith diet alone, additional 
sulphonylurea or w ith basal insulin supplement, and the aim was to lower the 
fasting blood glucose level to below 6mmol/l (Turner 1985). The degree to which 
these treatments reduced HbA^c concentration was studied over one year. 
Sulphonylurea and insulin treatm ent lowered blood glucose and HbA^c levels 
significantly, both groups having HbA^c levels significantly lower than the diet 
treated group at one year. This group had l it t le  change in blood glucose or HbA^c 
concentrations.
Estimation of GHb levels provide an important tool fo r c lin ica l research in 
diabetes, particularly in patients whose blood glucose levels may be subject to wide 
fluctuations. GHb measurements can be performed in the non-fasting state, and 
hence, may be more convenient in the management o f diabetes. Comparison of 
d iffe rent treatm ent regimens or patient groups are possible. As a diagnostic tool, 
estimation o f GHb may not be as precise as the OGTT (Flock e ta l.  1979; Miedema 
&z Casparie 1984) but its convenience and lack o f acute dependence on variables 
such as patient cooperation, time of day, stress and food intake, make i t  an 
invaluable clin ica l tool (Gabbay 1982).
1:9:3 Glycosylated Haemoglobin in Pregnancy
The measurement o f GHb is well established as a retrospective index of 
glucose control in diabetes (Goldstein et al. 1982), but i t  is perhaps most useful in 
periods of labile control, such as during pregnancy (Jovanovic & Peterson 1981). In 
non-diabetic women, HbA^c levels progressively decrease from the f irs t to the 
third trim ester of pregnancy (Kjaergaard & D itzel 1979). Levels also decrease 
during the third trim ester in diabetic women (Schwartz et al. 1976), but are higher
than those in non-diabetic pregnant women (Hall et al. 1983a). The fa ll in GHb 
levels in non-diabetic women may be due to the increase in red cell volume and 
decrease in fasting blood glucose concentration that occurs during pregnancy (Lind 
& Gheyne 1979).
M ille r and co-workers (1981) compared the to ta l HbA^c levels in early 
pregnancy o f diabetic women who delivered infants w ith major congenital 
anomalies w ith levels in women who delivered infants free of anomalies. Their 
results revealed a significantly higher incidence of anomalies in the infants of 
subjects w ith raised HbA^c levels. They concluded that poorly controlled diabetes 
in early pregnancy was associated w ith an increased risk of major structural 
malformations in the offspring, but as these malformations have probably been 
caused before the subject has come to medical attention, good metabolic control 
should be attained prior to conception, where possible.
Glycosylated plasma proteins in addition to GHb have been studied in 
maternal and cord blood samples in non-diabetic and diabetic women at delivery 
(Hall e ta l.  1983b). The maternal blood samples showed significantly higher levels 
o f glycosylated plasma proteins, GHb and glucose concentration than cord blood in 
non-diabetic and diabetic women. The a ffin ity  chromatography method was used 
so that fe ta l haemoglobin would not in terfere w ith the GHb results, which was 
demonstrated by their results. The lower levels o f glucose and glycosylated 
proteins suggest that the fetus utilises glucose more rapidly than the mother.
I t  has been suggested that GHb levels during pregnancy can be used to predict 
infant b irth weight, as maternal hyperglycaemia results in excess glucose crossing 
the placental barrier, which promotes fe ta l insulin production and may result in
increased b irth weight (Cohen 1986a). However, there are conflic ting  results on 
this hypothesis, possibly due to the fac t that macrosomatia develops by the 32nd 
week of gestation in women who have been hyperglycaemic for several weeks. I f  
the glycaemic control normalised a fte r this time, GHb levels would be lowered by 
delivery, whereas the infant would s till be large fo r its gestational age, as a result 
o f the previous hyperglycaemia (Jovanovic & Peterson 1981).
A ttem pts to use HbA^c levels during pregnancy for diagnostic or screening 
purposes to detect gestational diabetes have not been successful, due to the 
overlap of the ranges o f results (M ille r et al. 1979). GHb values are, however, 
useful in the monitoring of glycaemic control in pregnant diabetic women. 
Glycosylated plasma proteins may also be a useful index of glycaemia over a 
shorter tim e period than GHb, and so measurement o f both these parameters would 
yield useful information during pregnancy.
1 : 1 0 The Pathogenesis o f Diabetic Complications
The general consensus now subscribes to the view that sustained 
hyperglycaemia contributes to the pathogenesis of several complications of 
diabetes. During hyperglycaemia, glucose may be over-utilised by the follow ing 
pathways: (i) the enzymatic conversion to sorbitol and fructose, leading to osmotic 
damage; and (ii) non-enzymatic attachment of glucose to free amino groups of 
proteins, which may alter the ir structural and functional properties (Wieland 1983). 
The sorbitol pathway w ill be brie fly described in the following section, followed by 
non-enzymatic glycosylation of haemoglobin and other proteins and the ir role, in 
the development of diabetic complications.
1:10:1 The Sorbitol Pathway and Diabetic Complications
In those tissues o f the body which are re la tive ly impermeable to glucose in 
the absence of insulin, there are substantial periods when in trace llu lar glucose 
concentrations are depressed in diabetes. Following insulin therapy, there is a 
sudden flux of glucose into the cell. These tissues include adipose tissue, muscle 
and erythrocytes. In tissues which are freely permeable to glucose, there are long 
periods o f raised intracellu lar glucose concentration, w ith short periods o f reduced 
concentration following insulin therapy. These tissues include liver, kidney, blood 
vessels, retina, lens, brain and peripheral nerves, and i t  is amongst this group of 
tissues that the major complications o f diabetes occur (A lberti & Press 1982).
The sorbitol pathway consists of two enzymes that catabolize the 
conversion o f free glucose to its sugar alcohol, sorbitol, and the further conversion 
of sorbitol to fructose. The enzymes are, respectively, aldose reductase and 
sorbitol dehydrogenase. There is evidence to suggest that aldose reductase is
highly localised to certain cell types w ithin tissues and this localisation is 
important fo r correlating the site o f sugar alcohol accumulation w ith the site of 
abnormality (Gabbay 1973).
Aldose reductase has a low a ffin ity  fo r glucose, but in diabetes the raised 
intracellu lar concentration o f glucose causes increased formation of sorbitol. Once 
formed, sorbitol cannot easily penetrate the cell membrane, and so the molecules 
are trapped, contributing to the accumulation (Gabbay 1973). The sorbitol pathway 
has been demonstrated in many tissues, but i t  is only in the lens, sciatic nerve and 
renal papilla tha t su ffic iently high concentrations of sorbitol have been 
demonstrated which may be of osmotic importance.
In the lens, the e ffec t o f sorbitol may be an osmotic one, w ith increased 
uptake of water and concomitant influx o f sodium ions and loss of potassium ions. 
The amino acid concentrating mechanism loses its function and the process of 
swelling and electrolyte imbalance continues. These changes lead to cataract 
formation in diabetes, and in itia l animal studies have shown that inhibition of the 
aldose reductase enzyme, which prevents accumulation of sorbitol, can prevent the 
osmotic damage (Gonzalez e ta l.  1983).
Increased peripheral nerve polyol pathway a c tiv ity , resulting from  
hyperglycaemia and leading to abnormal nerve sorbitol and fructose accumulation, 
has been proposed as a pathogenic factor in diabetic neuropathy. Osmotic swelling 
is thought to produce functional and morphological changes in diabetic nerve and 
this theory has prim arily been derived from animal studies. However, the 
concentration o f sorbitol reached in nerve cells is much lower than that reached in  
lens tissue (Finegold et al. 1983). Winegrad et al. (1976) showed that depletion of
myo-inositol was involved in the development o f neuropathy, and i t  has since been 
demonstrated that aldose reductase inhibitors prevent the accumulation o f polyols 
and the depletion of myo-inositol, but the interre lation of these processes has not 
yet been explained (Finegold et al. 1983).
Recently, much interest has been shown in the prevention or reversal o f 
neuropathy by aldose reductase inhibitors, but the evidence is s till inconclusive 
(Yue et al. 1982a; Fagius et a l. 1983). The mechanisms by which increased sorbitol 
levels in nerve cells contribute to the development of neuropathy is not yet fu lly  
understood, but sim ilar changes, also prevented by aldose reductase inhibition, have 
been shown in the glomeruli o f rats w ith experimental diabetes (Gohen et al. 1985). 
Sorbitol accumulation and myo-inositol depletion seem to have a role in the 
development o f neuropathy, but prevention of these changes has only a lim ited  
e ffec t on vascular changes, where increased permeability can be lessened, but not 
the increased cross-linking o f collagen in vascular tissue (Williamson et al. 1985).
1:10:2 Glycosylated Haemoglobin and Diabetic Complications
Investigation of the effects o f glycosylation o f haemoglobin on its a ffin ity  
fo r oxygen have been shown to be insignificant (Samaja et al. 1982) as described in 
Section 1:6.
The oxygen a ffin ity  of diabetic red cells, due to the presence of increased 
level o f GHb, is slightly greater than that o f normal red cells, but this does not 
have any serious e ffec t on oxygen or carbon dioxide transport (Bunn et al. 1978). 
Certain haemoglobinopathies produce greater shifts in the oxygen dissociation 
curve w ithout deleterious effects on tissue oxygenation, which confirms the 
findings that the minor changes in oxygen a ffin ity  associated w ith  increased
glycosylation have no appreciable e ffec t on oxygen transport (Bunn 1981c). Thus, 
although investigations of GHbs have provided c ritica l insights into structure- 
function relationships, the principal c lin ica l contribution derived from studies of 
the minor haemoglobin components in diabetes remains the conclusive 
demonstration that their measurement can reliably assess integrated blood glucose 
levels over the preceding 6-8 weeks (Cohen 1986a).
In animal studies designed to address the question o f the relationship 
between glucose control and the sequelae of diabetes, certain evidence has been 
conclusive. For example, Bloodworth & Engerman (1972) clearly showed that 
insulin therapy that normalised serum glucose in dogs eliminated retinopathy, 
whereas insulin therapy that did not succeed in normalizing glucose levels was 
associated w ith retinopathy and cataract formation.
In man, studies have been more controversial. Determination of GHb has
allowed re-evaluation of the relationship between hyperglycaemia and
complications. The red cell may serve as a model fo r several types o f cells in the
body that do not require insulin fo r glucose uptake; the sequelae of diabetes are
ir\
associated w ith those tissues that are insulin-dependent (Cerami e t al. 1979).
Long-term prospective clin ica l studies, in which GHb is monitored fo r 
years and the incidence o f complications in patients w ith normal or elevated levels 
are compared, would be needed before the contribution of hyperglycaemia to the 
development o f complications could be assessed. Short-term studies have, 
however, shown promising results w ith respect to uncovering the links between the 
severity and duration o f hyperglycaemia and development or progression of 
sequelae. For example, the significant correlation between GHb and cholesterol
levels that has been found in some studies (Peterson et al. 1977) may suggest a role 
fo r hyperglycaemia in the development o f heart disease. In some subsequent 
studies this relationship between trig lyceride concentrations and GHb levels was 
not found (Klujber et al. 1979), but most studies have confirmed the relationship 
(Moore e ta l.  1979).
With respect to microangiopathic complications the results of one study 
failed to show a correlation between muscle capillary basement membrane 
thickness and GHb (Koenig et al. 1076) whereas another reported a decrease in 
quadriceps capillary basement membrane width a fte r 8 to 10 months of optimum 
diabetic control and GHb concentrations (Peterson et al. 1980). A fte r  two years of 
treatm ent w ith continuous subcutaneous insulin infusion, GHb levels and skeletal 
muscle capillary basement membrane width in 13 IDDM patients were both 
significantly reduced compared to values obtained before in itia tion  of the 
intensified insulin regimen (Raskin et al. 1983). Ten control patients in this study 
received conventional insulin therapy and showed no change in GHb levels or 
capillary basement membrane width. Capillary basement membrane thickness 
correlated w ith GHb levels in a study o f 39 IDDM patients over 2 j years (Sosenko 
et al. 1984). An association between raised GHb and presence of retinopathy was 
found in a study o f 149 NIDDM patients (Howard-Williams et al. 1984). The 
patients w ith retinopathy had significantly greater glycaemia, shown by higher 
fasting plasma glucose levels at diagnosis, larger mean values fo r fasting plasma 
glucose 1,-3 and 5 years later in addition to higher random plasma glucose and GHb 
7 years later. A significant relationship was found between HbA-^ levels and 
prevalence of diabetic retinopathy in a randomly selected group of IDDM and 
NIDDM subjects (Monson et al. 1986). The Kroc Collaborative Study Group, 
however, found an in itia l worsening of retinopathy in patients w ith  IDDM treated
w ith continuous subcutaneous insulin infusion for eight months (Kroc 1984). These 
results suggested that a longer-term tr ia l may be needed to study retinopathy 
changes, as p re -tria l elevated AERs fe ll in the group treated w ith continuous 
infusion. A group of NIDDM subjects demonstrated a close relationship between 
GHb levels and the presence of retinopathy (Nathan et al. 1986) and although the 
study was cross-sectional in design, they were also able to show that duration was 
another important, independent factor.
A large-scale detailed screening study involving over 500 diabetic subjects 
(IDDM and NIDDM) revealed a strong association between GHb and presence o f 
retinopathy (Nielsen & D ietzel 1985). No relationship was found between GHb and 
macrovascular disease, and the results emphasized the suggestion that the 
development of microvascular disease depends on the quality of blood glucose 
control whereas that of macrovascular disease appears unrelated to chronic 
hyperglycaemia.
Since Tchobroutsky wrote his review on the association o f glycaemic 
control and the development of microvascular complications in 1978, techniques 
such as home blood glucose monitoring, GHb measurements and insulin pump 
treatment have become widely available. In a recent review of the findings o f 
many studies over the intervening years, Hanssen et al. (1986) concluded that 
glycaemic control was an important factor fo r the development and progression o f 
microangiopathy. Monitoring the GHb levels at regular intervals may therefore be 
a crucial factor in the attempt to retard the progression o f complications.
I t  is clear that more analyses are needed, which focus on specific c lin ica l 
parameters and levels o f glycosylation (or advanced glycosyiation end products; see 
Section 1:11) over tim e in individual tissues. Unfortunately, the lim ited amounts of 
types of tissues that can be obtained by biopsy from living subjects present 
obstacles to these kind of studies. Skin, fo r example, is one tissue that can be 
sampled re la tive ly easily, and Lyons & Kennedy (1985) found a correlation between 
GHb and glycosylation of skin tissue.
Measurement o f glycosylated proteins in the tissues o f the body, 
particularly those involved in the complications o f diabetes, should help to 
elucidate the processes involved in their development. The same chemical 
reactions that are involved in glycosylation o f haemoglobin cause sim ilar 
modifications in other proteins.
1 : 1 1 Advanced Glycosylation End Products
Non-enzymatic glycosylation begins in all cases w ith the attachment of 
glucose to the groups o f protein via nucleophilic addition, resulting in the 
formation of a Schiff base. The labile adduct rapidly reaches equilibrium in vivo 
reflecting ambient glucose levels.
Over a period of weeks a slow chemical rearrangement takes place, 
resulting in the formation of a stable but chemically reversible product (Higgins & 
Bunn 1981). The Amadori products do not accumulate indefin ite ly even on long- 
lived proteins, because equilibrium is reached a fter a few weeks. Once equilibrium 
has been attained, levels of stable glycosylated protein reach a steady-state value. 
The quantity o f Amadori product found on a protein reflects not only blood glucose 
concentration, but also the ha lf-life  of the protein (Cerami 1985).
The equilibrium is reached a fte r 21-28 days, which accounts for the shorter 
than expected integral o f ambient glucose found on haemoglobin, since the red cell 
has a h a lf-life  o f 60 days. The amount o f Amadori product remains constant (a fte r 
equilibrium has been reached) whether the protein has a ha lf- life  o f weeks or years.
Proteins that have a much slower turn-over rate than, say, haemoglobin, 
accumulate advanced glycosylation end-products (Brownlee et al. 1984). 
Crystallins, collagen, myelin and elastin, fo r example, form these products very 
slowly from the Amadori adducts, through a series of fu rther reactions, 
rearrangements and dehydrations. The end-products have a characteristic yellow- 
brown pigmentation, fluoresce and cause cross-linking between proteins (Finot
1982). The formation of these end-products is extremely slow, but as they are 
chemically irreversible, there is a steady build-up throughout the life  of the 
protein.
Recent studies by Chang and co-workers demonstrated the presence of 
advanced glycosylation products on albumin and globulin molecules in normal 
subjects (Chang et al. 1985). The substance measured was 2-(2-furoyl)-4(5)-(2- 
furanyl)-lH-im idazole (FFI) which had been isolated from acid hydrolysates of 
bovine serum albumin and poly-L-lysine which had been incubated w ith glucose. 
Antibodies were raised to this molecule, and a radioimmunoassay developed for its 
measurement. The research group is continuing w ith this investigation, to discover 
i f  FFI is present in greater than normal quantities in proteins from ageing and 
diabetic subjects.
Brownlee et al. (1985) have discovered that FFI has cytotoxic potential. 
Furan rings have been associated with cyto tox ic ity , so i t  was thought that the 
advanced glycosylation end-products, containing furan, m ight also be cytotoxic. 
FFI was shown to be capable o f causing ceil death at concentrations as low as 0.5 
mmol/1, and the percentage o f lymphocytes killed increased w ith  FFI 
concentrations in a dose-dependent manner. The ab ility  of the cytochrome P-450 
mono-oxygenase system to mediate the covalent binding of FFI to macromolecules 
was studied. In the absence o f the mono-oxygenase system binding was inhibited. 
The results suggest that the development o f diabetic complications have not only a 
hyperglycaemia-induced metabolic component (i.e., increased FFI) but also a 
genetic component, involving inherited variation in levels of P-450 enzymes.
1 : 1 2 Non-Enzymatic Glycosylation o f Other Proteins
In recent years i t  has become increasingly clear that non-enzymatic 
glycosylation, long known to food chemists as the ’browning' reaction (or Maillard 
reaction) tha t occurs in baked or stored foodstuffs (Saltmarch & Labuza 1982) has 
considerable relevance in diabetes. The Maillard reaction, which occurs between 
reducing sugars and free amino acids and proteins, occurs readily during the 
preparation and storage of foods. In food proteins, the reaction involving lysine is 
the most important nutritiona lly . The deoxyketosyl-lysine molecule formed in the 
early stage o f the reaction is not available biologically. In the la te r stage o f the 
reaction, which produces browning, the d igestib ility  o f the protein is decreased and 
other amino acids are destroyed (Finot 1982).
1:13 Glycosylation of Tissue and Structural Proteins
1:13:1 Lens Crystaliins
The e ffec t o f non-enzymatic glycosylation on structural properties o f 
proteins has been best studied in the lens, which was one o f the f irs t tissues 
examined in detail (Stevens et al. 1978). Lens crystaliins were shown to aggregate 
and precipitate more rap&itj in solutions containing glucose than in sugar-free 
medium. Inhibition o f this aggregation by reducing agents, coupled w ith  the 
increased disulphide content o f cataractous lens, led to the hypothesis tha t 
glycosylation increased the susceptibility o f sulphydryl groups to oxidation, 
inducing formation o f disulphide-linked protein aggregation (Stevens et al. 1978). 
Subsequent studies have shown an increase in protein glycosylation in cataractous 
lenses in diabetic subjects (Kasai e ta l.  1983).
Incubation of lens protein w ith glucose in v itro  leads to non-enzymatic 
glycosylation, intermolecular disulphide bond formation, and protein aggregates 
that d iffra c t ligh t. These findings mimic the state of proteins found in the diabetic 
lens. With longer incubation times, these non-enzymatically glycosylated proteins 
can undergo further re-arrangements to form yellow-brown pigments that act as 
molecular cross-links (Monnier & Cerami 1982). In in itia l studies Cerami and co- 
workers demonstrated that the e-amino groups o f lysine residues in bovine and ra t 
lens crystaliins became glycosylated when incubated in v itro  w ith glucose (30mM) 
or glucose-6-phosphate (5mM) and that under these conditions the lens also 
developed an opalescence reminiscent o f the cloudy cataracts o f diabetes (Cerami 
et al. 1979). The greatest extent o f glycosylation, measured as ^ C  hexose 
incorporation was found to involve a-crystallins, although carbohydrate was found 
associated w ith all the crystaliins. This increase in glycosylation has been 
demonstrated in vivo in alloxan-induced diabetic rats (Cerami et al. 1979).
Since neutralization of a charged lysine residue can create conformational 
changes in a-crystallins that expose inaccessible sulphydryl groups, i t  is believed 
that non-enzymatic glycosylation exerts a sim ilar e ffect, altering the te rtia ry  
structure of the protein and unmasking hidden sulphydryl groups. These exposed 
groups then become susceptible to oxidation and can form disulphide cross-links 
(Cohen 1986).
Recent detailed studies by Liang et al. (1986) have shown that a-crysta llins 
are glycosylated to a greater degree than other crystaliins (two to four times as 
much). The extent of glycosylation depends not only on the lysine content, which 
does not vary much among the crystaliins, but also on the accessibility o f the 
surface areas where lysine residues are located.
Non-enzymatic glycosylation is a normal ageing process which is enhanced 
in diabetic patients (Kennedy & Baynes 1984). Garlick and co-workers (Garlick et 
al. 1984) found that glycosylation increased w ith ageing in non-diabetic lenses and 
was two-fold higher than normal in diabetic lenses.
The accumulation of sorbitol in the lens, as a consequence o f poor diabetic 
control, also has a role in the development o f cataracts (Wieland 1983) and i t  is not 
yet clear which of these metabolic changes is the more significant (Kennedy & 
Baynes 1984).
1:13:2 Nerve Proteins
Increased glycosylation of myelin and myelin-associated proteins has been 
noted in both the peripheral and central nervous system in diabetes (Vlassara et al.
1983). The two- to five-fo ld  increase in glycosylation of these proteins is
comparable to increases measured for plasma proteins. Proteins in sciatic nerves 
from alloxan-diabetic rats and in femoral nerves from alloxan-diabetic dogs were 
shown to have increased glycosylation compared to nerve proteins in non-diabetic 
animals (Vlassara et al. 1981). The measurements were made using an adaptation 
o f the a ffin ity  chromatography technique, and a three-fold difference was found 
between diabetic and non-diabetic samples. The exact nature of the proteins 
undergoing the glycosylation in vivo was not identified, but they were believed to 
consist o f axonal and myelin proteins. Subsequent studies by Vlassara and co- 
workers (Vlassara et al. 1983) have demonstrated myelin to be the principal nerve 
constituent undergoing excessive glycosylation. Since the involved peripheral 
nerve myelin is the main structural protein of the myelin sheath, the suggestion 
that non-enzymatic glycosylation might a lte r its in tegrity  or the functional 
properties o f the nerve, seems like ly. The excessively glycosylated high molecular 
weight species of central nervous system myelin may represent cross-linked 
proteins derived from interactions as a result o f advanced glycosylation end- 
products.
An important insight into a possible mechanism by which excess 
glycosylation contributes to the development of diabetic neuropathy was provided 
by the demonstration that macrophages specifically recognise glycosylated myelin. 
Vlassara and co-workers showed that this recognition led to endocytosis and 
intracellu lar accumulation o f myelin, and demonstrated that this accumulation was 
two to three times higher in diabetic than in non-diabetic subjects (Vlassara et al.
1983).
1:13:3 Collagen and Basement Membrane Proteins
Collagen is the major fibrous protein o f connective tissues and is a 
principal constituent of basement membranes. Collagenous proteins are rich in 
lysine and hydroxylysine, generally have a long ha lf- life  and are continuously 
exposed to ambient levels o f glucose in the vascular compartment and extracellu lar 
fluids. Since variables such as the number o f free amino groups in and the resident 
time of a protein determine the extent of glycosylation in vivo, collagen would be 
expected to be excessively glycosylated in diabetic subjects. Examination of 
several collagens has confirmed that this is the case, and a two- to three-fo ld 
increase has been found when non-enzymatic glycosylation of collagens from 
tissues of diabetic subjects were compared to control samples (Vogt et al. 1982). 
Type I and type II collagens and glomerular basement membrane, as well as aortic, 
skin and tendon collagen all undergo glycosylation (Cohen et al. 1981; Kohn & 
Schnider 1982).
Kohn and co-workers studied human collagen from a number of sites and 
found an age-related decrease in solubility and an increase in glycosylation of skin 
collagen, both of which were also marked in diabetes. Many o f the debilities that 
characterise the ageing syndrome can be explained by the cross-linking o f 
macromolecules such as collagen, and these changes have also been demonstrated 
in diabetes. Glycosylation of skin collagen was found to be less than that o f 
tendon, possibly due to the greater turnover of skin collagen. Collagen alterations 
in diabetes were most apparent in samples from younger adult subjects, suggesting 
than an equilibrium had been reached in the older samples.
Tissue proteins from heart, liver and kidney samples from diabetic rats 
demonstrated higher non-enzymatic glycosylation (Yue et al. 1983a). This group
went on to show enhanced glycosylation in tendon collagen in diabetic rats, and 
showed that levels o f glycosylation correlated w ith increased thermal s tab ility  o f 
collagen (Yue et al. 1983b). Thermal s tab ility  of collagen normally increases w ith 
age, but this change had been brought about a fte r only 4-8 weeks duration of 
diabetes in the ra t.
Lyons & Kennedy (1983) clearly demonstrated enhanced skin collagen 
glycosylation in diabetic patients, and found a positive correlation w ith  GHb 
values. However, when samples from patients w ith lim ited jo in t m obility were 
compared w ith those w ithout lim ited m obility, no difference in levels o f 
glycosylation of collagen were found.
In te rs titia l and. basement membrane collagens form intermolecular cross­
links that play an important role in the s tab ility  and physicochemical properties of 
connective tissue. The firs t step in the generation of these cross-links is an 
oxidative deamination of specific lysine and hydroxylysine residues, which enables 
the formation of cross-links by condensation between these reactive aldehydes of 
lysine and hydroxylysine and free e-amino groups on these amino acids. Since 
many of these e-amino groups have been glycosylated, i t  is possible that the 
normal cross-linking is not in itia ted (Cohen 1986a). Such a result would a ffec t the 
packing and permeability of basement membranes and may help to explain the 
increased permeability o f membranes to serum proteins.
However, this seems to contradict the findings of Yue et al. (1983b) of 
increased thermal s tab ility  in excessively glycosylated collagen. The explanation 
may relate to the formation of abnormal cross-links or covalent interactions, 
particularly in the insoluble fraction rather than in newly synthesised collagen.
Glycosylation leads to the formation of advanced glycosylation end-products, which 
may lead to formation of abnormal cross-links, and the reactive groups formed can 
trap, condense or form covalent bonds w ith non-glycosylated proteins such as 
serum albumin, IgG or lipoprotein (Brownlee et al. 1984; Brownlee et al. 1983). 
This may explain the increased concentration of albumin in basement membranes 
o f patients w ith diabetic nephropathy (Michael & Brown 1981).
The trapped or bound proteins retain their ab ility  to form immune 
complexes, w ith appropriate antibody or antigen, suggesting a mechanism by which 
non-enzymatic glycosylation could in itia te  or perpetuate immune injury. Bassiouny 
and co-workers (1983) showed that glycosylated collagen induced antibody 
production specific to the modified sites in the collagen. However, as they 
glycosylated collagen in v itro  and produced collagen w ith a glucitollysine-collagen 
adduct in which the ketoamine structure had been chemically reduced, rather than 
glycosylated collagen which would be produced in vivo, the results do not 
correspond to the in vivo situation. More recently, auto-antibodies were shown to 
be present fo r native albumin, but none were detected that were specific fo r 
glycosylated albumin (Gregor et al. 1986). Their results showed that there was a 
five-fo ld  increase in incidence o f albumin antibodies in a diabetic population. I t  is 
s till not known why an endogenous substance, such as albumin, becomes antigenic, 
but one theory is that association w ith an antigenic region provided, fo r example, 
by a v ira l particle, might render albumin antigenic.
There is however, a characteristic deposition of albumin and IgG that has 
been detected w ith immunofluorescent techniques in the microvascular m atrix o f 
tissues from diabetic patients (Chavers et al. 1981), that has not yet been fu lly  
explained.
The significance of capillary basement membrane changes w ith respect to 
nephropathy in diabetes w ill be discussed in a la ter section.
1:14 Glycosylation of Blood Components
1:14:1 Coagulation Proteins
The amount of glucose bound to lysine residues in fibrinogen purified from 
the plasma o f poorly controlled insulin-dependent diabetics is approximately l£  
times that bound to fibrinogen purified fron non-diabetic subjects (Lutjens et al. 
1985). Since lysine is the amino donor fo r fib rin  cross-linking and since fib rin  and 
fibrinogen (from which the fibrinopeptides A and B are split by the action of 
thrombin to form fibrin) are glycosylated to a sim ilar extent, i t  is possible that 
glycosylation of lysine residues interferes w ith fibrinogen and/or fib rin  function or 
processing. One such suggested e ffec t o f the attachment o f glucose would be to 
compromise the availability of lysine residues in fib rin  to the fibrin-stabilis ing 
factor (Factor XIII) and, hence, the formation o f intramolecular cross-links. 
However, a recent study examining the effects of in v itro  glycosylation of 
fibrinogen did not confirm  this suggestion, in that glycosylation at a level o f 3.8 
mol o f glucose per mole o f protein altered neither c lotting tim e nor Factor XIII 
cross-linking of fibrinogen (Ney et al. 1985). Glycosylation of fib rin  achieved by in 
v itro  incubation w ith glucose results in a reduced susceptibility to degradation by 
the fib rino ly tic  enzyme, plasmin (Brownlee et al. 1983). Since lysyl residues o f  
fib rin  are specific sites of plasmin hydrolysis, excess non-enzymatic glycosylation 
could in terfere w ith the degradation of deposited fib rin  and lead to its 
accumulation in the tissues. A high level o f glycosylation is apparently required to 
produce this e ffec t on plasmin-mediated fibrinolysis, since the study by Ney and 
co-workers demonstrated that the susceptibility to plasmin degradation o f fib rin  
formed from fibrinogen glycosylated at a level o f 3.8 mol/mol was not reduced 
compared to that formed from native fibrinogen. However, even this level o f 
glycosylation was suffic ient to slow the rate o f cleavage of fibrinogen by plasmin.
1:14:2 Erythrocyte Membrane Proteins
Another advance o f potential pathochemical interest, was the observation 
that glucose was also bound by the ketoamine linkage to erythrocyte membrane 
proteins, and again there is a higher degree of glycosylation in red cells from 
diabetic patients (M ille r et al. 1980; McMillan & Brooks 1982). There was a close 
correlation between lysine-bound glucose of erythrocyte membranes and that of 
haemoglobin, suggesting that the ketoamine linkages persist throughout the life  
span of the erythrocytes (Wieland 1983). The increased glycosylation may a lter the 
permeability o f the red cell. Diabetics have been shown to have slightly decreased 
red cell survival, perhaps owing to decreased deformability, but whether increased 
glycosylation contributes to these changes is unclear (Bunn 1981d).
1:4:3 Lipoproteins
Non-enzymatic glycosylation of low-density lipoproteins (LDL) has been 
implicated in the pathogenesis of macrovascular disease, which has an increased 
incidence in diabetes (Wieland 1983). Incubation of human serum lipoproteins w ith 
glucose in v itro  results in the covalent binding o f glucose to e -amino groups of 
lysine residues in the apolipoproteins of LDL, VLDL (very-low-density lipoproteins) 
and HDL (high-density lipoproteins). Glycosylation of apolipoprotein-B o f LDL 
purified from serum of diabetic subjects showed a two- to three-fold increase 
compared w ith non-diabetic samples (W itztum et al. 1982). This m odification is of 
special interest as i t  is known that chemical modification of lysine amino groups of 
apolipoprotein-B, e.g., by acetylation, interferes w ith the specific receptor- 
mediated cellular LDL uptake and favours cholesterol accumulation (Wieland 1983). 
A decreased uptake o f glycosylated LDL was demonstrated by W itztum and co- 
workers which may lead to prolonged residence of LDL in plasma, contributing to 
elevated plasma levels. I f  the life -tim e  of glycosylated LDL in plasma is
prolonged, i t  may undergo denaturation or enzyme-catalyzed modifications that 
then target i t  to tissues other than those normally involved in LDL degradation. 
Glycosylated LDL may also be metabolised d iffe rently  at crucial sites, such as the 
arteria l wall (W itztum et al. 1982).
More recent studies using guinea pig samples (Steinbrecher & W itztum
1984) showed clear indications that glycosylation o f as lit t le  as 2-5% of the lysine 
residues o f LDL decreased LDL catabolism by 5-25% and the degree of inhibition 
o f catabolism was linearly related to the extent o f LDL glycosylation. Curtiss and 
Witztum (1983) showed that excess non-enzymatic glycosylation o f LDL also occurs 
in human diabetic subjects, the overall level o f glycosylation in poorly controlled 
patients was up to four times greater than in non-diabetic subjects.
1:14:4 Plasma Proteins
The discovery o f glycosylated albumin and other plasma proteins and the ir 
elevation in diabetes (McFarland et al. 1979; Dolhofer & Wieland 1979; Guthrow et 
al. 1979; Yue et _al. 1980; Ma et al. 1981) offered another tool fo r monitoring 
metabolic control, d iffering from the glycosylated haemoglobin measurements, in 
that they re flec t fluctuations and glycaemia over a shorter period o f tim e. 
McFarland and co-workers demonstrated close correlations between glycosylated 
serum proteins and GHb, glycosylated albumin and fasting blood glucose, and 
suggested that glycosylated serum protein measurements were a sensitive indicator 
o f glycaemic control. Kennedy et al. (1979) obtained a much poorer correlation 
when they compared GHb with protein-bound hexose, but a clear difference was 
seen between diabetic and non-diabetic levels. Glycosylated serum proteins were 
assessed fo r usefulness as a measure o f short-term  glycaemia. Treatment aimed at 
improving control in poorly controlled diabetic patients resulted in a fa ll o f 37% in
glycosylated serum protein in one week, whereas GHb decreased only 8% (Kennedy 
et al. 1981). These results were in agreement w ith a study (Day et al. 1980) 
comparing glycosylated serum proteins and GHb levels a fte r changes in blood 
glucose levels in rats. Glycosylated albumin and serum protein levels were more 
sensitive to changes in glycaemic control than GHb levels, as a result of the 
shorter h a lf-life  o f serum proteins (Dolhofer & Wieland 1980).
The importance of increased glycosylation of serum proteins was 
suggested to be due to the reduced solubility of the affected protein (Kennedy et 
al. 1982). Kennedy and co-workers demonstrated reduced solubility o f 
glycosylated albumin, but were unable to show any changes in plasma viscosity as a 
result o f increased glycosylation of plasma proteins.
Human serum albumin is a single-chain polypeptide o f 585 residues which 
comprises about 60% of the plasma protein and is the major contributor to the 
oncotic pressure o f blood.
There is now evidence implicating the non-enzymatic glycosylation of 
albumin in the pathophysiology o f diabetic microangiopathy by methods quite 
d istinct from those invoked fo r GHb. Although glycosylation of albumin does not 
a lter its circulating h a lf-life  or catabolism, i t  can induce a conformational change 
in the protein and a lter its ligand-binding properties (Shaklai et al. 1984). Hemin 
a ffin ity  was unaltered by glycosylation in vivo whereas the a ffin ity  o f b ilirub in  fo r 
glycosylated albumin was about 50% o f its  value fo r the non-glycosylated form . 
The glycosylated form appears to be taken up more avidly than native albumin by 
endothelial cells (Williams et al. 1981). This process involves m icropinocytic 
vesicles of endothelial cells, which participate in the bidirectional transport of
proteins across the capillary wail. Glycosylation of albumin and other circulating 
proteins in poorly controlled diabetes may increase trans-endothelial transport and 
contribute to the increased capillary permeability associated w ith diabetes. In 
support o f this concept is the finding that the passage of glycosylated albumin 
through the glomerular filtra tio n  barrier is enhanced relative to that o f native 
albumin in diabetic patients w ith and w ithout microalbuminuria as well as in non­
diabetic subjects (Ghiggeri et al. 1984). In diabetic subjects, the clearance of 
albumin correlated w ith the serum concentration o f glycosylated albumin, and the 
urinary-to-serum glycosylated albumin ratio correlated inversely w ith  albumin 
clearance. The reason fo r the preferentia l excretion o f glycosylated albumin was 
suggested to be a result o f the increased negative charge on the molecule (Ghiggeri 
et al. 1985). A recent report by Kverneland et al. (1986) demonstrated an 
increased anionic charge as a result o f glycosylation, and suggested that this m ight 
a ffec t its filtra tio n  by the glomerular barrier.
Glycosylated albumin, w ith respect to the sites of glycosylation, has been 
studied in detail. Candiano et al. (1984) showed that glycosylated albumin was a 
heterogeneous molecule, and that the addition of carbohydrates could occur at 
many sites. The rate of non-enzymatic glycosylation of albumin in vivo is 
approximately 9 times that o f haemoglobin (Garlick & Mazer 1983).
A report that demonstrated that repeated intravenous in jection o f 
glycosylated plasma proteins produced glomerular basement membrane thickening 
in non-diabetic mice is also o f interest (McVerry et al. 1980). This does not appear 
to be due to binding of exogenously administered glycosylated albumin to the 
basement membrane (Jeraj et al. 1983) although binding of endogenous albumin is 
known to occur (M ille r & Michael 1976).
Albumin is not only the major contributor to plasma oncotic pressure, but 
also serves as a plasma carrier fo r many drugs and metabolites. In plasma less than 
Q.1% o f non-esterified fa tty  acids are free in solution, the remainder circulating as 
a fa tty  acid/albumin complex. Serum albumin has a great capacity to bind fa tty  
acids, and i t  has been suggested that glycosylation might in terfere w ith this 
function. A study reported recently, however, showed that albumin glycosylated to 
a level o f 1-3 mol glucose per mol albumin, had a sim ilar a ffin ity  fo r binding 
palm itic acid (Murtiashaw & W interhalter 1986).
Thus, the usefulness of glycosylated albumin as an assessment o f medium- 
term blood glucose control has been established (Kemp et al. 1984), but its role in 
the pathogenesis of diabetic complications remains unclear. The changes that 
occur during the development o f nephropathy, and the possible roles o f 
glycosylated proteins, w ill be described.
1:15 Diabetic Nephropathy
I t  has been recognised for some time that renal disease is an almost 
invariable, though in itia lly  insidious, concomitant o f diabetes. Interest in the renal 
aspects o f diabetes was kindled by the report of K im m elstiel & Wilson (1936) on 
nodular glomerulosclerosis. Subsequent studies have demonstrated that 
prolongation of life  by means o f insulin and antibiotics was often at the cost o f 
renal disease (Churg & Dolger 1979).
The natural history o f renal involvement in diabetes follows a 
characteristic pattern. A fte r a long period, 10-20 years or more in IDDM, and 
usually less in NIDDM, structural components in the kidney are enlarged w ith 
concomitant hyperfunction. Thereafter, in a large proportion of the patients 
(around 30-50%) renal function starts to deteriorate, f irs t indicated by proteinuria. 
The in itia l phase o f abnormal increase in protein excretion is not detectable by the 
commonly used method, i.e., Albustix (Ames L im ited, Stoke Poges, UK) more 
sensitive methods such as radioimmunoassay are required (Keen & Chlouverakis 
1963).
A series of stages in the development o f renal changes in diabetes has 
been described (Mogensen et al. 1983) and are as follows:
Stage 1 is characterized by early hyperfunction and hypertrophy, the 
changes may be detectable at diagnosis, before treatm ent begins. Urinary albumin 
excretion is increased, to a greater extent during exercise. Onset o f treatm ent 
may partia lly reverse these changes.
Stage 2 develops over many years, and is characterized by morphologic 
lesions w ith no signs of c lin ica l kidney disease. GFR is raised, albumin excretion is 
normal, except during exercise. When metabolic control is inadequate, albumin 
excretion rises. Some patients do not progress any further than this stage.
Stage 3, called incipient diabetic nephropathy, is characterised by 
continually raised albumin excretion, or microalbuminuria. This is greater than 
normal excretion, but below that measurable by Albustix. This w ill be defined in 
more detail in a la ter section. Albumin excretion and blood pressure may rise 
slowly over a number of years, and GFR is also elevated.
Stage 4 can be defined as overt diabetic nephropathy, characterised by 
persistent proteinuria (> 0.5g/24h). Blood pressure is raised and GFR declines.
Stage 3 is end-stage renal fa ilure, w ith development o f uraemia as a 
result o f the nephropathy.
The firs t three stages w ill be considered in more detail, w ith  particular 
emphasis on microalbuminuria and the possible involvement of increased protein 
glycosylation on its development.
1:15:1 Evolution of Diabetic Nephropathy
I t  is now well established that GFR is raised in early IDDM (Mogensen 
1971a; Mogensen 1971b). The metabolic derangement associated w ith diabetes has 
been shown to be involved in the changes in GFR. There are, however, conflic ting  
reports of the effects o f raising the blood glucose level on GFR. Mogensen (1971c) 
and co-workers demonstrated that elevated blood glucose was not alone su ffic ien t
to cause a significant increase in GFR, but a more recent study by Christiansen et 
al. (1986) showed a significant increase in GFR following an oral glucose load, in 
diabetic patients w ith near-normal blood glucose levels preceding the test. By 
contrast, a sim ilar challenge to patients w ith hyperglycaemia was followed by a 
decline in GFR. Thus, the blood glucose values before the glucose load are o f great 
importance to the outcome of this challenge on renal haemodynamics; an 
observation which explains the d iffe rent results in the studies. Christiansen and 
co-workers concluded that the glucose-mediated elevation of GFR was, at least in 
part, explained by vasodilation o f the renal arterioles.
Changes in the diabetic kidney occur very early in the course of the 
disease, and abnormalities may even be present at diagnosis. Following the onset 
of treatm ent fo r diabetes, these changes may be normalised (V iberti et al. 1981). 
There are, however, conflicting views on whether or not these early changes are a 
result o f kidney enlargement and concomitant glomerular changes. Mogensen et al.
(1983) state that the kidney may be enlarged at an early stage o f diabetes, but 
V iberti et al. (1981) state that no glomerular changes can be seen for the f irs t one 
or two years a fte r diagnosis. Early reversible kidney enlargement at diagnosis is, 
however, frequently demonstrated (Gatling 1983).
The second stage o f the development o f renal changes is characterised by 
the development of glomerular lesions, w ith raised GFR (Mogensen 1985). This 
stage may last many years, w ith some patients remaining at this stage fo r the rest 
of the ir lives. However, in a large number of diabetic patients, the renal changes 
progress slowly until microalbuminuria is a permanent finding (Keen & V iberti 
1981).
1:15:2 Microalbuminuria
Microalbuminuria can be defined as an albumin excretion level which is 
greater than normal but lower than Albustix-positive or c lin ica l proteinuria, which 
is detectable w ith the Albustix at 30mg/100ml or 0.5g per 24 hours (Christiansen et 
al. 1985).
Studies have shown that in IDDM, a raised AER is a good predictor o f the 
development o f Albustix-positive proteinuria and renal fa ilure (V iberti et al. 1982; 
Parving et al. 1982; Mathiesen et al. 1984; Mogensen & Christensen 1984). Two 
other studies have demonstrated that a raised AER predicts m orbidity and 
m orta lity  in NIDDM patients (Ja rre tt et al. 1984; Mogensen 1984a). However, each 
o f the groups carrying out these studies has used d iffe ren t conditions for measuring 
AER and d iffe rent terminology.
A summary o f the urine collections used and definitions o f 
microalbuminuria from the various groups of workers are shown in Table 1:4. The 
level o f AER that was found to predict c lin ica l proteinuria differed between the 
groups. The Steno Memorial Hospital Group (Parving, Mathiesen and co-workers) 
reported a value of 28pg/min as the upper lim it o f the ir normal range, above which 
subjects were more like ly to develop proteinuria (Parving et al. 1982). A la te r 
study showed that a value of 70pg/min predicted proteinuria (Mathiesen et al.
1984) both studies used a 24-hour urine sample. The Aarhus group (Mogensen and 
co-workers) defined 15pg/min on a short-term urine sample at rest, as the 
predictive value in IDDM subjects (Mogensen & Christensen 1984), but defined 
30pg/min on an early morning sample, as the predictive value in NIDDM subjects 
(Mogensen 1984). The Guy's Hospital group (V iberti, Ja rre tt and co-workers) 
showed that a level o f 30qg/min on a timed overnight sample was predictive of
Table 1:4
Definitions o f Microalbuminuria by D ifferent Groups
Study
Parving et al. 1982
V iberti e t al. 1982
Mathiesen et al. 1984
Mogensen and Christen-
sen
1984
Mogensen 1984 
Ja rre tt et al. 1984
Urine Sample 
Collected
A t Risk 
Level o f AER
24-hour 28gg/min
Timed overnight 30pg/min 
24-hour 70pg/min
Short-term at 
rest
15pg/min
Morning sample 30pg/min
Timed overnight JOpg/min
IDDM or 
NIDDM
IDDM
IDDM
IDDM
IDDM
NIDDM
NIDDM
la ter proteinuria in both IDDM and NIDDM subjects (Viberti et al. 1982; Ja rre tt et 
al. 1984). These differences may be due to d iffe rent lengths of follow-up (6 years 
fo r the Steno group, 10 years fo r the Aarhus group and 14 years for the Guy's 
group) and differences in sample collection and tim ing.
Epidemiological studies measuring the prevalence o f microalbuminuria 
have shown that i t  is common among a diabetic c lin ic population. Mogensen (1983) 
found that almost 12% o f the c lin ic population could be classed as having 
microalbuminuria, w ith a further 12% showing in te rm itten t or persistent A lbustix- 
positive proteinuria. Many groups have followed the development o f nephropathy 
in patients w ith microalbuminuria over a number of years (Viberti A Wiseman 1983; 
Parving et al. 1982; Andersen et al. 1983).
The studies find that approximately 40% o f IDDM patients w ill, in time, 
develop clin ica l proteinuria. When only those patients w ith microalbuminuria at 
the sta rt of the study were considered, almost all had developed proteinuria at the 
follow-up (Mogensen & Christensen 1984; V iberti et al. 1982). A large survey of 
IDDM subjects by Steno group (Borch-Johnsen et al. 1985) showed that the 
development o f proteinuria was a major life-threatening complication, as more 
than 80% of these subjects died, compared w ith less than 25% w ithout proteinuria.
1:15:3 Development of Kidney Changes
The healthy kidney acts as an extremely good f i l te r  system. The nephron is 
the functional unit in the kidney, f iltra tio n  taking place in the glomerulus. This is 
made up of a small tu ft  of capillaries surrounded by the epithelial cells o f the 
Bowman’s capsule. The mesangial cells form a supporting network fo r the 
capillaries and are involved in basement membrane turnover. This membrane is 
made up largely o f glycoproteins, one o f the major ones being negatively charged 
sialoglycoproteins.
The passage o f molecules through the filtra tio n  barrier o f the glomerulus 
depends on shape, size and e lectrica l charge (Aronoff et al. 1981). Studies using 
neutral dextran molecules have shown that up to a radius of 2nm, there is no 
restriction to filtra tio n , but above that, measurable restriction occurs up to a 
radius of 4.2nm, beyond which there is complete restriction (Brenner et al. 1978). 
Albumin has a radius of 3.6nm and so could, in theory, pass freely through the 
glomerular filtra tio n  barrier i f  filtra tio n  rate was based on size alone. Studies 
using uncharged dextran molecules, and negatively charged dextran sulphate 
molecules have demonstrated that the filtra tio n  of negatively charged molecules is 
retarded in comparison w ith uncharged molecules. This is thought to be due to the
negatively charged glycoproteins in the glomerular basement membrane (Brenner 
et al. 1978). Changes in both structure and composition of the glomerular capillary 
wall have been detected w ithin a few years of the onset o f IDDM, including 
progressive thickening of the glomerular basement membrane and reduction of the 
negatively charged sialoglycoprotein content (Friedman et al. 1983). Despite these 
early changes, the filtra tio n  properties of the glomerular capillary wall in a 
diabetic subject may remain quite normal fo r several years. A normal or slightly 
elevated rate of glomerular filtra tio n  occurs. Selectivity fo r neutral dextran 
macromolecules remains unchanged and leakage of large plasma proteins into the 
urine is negligible (Mogensen 1971a). However a fte r a number o f years there are 
important changes in the membrane properties of the glomerular capillary wall, 
w ith concomitant lowering of GFR and the development w ith in  the glomerular 
membrane of a small number of large pores which allow large plasma proteins to 
pass through.
Osterby et al. (1983) have studied glomerular basement membrane changes 
throughout the development o f c lin ica l nephropathy. During the early stages, up to 
five years duration of diabetes, there is considerable thickening of the glomerular 
basement membrane, developing to a 100% increase in membrane thickness when 
clin ica l nephropathy has been diagnosed. The causes of the early increase in GFR 
have s till not been determined. The role of the increase in kidney volume and by 
implication glomerular filtra tio n  surface area, in the elevation of GFR has been 
investigated by Wiseman & V iberti (1983). They found a positive correlation 
between GFR and kidney volume in those diabetic patients w ith raised GFR, but no 
correlation in non-diabetic subjects dr those diabetic subjects w ith normal GFR. 
They concluded that an increased kidney volume was necessary fo r the 
development of elevated GFR, but would not cause the elevation of GFR.
One model of the development o f albuminuria suggests that the observed 
increases in mesangial volume and capillary basement membrane thickness leads to 
a decrease in the available glomerular f iltra tio n  surface, which occurs unevenly, so 
that a compensatory increase occurs in those nephrons which have been spared. 
This results in an increase in the single nephron glomerular flow and trans-capillary 
hydraulic pressure, causing a loss of the se lectiv ity function of the glomerulus 
leading to increased protein excretion (Mauer et al. 1983). This hypothesis is in 
agreement w ith c lin ica l observations (Mogensen 1982; Parving et al. 1983), but i t  
implies that clin ica l nephropathy only develops in patients who have advanced 
glomerulosclerosis. More recent studies have, however, shown that thickening of 
the glomerular basement membrane and mesangial expansion have been found in 
patients w ith long-standing diabetes who had no proteinuria (Thomsen et al. 1984).
Deckert and co-workers (1984) compared kidney biopsies from diabetics w ith 
no sign of clin ica l nephropathy w ith diabetics w ith early c lin ica l nephropathy, and 
found no difference in the amount of mesangial tissue or the area o f open 
capillaries between the two groups. They concluded that the development of 
albuminuria was not due to these morphological changes alone, and suggested that 
a change occurs in the glomerular basement membrane that is not linked w ith  the 
basement membrane thickening or glomerular haemodynamics. This in itia ting  
change might be a reduction of the negative charge of the glomerular filtra tio n  
barrier, causing a lowering o f the charge selective properties o f the glomerulus.
Haemodynamic factors such as renal plasma flow (Mogensen 1971b) and 
increased hydraulic pressure are most likely to contribute to the elevation o f GFR 
(Mogensen et al. 1981), but whether or not these are more im portant than the 
morphologic alterations is s till unknown.
The increased levels of albuminuria are known to be glomerular in origin in 
the early stages, as normal tubular function has been demonstrated by the presence 
o f normal levels of urinary f32-microglobin (Viberti et al. 1982a). Tubular 
proteinuria is characterised by large increases in $2-microglobin (molecular weight 
11,800 daltons, radius 1.6nm) and indicates loss of the reabsorptive capacity of the 
tubules, found in nephropathy.
The relative urinary concentrations of albumin and immunoglobulin (IgG) a 
larger and essentially neutral molecule (molecular weight 160,000 daltons, radius 
5.5nm) change as the level o f microalbuminuria increase. A t low excretion rates 
the ratio is the same as in a non-diabetic subject, indicating that the se lectiv ity  o f 
the pores for molecular size and charge is unaltered. However, as the levels o f 
microalbuminuria rises, the level o f urinary IgG does not rise at the same rate, 
indicating that pore size is unchanged, but that the membrane has lost some o f its 
charge se lectiv ity. As albumin is a polyanionic molecule, its increased filtra tio n  
may be due to a loss of the fixed negative charge on the glomerular membrane 
(Viberti & Keen 1984). In advanced nephropathy size selectiv ity is also lost (V iberti 
et al. 1983).
Recent cytochemical studies (Vernier et al. 1986) demonstrated the presence 
o f anionic sites in the normal human kidney, and a decrease in the number o f these 
sites w ith increasing albumin excretion.
The effects o f glucagon and growth hormone on glomerular hyperfiltra tion  
have been investigated by Wiseman et al. (1985). They found that diabetic subjects 
with raised GFR had sim ilar plasma concentration of glucagon and growth hormone 
when compared w ith diabetic subjects w ith normal GFR.
Detailed studies in the streptozotocin-diabetic ra t have helped to identify a 
number o f biochemical abnormalities implicated in the accumulation o f glomerular 
basement membrane and its increased permeability (Cohen 1986b). Three major 
mechanisms have been described which link hyperglycaemia w ith tissue damage. 
The firs t involves changes in glomerular basement membrane collagen synthesis 
and turnover. In vivo studies have demonstrated increased collagen synthesis 
associated w ith diabetes and decreased turnover, which may contribute to the 
accumulation o f the glomerular basement membrane. The second mechanism 
involves increased non-enzymatic glycosylation of collagen, as described earlier. 
Excess glycosylation o f basement membrane collagen may interfere  w ith  normal 
cross-link formation and may promote the formation of abnormal cross-links, 
possibly via the condensation reaction of two e -amino bound glucose molecules 
(Brownlee et al 1984). Increased levels of glycosylated proteins have been found in 
renal biopsies taken from diabetic patients w ith nephropathy (Miura et al. 1985) 
supports this hypothesis. Finally, changes in the polyol pathway, resulting in the 
intracellu lar accumulation of sorbitol, have also been implicated (Cohen 1986a).
Structural data have recently been obtained from kidney biopsy m ateria l 
from young, long-term diabetics w ith signs o f kidney dysfunction. Osterby and co- 
workers (1986) studied biopsy material from patients showing a range of severity of 
microalbuminuria through to c lin ica l nephropathy. The long-term diabetic samples 
demonstrated thickening of the peripheral basement membrane, increased 
mesangial volume and mesangial basement membrane-like material as a fraction  of 
the tu ft volume, when compared with short-term  diabetic samples. Duration of 
diabetes was found to correlate positively w ith these structural changes.
A marked glomerular hypertrophy was found in the long-term diabetics, 
greater than that found in the early hyperfiltra tion  stage. This hypertrophy in
long-term diabetics may be due to compensatory mechanisms in the open glomeruli 
when a certain number of glomerular tu fts  have become occluded and ceased 
functioning. With increasing duration of diabetes, a decrease of to ta l peripheral 
capillary wall surface was found which correlates w ith GFR. Glomerular closure 
may be the most important event in the later stages of diabetic glomerulopathy.
Horlyck et al. (1986) showed that the phenomenon of glomerular occlusion 
occurs in clusters and is not randomly distributed throughout the renal cortex. 
When advanced glomerulopathy has developed, compensatory mechanisms take 
place in an attem pt to retain glomerular function. Studies have shown clear-cut 
relationships between structure and function in relation to the changes in GFR; the 
early elevation and later decline closely fo llow  the to ta l f iltra tio n  surface area 
(Steffes et al. 1986).
Despite these recent advances, more information is s till needed on the 
complex interactions between the morphologic lesions leading to glomerular 
sclerosis and the clin ical manifestations of advanced nephropathy, hypertension, 
fa lling GFR and proteinuria.
1:16 Factors Which May A ffec t Microalbuminuria
1:16:1 Blood Pressure and Microalbuminuria.
I t  has been known for several years that raised blood pressure, or
hypertension, is associated w ith elevated albumin excretion (Parving et al. 1974). 
The albumin excretion rate in patients treated effective ly fo r hypertension was 
found to be significantly lower (w ithin the normal range) than that in patients w ith 
untreated hypertension. Mogensen (1976) demonstrated that antihypertensive
treatment reduced albumin excretion in long-term diabetic patients w ith  
proteinuria. The trans-capillary escape rate was found to be higher in diabetic 
subjects w ith hypertension than normotensive diabetics (O'Hare et al. 1983). These 
workers showed that hypertension elevated the trans-capillary escape rate 
independently o f other factors, such as poor metabolic control and
microangiopathy. Blood pressure correlated strongly w ith AER, and hypertension 
was shown to characterise those patients at risk o f developing proteinuria
(Wiseman et al. 1984). Hasslacher et al. (1985) confirmed these findings but 
concluded that metabolic control determines the early course of nephropathy, 
while blood pressure is more important in the later stages.
The e ffec t o f anti-hypertensive treatment on albumin excretion rate was 
investigated in IDDM patients w ith microalbuminuria, or incipient nephropathy, 
(Hommel et al. 1986) and clin ica l nephropathy (Parving et al. 1985). The patients 
w ith microalbuminuria had lowered AER during acute blood pressure reduction, 
which strongly suggests that haemodynamic factors are im portant in the 
development of microalbuminuria. The enhanced albumin excretion in long-term  
IDDMs was also shown to be pressure dependent. A simple explanation may be that 
reducing arteria l blood pressure in turn reduces glomerular capillary pressure.
I t  is well documented that hyperfiltra tion and hyperfusion are frequently 
present in IDDM patients w ithout c lin ica l microangiopathy (Christiansen et al. 
1981). GFR was w ithin the normal range in the majority of patients w ith 
microalbuminuria (Wiseman et al. 1984), however single nephron GFR may be 
elevated as a result o f a reduction in the number of functioning glomeruli.
Long-term antihypertensive treatm ent can reduce albuminuria and prevent 
the decline in GFR in patients w ith microalbuminuria (Christensen A Mogensen 
1986), which confirms the findings o f the other acute studies o f antihypertensive 
therapy. A ll o f these studies support the suggestion that elevated trans-glomerular 
hydrostatic pressure and increased transglomerular protein passage are im portant 
factors in the development and progression of diabetic glomerulopathy (V iberti 
1983). The results support the conclusions of Hommel and co-workers (1986) that 
early treatm ent w ith antihypertensives may be able to retard the development of 
microangiopathy. This would prevent the enhanced loss of proteins through, and 
their deposition in, the walls o f the microvasculature, tha t are so frequently found 
in diabetic individuals.
1:16:2 Metabolic Control and Microalbuminuria
Prospective studies (Viberti et al. 1982a; Parving et al. 1982) have shown 
that certain rates of AER above the normal range, but fa lling short o f c lin ica l 
proteinuria, in IDDM patients are highly predictive of la ter proteinuria. However, 
these studies were not designed to discover the factors responsible fo r the 
microalbuminuria. Several reports have suggested a relationship between 
glycaemia and urinary albumin excretion in man (Viberti et al. 1979; V iberti a t al. 
1981; Parving et al. 1976). A detailed study by Wiseman et al. (1984) in which 
blood pressure and glycaemic control were compared between IDDM subjects w ith
varying degrees of microalbuminuria. The groups with higher levels of 
microalbuminuria had significantly higher GHb values and blood pressure. Similar 
relationships between glycaemic control and AER have been confirmed (Rowe et 
al. 1984; Taylor et al. 1986) and Young and co-workers (Young et al. 1986) also 
demonstrated an association between glycaemic control and a number o f neural and 
microvascular complications.
None o f these studies, however, indicate whether or not the glycaemic 
control has a causal role in the development and progression of microalbuminuria. 
V iberti et al. (1983) investigated the e ffec t of rigorous blood glucose control on 
AER and showed that microalbuminuria could be reversed, but c lin ica l proteinuria 
remained unchanged. Short-term improvements in . glycaemic control, using 
continuous subcutaneous insulin infusion (CSII) can substantially reduce 
microalbuminuria in as l i t t le  as three days (Viberti et al. 1979), three weeks 
(V iberti et al. 1981) or four weeks (M iltenyi et al. 1983). Christiansen & Parving
(1984) were unable to reduce albuminuria in a group of IDDM subjects w ith c lin ica l 
nephropathy and normal GFR a fte r five days o f s tr ic t metabolic control. Improved 
metabolic control fo r one week in short-term IDDM subjects lowered cardiac 
output, forearm blood flow and blood pressure significantly (Mathiesen et al. 1983). 
These results indicate that poor metabolic control o f short duration is associated 
with elevated cardiac output and peripheral blood flow, which can be corrected by 
short-term improved glycaemic control. The early stages of microalbuminuria can 
be reversed, but clin ical nephropathy cannot be improved by s tr ic t glycaemic 
control (Christiansen & Parving 1984).
Longer-term correction of metabolic control has also been investigaed 
using CSII. Raskin et al. (1983) demonstrated that two years o f meticulous control
significantly reduced the width o f skeletal muscle capillary basement membrane. 
One year o f CSII reduced GFR to normal but did not reduce kidney volume in IDDM 
patients w ith elevated GFR and enlarged kidneys (Wiseman et al. 1985). A close 
correlation has previously been demonstrated between these two variables 
(Christiansen et al. 1981) but Wiseman and co-workers were unable to explain fu lly  
why GFR should respond to improvement of glycaemic control but kidney volume 
did not.
There are conflicting results on the effects of long-term s tr ic t glycaemic 
control. V iberti et al. (1983) showed no improvement in AER in a group o f patients 
w ith clin ica l nephropathy, whereas the Kroc Collaborative Study Group (1984) 
demonstrated a reduction in mean AER in a group o f patients w ith a range o f levels 
o f in itia l AER. Most recently studies investigating improved glycaemic control fo r 
one year or two years, using CSII in a group o f patients w ith m icroalbuminuria 
resulted in reduced kidney size (Feldt-Rasmussen et al. 1986) but no change in AER 
or GFR in either study (Hanssen et al. 1986).
The e ffec t o f improved glycaemic control is therefore equivocal and may 
depend on the level o f albuminuria and disease duration when the improvement is 
in itia ted (Feldt-Rasmussen e ta l.  1986).
1:16:3 Protein Intake and Microalbuminuria
The e ffec t o f lowering the dietary protein intake on GFR and AER has 
recently been investigated (Viberti et al. 1986). This study suggests that diabetics 
w ith raised GFR respond to changes in glycaemia and protein intake in a d iffe ren t 
way from diabetics with normal GFR or non-diabetic subjects. D ietary protein 
appears to be a strong and independent influence on GFR, as reduction in protein
intake led to a prompt fa ll in GFR in all subjects w ith microalbuminuria. Lowering 
the protein intake (77 - 22 g/day reduced to 47 - 7 g/day) in a group o f patients 
w ith c lin ical nephropathy, however, reduced AER but le f t  GFR unchanged (Bending 
et al. 1986a). Blood glucose and blood pressure were the same fo r the groups on a 
normal or reduced protein intake.
The reasons for these heterogeneous responses to reduced protein intake 
are s till unclear but improvements to the deterioration of glomerular charge and 
size selectiv ity that occur in diabetes has been suggested (Bending et al. 1986b).
1:17 Research Objectives
The aims of the research work were:
(i) To develop a sensitive immunoassay system suitable for measuring Gly-Alb 
in plasma and urine
(ii) To apply the technique in a study of the e ffec t of glycosylation on the 
elim ination o f albumin
and
(iii)  To investigate the application of GHb measurement as a screening tool fo r 
diabetes mellitus.
CHAPTER 2
DEVELOPMENT OF AN ASSAY SYSTEM FOR GLYCOSYLATED ALBUMIN
2:1 Introduction to Enzyme Immunoassay
Since the development of the competitive binding assay based on the use of 
radiolabelled ligands, as published by Yalow & Berson (1959), this technique has 
found widespread and diversified application. The specific ity o f radioimmunoassay 
(RIA) led to increasing acceptance and use of this methodological principle, the
sensitivity o f the method allows accurate quantitative measurements of many
125biologically active compounds. However, I-labelled reagents have a re la tive ly 
short she lf-life , costly equipment is required fo r obtaining the results, and special 
safety measures have to be observed in the handling and disposal o f the reagents.
As a result o f these disadvantages, alternatives to the radio-label have been 
sought. Several possibilities have been investigated, including chemiluminescent 
and bioluminescent groups (Velan & Halmann 1978; Pazzagli et al. 1981), 
fluorescent groups (Soini & Hemmila 1979), metal atoms and stable free radicals 
(Schall & Tenoso 1981). These alternatives have all been found to have the ir own 
advantages and disadvantages, as discussed by Schall & Tenoso (1981) who 
concluded that no one label or method could be singled out as the best replacement 
fo r RIA.
Enzymes have also been used as labels in immunoassay systems, and the ir 
applications and lim itations discussed in detail (Scharpe et al. 1976; Wisdom 1976; 
and Blake & Gould 1984). Enzyme immunoassay (EIA) has provided the most 
convenient means by which the sensitivity and specific ity of RIA can be more 
generally applied. The reagents used are already employed in many laboratories
and are thus not associated w ith special hazards. The enzymes used as labels are 
cheap and may be stored for several months at 4°C. Once conjugated to an 
antibody or antigen, the labelled substance also has a she lf-life  o f up to a year.
There are several d iffe rent types of EIA, among the most frequently used 
being enzyme linked immunosorbent assays (ELISA), in which the separation step o f 
the assay is fac ilita ted  by the attachment of either a soluble antigen or antibody to 
an insoluble solid phase. These techniques were pioneered by Van Weemen & 
Schuurs (1971) and Engvall & Pearlman (1972) and can be sub-divided into three 
main types: competitive ELISA, sandwich ELISA for antibody or antigen, and
double antibody ELISA. The methods used in the development o f the assay in this 
study were all adaptions o f a sandwich ELISA technique.
2:1:1 Sandwich ELISA for Antibody or Antigen
In the assay for antibody, antigen is adsorbed onto the solid phase. The 
sample containing the antibody to be measured is added, followed by the addition 
o f a second antibody specific to the antibody to be measured. The amount o f 
enzyme activ ity  bound to the solid phase is therefore proportional to the amount of 
antibody present in the sample.
In the assay for antigen, antibody is attached to the solid phase in excess 
followed by incubation w ith the sample containing antigen to be measured. A fte r 
washing, enzyme-labelled antibody is added to the solid phase. The enzyme 
activ ity  bound to the solid phase is proportional to the quantity o f antigen present 
in the sample (Clark & Adams 1977). This technique is only suitable fo r antigens 
w ith more than one antigenic determinant.
2:1:2 Practical Aspects
There have been other adaptions to the basic ELISA system and new assays 
are being developed all the time, but the principles and practical aspects involved 
remain the same. Either antibody or antigen is adsorbed on to a solid phase. This 
is a passive process, the speed o f which can be varied by altering the temperature 
o f this f irs t incubation. A fte r adsorption has taken place, the excess, unbound 
antibody or antigen, must be removed by thorough washing.
The solid phase can come in a variety of forms; particles of cellulose, 
polyacrylamide, silicone rubber, cross-linked dextrans, m icrocrystalline glass and 
plastic have all been used. These, however, all need a centrifugation step which 
complicates the assay.
Tubes, beads, discs and microplates have been tested, removing the need fo r 
centrifugation and o f these, microplates have been found to be the most 
convenient. They can be made of polystyrene, polyvinyl or polypropylene. 
Microplates made o f polyvinyl have been found to adsorb immunoglobulin more 
thoroughly than the polystyrene plates (Voller et al. 1979).
The coating incubation is often carried out at an alkaline pH and the 
concentration o f protein which gives satisfactory coating is normally between 1 
and lOpg/m l (Voller e t al. 1979). This process can be carried out overnight at 4°C 
or more quickly, in one to three hours, at 20-25°C.
Once the solid phase has been coated, excess coating reagent must be 
removed and the microplate washed. Phosphate buffered saline (PBS) containing a 
detergent such as Tween 20, and a protein, such as gelatin is used. These additives 
block the remaining free binding sites and so reduce the background which is 
caused by the non-specific uptake of protein.
2:1:3 Conjugates and Conjugation Techniques
A wide variety o f enzymes have been used for labelling antibodies and 
antigens, including alkaline phosphatase, horseradish peroxidase, 3-D- 
galactosidase, glucose oxidase, urease, acetyl cholinesterase and glucoamylase. 
The firs t two have been most widely used because of their low cost and ease of 
conjugation. The reactive groups necessary fo r the linkage are shown in Table 2:1.
2 :l:3 :i Glutaraldehyde Method
The simplest way to link antibody or antigen to an enzyme is by using a cross- 
linking agent such as glutaraldehyde (Avrameas 1969). The cross-linking can be 
achieved in a one-step procedure where enzyme, antibody and glutaraldehyde are 
mixed together. A free N h^ group is needed on each molecule to be conjugated, 
and the glutaraldehyde group forms a bridge between the two. As the method is so 
non-specific, i t  yields a heterogeneous conjugate m ixture, resulting in a loss o f 
antibody activ ity .
In order to prevent this polymerisation, a two-step method was developed fo r 
use w ith horseradish peroxidase. This method is based on the principle that 
glutaraldehyde in excess reacts w ith one or two free amino groups present in
Table 2:1 Summary of the Reactive Groups Required for
Conjugation Reactions on Enzyme and Antibody
i GLUTARALDEHYDE -n h 2 + n h 2-
ii PERIODATE 2 vicinal -OH groups on sugar + NH2~
ii i  DIMALEIMIDE -RSH + -RSH
iv MALEIMIDE ESTER -NH2 + -RSH
v MIXED ANHYDRIDE -COOH.+ -NH,
vi CARBODIIMIDE -COOH + -NH,
peroxidase, via only one o f its two active aldehyde radicals. A fte r removal of the 
excess glutaraldehyde, the enzyme, now w ith active aldehyde groups, is reacted 
w ith added antigen or antibody in a second reaction (Avrameas & Ternyck 1971).
Glutaraldehyde reacts mainly through the e -amino groups of lysine residues 
under m ild conditions and a Schiff base is formed w ith a five-carbon spacer group.
2 :l:3 :ii Periodate Method
This method is most suitable fo r peroxidase as i t  requires carbohydrate 
groups on the enzyme, o f which peroxidase has eight per molecule (Butler & Chen 
1967). The carbohydrate chains are oxidised by sodium periodate to form aldehyde 
groups which react w ith e -amino groups on the antibody to form  a Schiff base. 
The cross linkages are then stabilised by reduction w ith sodium tetraborate.
2 :l:3 :iii Dimaleimide Method
Dimaleimide derivatives react w ith th io l groups of proteins. The most 
commonly used o f these reagents is N, N'-O-phenylenedimaleimide, which has been 
used with (3-galactosidase (Kato et al. 1975). The protein to be conjugated, fo r 
example, immunoglobulin G (IgG), is f irs t treated w ith 2-mercaptoethylamine to 
reduce the sulphide bond in the hinge of IgG to th io l groups, w ithout a ffecting the 
other disulphide bonds in the molecule. The treated IgG is then combined w ith 
dimaleimide and conjugated w ith f3-galactosidase (Ishikawa et al. 1980).
2 :l:3 :iv  Maleimide Ester Method
This was firs t carried out by Kitigawa in 1976 who coupled 8-galactosidase to 
insulin. Maleimide groups are introduced into the protein to be conjugated by
reacting with the N-hydroxysuccinamide ester o f maleimidobenzoic acid, w ith the 
amino groups of the insulin. A fte r removal o f the excess reagent, 3-galactosidase 
is added and thioester bonds form between the th io l groups of the enzyme and the 
double bond o f the maleimide moiety.
2 :l:3 :v Mixed Anhydride Method
This is a simple, d irect procedure that does not require the preparation and 
isolation o f an active derivative (Erlanger et al. 1957). The protein to be 
conjugated is converted to an acid anhydride at a low temperature in organic 
solvents, which is then mixed w ith the pre-cooled enzymes and the anhydride 
groups react w ith the amino groups of the enzyme.
2 :l:3 :v i Carbodiimide Method
This method has been widely used, most commonly to couple peroxidase or 
alkaline phosphatase to antigens or antibodies in water-soluble conditions. 
Carbodiimides activate carboxyl groups present in proteins, w ith subsequent 
coupling o f these groups to free amino groups and the formation o f a peptide bond 
(Goodfriend et al. 1964).
2:2 Introduction to Methods
The conjugation methods used, and the ELISA systems investigated, w ill be 
described firs t, followed by the results of the various methods. Discussion of the 
results w ill follow, w ith reasons for the various systems that were tested. The aim 
was to develop a specific assay for G ly-Alb using the a ffin ity  ligand amino phenyl 
boronic acid in place of a specific antibody for G ly-Alb, as glycosylated proteins 
have been shown to be poor immunogens (Brownlee et al. 1984). As APBA is 
specific fo r glycosylated proteins (Mallia et al. 1981) i t  was thought that a specific 
sensitive assay system could be developed fo r G ly-Alb w ithout raising antisera to 
the molecule.
2:2:1 Materials
Poly-L-lysine, glyceraldehyde, horseradish peroxidase, alkaline phosphatase 
(from ca lf intestine), amino phenyl boronic acid, 0-phenylenediamine, Tween 20, 
gelatin, p-nitrophenylphosphate, and human albumin were all obtained from  Sigma 
Chemical Company, Poole, Dorset. Sephacryl was obtained from Pharmacia Fine 
Chemicals, Uppsala, Sweden. Sheep anti-human albumin (Batch HP/S/641 III A) was 
obtained from Guildhay Antisera, University o f Surrey, Guildford. Glyco-Gel B was 
obtained from Pierce and Warriner (UK) L im ited, Chester, UK.
A ll other chemicals were obtained from British Drug Houses Chemicals 
Lim ited, Poole, Dorset.
The microplate washer was obtained from T itertek, Flow Laboratories 
Lim ited, Scotland, UK. The MR600 microplate reader and PVC microplates were 
obtained from Dynatech Laboratories Lim ited, Billingshurst, West Sussex, UK.
2:2:2 Methods
Preparation of Reagents
The following buffers were prepared for use in the methods.
Buffer A: 0.05M sodium carbonate bicarbonate buffer, pH 9.6, containing 1.59g
Na2CC>2 and 2.93g NaHCO^ per litre .
Buffer B: 0.01M phosphate buffered saline, pH 7.4, containing 8g NaCl, 0.2g
KH2PO^, 2.9g NaH2PO^, 0.2g KC1 and 0.5ml Tween 20 per litre .
Buffer C: Buffer B containing 0.5g gelatin per litre .
Buffer D: Substrate buffer fo r alkaline phosphatase, containing 97ml
diethanolamine, lOOmg MgCl2.6H20 , 0.2g NaN^ per litre . Adjusted 
to pH 9.8 w ith  1M HCI. lm g p-nitrophenylphosphate added.
Buffer E: Substrate buffer fo r horseradish peroxidase, 0.2M phosphate, pH 6.0,
containing 24.3ml 0.1M c itr ic  acid (1.92g/100ml) and 25.7ml 0.2M 
phosphate (2.84g Na2HPO^/100ml) 40mg 0-phenylenediamine and 
40pl 30% H20 2 added immediately prior to use.
Buffer F: 0.2M sodium carbonate, pH 9.5, containing 21.2g Na2CO^ and 16.8g
NaH 0^ per litre .
Buffer G: Im M  sodium acetate buffer, pH 4.4, containing 25mls sodium acetate
solution (8.2g/l) and 75mls acetic acid (6.0g/l).
Buffer H: 0.01M sodium carbonate, pH 9.5, containing 1.06g Na2CO^ and 0.84g
NaHCO^ per litre .
Buffer I: 250mM ammonium acetate buffer, pH 8.5, containg 19.27g
ammonium acetate, 10.16g magnesium carbonate per litre . Adjusted 
to pH 8.5 w ith IN  NaOH.
Buffer J: 200mM sorbitol buffer, containing 36.4g sorbitol, 14.6g sodium
ethylenediaminetetracetic acid (EDTA) and 12.11g Tris 
hydroxymethyl aminomethane (TRIS) per litre .
2:3 Preparation of Conjugates
2:3:1 Conjugation of Poly-L-Lysine to Aminophenylboronic Acid
lOmg poly-L-lysine was dissolved in 5ml of degassed H20  and 5mg of 
aminophenylboronic acid (APBA) were added. Following the method of Avrameas 
(1969), lOOpl o f glutaraldehyde were added and the m ixture stirred at room 
temperature for three hours. The m ixture was dialysed against Buffer A overnight.
A 20ml column o f Sephacrjl (2cm diameter) was washed w ith Buffer A, and 
the dialysed conjugate mixture allowed to flow through the gel. 1ml fractions were 
collected in glass tubes and each fraction scanned using a Cary Scanning 
Spectrophotometer (Varian Associates L im ited, Walton-On Thames, UK), in quartz 
cuvettes between 220nm and 330nm.
The fractions containing conjugate, detected by a change in peak wavelength 
from the characteristic peak wavelengths o f PLL and APBA were pooled (Figure 
2:1) dialyzed against d istilled water, freeze-dried and stored at 4°C.
2:3:2 Partia l Purification of Sheep Anti-Human Albumin IgG and its Conjugation to 
Horseradish Peroxidase
The immunoglobulin was firs t partia lly  purified by salt precip itation 
(Campbell et al. 1970). Saturated ammonium sulphate was prepared by dissolving 
solid ammonium sulphate in water heated to 50°C and then cooled. 50ml sheep 
anti-human albumin antisera were placed in a beaker and 25ml saturated 
ammonium sulphate added dropwise w ith continual stirring. This avoided localised 
high concentrations of ammonium sulphate leading to non-specific precip itation o f 
protein.
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A fte r stirring for 30 minutes at room temperature, the m ixture was 
centrifuged at 1500g (in a Beckman 06 centrifuge) fo r 20 minutes. The supernatant 
was discarded and the pellet resuspended in saturated ammonium sulphate and then 
centrifuged.
The pellet was resuspended in saturated ammonium sulphate and centrifuged. 
The IgG pellet was resuspended in d istilled h^O and then dialyzed extensively 
against distilled H^O. The sheep anti-human albumin IgG was then freeze-dried 
and stored at 4°C.
The Conjugation Reaction
4mg horseradish peroxidase were dissolved in 1ml distilled water (Wilson & 
Nakane 1978) and 200|jl freshly made 0.1M sodium periodate added and the 
m ixture stirred fo r 20 minutes at room temperature. The m ixture was dialyzed 
against Buffer G at 4°C.
20pl Buffer F were added and immediately 8mg of the partia lly  purified, 
freeze-dried anti-human albumin IgG dissolved in l.O m l Buffer H added. The 
mixture was stirred for two hours at room temperature. lOOpl fresh sodium 
borohydride solution (4mg/ml in h^O) were added, and allowed to stand fo r two 
hours at 4°C. An equal volume (to the conjugate mixture) o f saturated ammonium 
sulphate was added and the m ixture centrifuged at 1500g fo r 20 minutes. The 
precipitate was washed tw ice using 50% saturated ammonium sulphate.
Finally, the pellet was dissolved in Buffer B and dialyzed extensively against 
Buffer B. An equal volume (to the dialysate) o f glycerol was added fo r storage at
2:3:3 Conjugation of Alkaline Phosphatase to APBA
0.1ml alkaline phosphatase solution (containing 4nmol o f enzyme) was added 
to 0.5ml o f 1,4 dioxan in a stoppered glass tube (Erlanger 1957). 28.5pl (119pmol) 
of tri-n-butylam ine were added, mixed, and the tube cooled in a water and ice 
m ixture to 10°C. 7.8pl (59.7pmol) o f isobutylchlorocarbonate were added quickly 
and mixed, the reaction m ixture was then le f t  to stand for 30 minutes at 10°C. 
1.48pg (8nmol) o f APBA were dissolved in 2ml deionised water and cooled to 4°C, 3 
minutes before the end o f the 30 minutes incubation of the enzyme m ixture, 0.1ml 
NaOH was added to the stirred, cooled APBA solution. With fast s tirring  2mi 1,4 
dioxan were added dropwise to the APBA solution, followed by the enzyme 
m ixture. The fina l solution was stirred at 4°C for four hours. The conjugate of 
alkaline phosphatase linked to APBA was dialyzed extensively against d istilled 
water and stored at 4°C.
2:3:4 Conjugation of APBA to Horseradish Peroxidase (a)
Bethell et al. (1979) described a method by which APBA could be attached to 
an activated Sepharose (Pharmacia) m atrix. This technique was investigated as a 
possible mode o f attachment o f APBA to an enzyme.
2mg horseradish peroxidase were dissolved in 0.2ml w ith stirring . lOOpg 1,1- 
carbonyl diimidazole were added and stirred fo r 30 minutes at room temperature. 
60pg of APBA in 0.1ml 1M sodium carbonate solution was added and stirred 
overnight at 4°C. The conjugate was dialyzed extensively against Buffer I and 
stored at 4°C.
2:3:5 Conjugation of APBA to Horseradish Peroxidase
An adaption of the periodate method of Wilson & Nakane (1978) was 
attempted, substituting APBA fo r the antibody.
4mg o f horseradish peroxidase was dissolved in 1ml of d istilled water, 0.2ml 
freshly made 0.1M sodium periodate was added and the m ixture stirred fo r 20 
minutes at room temperature. The m ixture was dialyzed against Buffer G 
overnight. 20pl o f Buffer F was added, followed immediately by lm g  of APBA in 
Buffer H.
The reaction m ixture was stirred fo r two hours at room temperature, 0.1ml 
of freshly prepared sodium borohydride solution (4mg/ml) was added and the 
conjugate m ixture allowed to stand fo r two hours at 4°C. A fte r extensive dialysis 
against Buffer B the conjugate was stored at 4°C.
2:4 Measurement o f Glycosylation of Anti-Hum an Albumin 
IgG, Horseradish Peroxidase and Alkaline Phosphatase
5pg of IgG was dissolved in distilled water, and the a ffin ity  separation 
method described in detail in the next Chapter in Section 3:3 carried out. The 
absorbance at 595nm o f both fractions was found and percentage glycosylation 
calculated, lm g of horseradish peroxidase (or alkaline phosphatase) was taken and 
dissolved in 10ml o f d istilled water. A 1:3 dilution o f this stock enzyme solution 
was made. 0.2ml of the diluted enzyme solution was applied to a 1ml a ffin ity  gel 
column w ith 150pl o f a 1:20 dilution of haemolysate, to reduce non-specific binding 
of the enzyme to the gel. 7mi o f Buffer I was added, followed by 3ml of Buffer J.
The wash and elution fractions were assessed fo r enzyme activ ity  in the 
following manner:
2ml o f Buffer I, 0.2mls of the wash or elution fraction, and 0.5ml substrate solution 
(Buffer D or E) were mixed together in a quartz cuvette. The reaction at 37°C 
estimated by change in absorbance, (i.e. rate of colour production) was found fo r 
wash and elution fractions using a reaction rate spectrophotometer calculator 
attached to the Cecil 292. The following calculation was carried out to estimate 
the percentage glycosylation of both enzymes.
Percentage glycosylation = AA elution fraction x3
 ------------------------    :--- X100
of the enzyme AA wash fraction  x8 + AA elution fraction  x 3
AA = change in absorbance in 1 minute
2:5 ELISA Methods
2:5:1 ELISA using Poly-L-Lysine and APBA Conjugate
Freeze-dried PLL-APBA conjugate was diluted in Buffer A at concentrations 
o f l-20 |jg /m l. Microplate wells were filled  in trip lica te  w ith 200pl o f these 
conjugate dilutions. The plate was washed w ith Buffer A to remove excess 
conjugate. Glycosylated albumin previously separated from human albumin, as 
described in Section 3:3, was diluted in Buffer I to give a concentration of 
500pg/ml. 150pl were added to each well. A row of wells were incubated with 
Buffer I containing no albumin. Horseradish peroxidase anti-albumin IgG 
conjugate, as prepared in Section 2:3:2 was diluted in Buffer B. Doubling dilutions 
from 1:200 to 1:6400 were made and 150pl of the dilutions added to the wells in 
duplicate fo r each coating concentration and incubated at room temperature for 
three hours. The plates were washed three times w ith Buffer B and the wells 
aspirated. 150pl o f substrate Buffer E were added to each well and incubated at 
37°C fo r 30 minutes. 50pl o f 2.5M were added to stop the reaction. The
absorbances of the wells were read at 490nm.
The method was repeated w ith the following modifications: (a) fu rther 
dilution o f the coating conjugate; (b) addition o f either gelatin or bovine 
gammaglobulin to Buffer I at 0.1%; (c) addition of gelatin or bovine gammaglobulin 
to Buffer B at 0.1%.
2:5:2 ELISA using APBA-Alkaline Phosphatase Conjugate
Anti-human albumin IgG was dissolved in Buffer A (25Mg/ml) and incubated 
for 3 hours at room temperature in polyvinyl chloride (PVC) microplates.
The wells were washed with Buffer C, human albumin was dissolved in Buffer 
C (5-100pg/ml) and 200 pi aliquots o f each concentration incubated in the wells fo r 
two hours at room temperature. Ten wells were incubated w ith Buffer C 
containing no human albumin. The wells were washed w ith Buffer C, and then 
200pl aliquots o f APBA-alkaline phosphatase conjugate in Buffer C at doubling 
dilutions (1:500 -1:4000) incubated in duplicate, overnight at 4°C. The wells were 
washed w ith Buffer C, and 200pl o f Buffer D were incubated fo r 30 minutes at 
37°C. The reaction was stopped w ith the addition of 50pl o f 3M NaOH, and the 
absorbance measured at 405nm.
The method was repeated using the following modifications: (a) lower and 
higher coating concentrations and (b) lower and higher APBA-alkaline phosphatase 
conjugate concentrations.
2:5:3 ELISA using the APBA-horseradish Peroxidase Conjugate, Prepared in 
Section 2:3:4
Anti-human albumin IgG was dissolved in Buffer A  (10, 50 and lOOpg/ml), 
and 150pl aliquots incubated in m icroplate wells overnight at 4°G. The wells were 
washed with Buffer C. Glycosylated albumin, diluted in Buffer C (20-500pg/ml) 
was added to the wells and incubated at room temperature for two hours. The 
wells were washed in Buffer C, then the APBA-horseradish peroxidase (prepared in 
Section 2:3:4) was added to the wells, diluted in Buffer C (1:100, 1:200 and 1:500 
dilutions). The enzyme conjugate was incubated at room temperature fo r three 
hours. A fte r washing w ith Buffer C, substrate was added to the wells (Buffer E) and 
incubated at 37°C for 30 minutes. 50pl o f 2.5M H^SO^ were added to the wells to 
stop the reaction and the absorbances read at 490nm.
The method was repeated to investigate several modifications: (a) further 
dilution o f glycosylated albumin, (b) fu rthe r dilution o f enzyme conjugate, (c) the 
coating incubation was carried out fo r three hours at 4°C and (d) addition of an 
extra incubation step. This consisted of incubating normal sheep antiserum in 
Buffer C (500 and 100ug/ml) in the wells at 37°C for two hours a fte r excess coating 
conjugate had been washed o ff  (Ishikawa e ta l. 1980).
2:5:4 ELISA using APBA-horseradish Peroxidase Conjugate Prepared in Section 
2:3:5
Microplate wells were coated with anti-albumin IgG diluted in Buffer A 
(10, 50 and lOOpg/m) and incubated at 4°C for three hours, or overnight. The wells 
were washed w ith Buffer C, and then incubated w ith glycosylated albumin diluted 
in Buffer C (50-500Mg/ml), the microplates were then incubated at room 
temperature for two hours. A fte r washing w ith Buffer C, peroxidase labelled 
APBA (as prepared in Section 2:3:5) was added to the wells. 1:200 and 1:500 
dilutions were made in Buffer C, and incubated fo r three hours at room 
temperature or overnight at 4°C. The m icroplate wells were washed w ith  Buffer 
C, and substrate (Buffer E) added. 50jjl o f 2.5M h^SO^ were added to each well 
and the absorbances read at 490nm. An extra step was also tested in this system. 
Sheep antiserum IgG was diluted in Buffer C (100 and 500pg/ml) and incubated fo r 
two hours at 27°C a fte r the plates had been coated and washed.
2:6 Results
2:6:1 Percentage Glycosylation of IgG, Horseradish Peroxidase and Alkaline 
Phosphatase
Anti-human albumin IgG was shown to be 6.8% glycosylated; horseradish 
peroxidase, approximately 5% glycosylated, and alkaline phosphatase, less than 
0.1% glycosylated.
2:6:2 APBA Poly-L-Lysine Conjugate Coated Plates
The absorbance values fo r this system showed no response to altering the 
concentration of any o f the components of the method. Even the lowest 
concentrations o f coating conjugate, antigen and antibody-enzyme conjugate 
combined yielded absorbance values greater than 2 (o ff the scale of the m icroplate 
reader). . The addition o f gelatin or bovine ^-globulin did not cause any 
improvement in the results and absorbances of greater than 2 were s till produced.
2:6:3 APBA Alkaline Phosphatase Conjugate Used as Enzyme Label
No standard curves could be constructed from the results of this method, as 
changes in conjugate or coating concentrations resulted in only minor changes in 
absorbance values. Thus, approximately horizontal lines would have resulted. A 
higher coating concentration of conjugate in the wells resulted in lower absorbance 
values.
2:6:4 APBA Horseradish Peroxidase Conjugate Used as Enzyme Label (Produced by 
the Method o f Bethel et al. 1979)
The blank wells, i.e. wells to which no antigen (albumin) had been added, gave 
higher absorbance values than the test wells. D iffe ren t tim ing schemes and
combinations o f concentrations o f the various constituents of the technique did not 
improve the results suffic iently.
As there was no significant response to d iffe rent coating concentrations and 
dilutions o f antigen no standard curves could be plotted. The non-specific binding 
or testJbackground ratio  was between 60% and 90%.
2:6:5 APBA Horseradish Peroxidase Conjugate Used as Enzyme Label (Produced by 
the Method o f Wilson & Nakane 1978)
This method also had background (NSB) absorbance values greater than 70% 
of the test values. The addition of the normal sheep IgG incubation step in the 
wells did not reduce the non-specific binding below 70%.
2:7 Discussion
The APBA moiety was investigated as a substitute for specific antibodies to 
glycosylated albumin, as the Gly-Alb molecule is so l it t le  d iffe rent from the 
albumin molecule (Shaklai et al. 1984), the production of specific antisera would be 
d iff ic u lt. Javid and co-workers (1978) raised antisera to human GHb, but they were 
not suffic iently  avid antibodies, and the method is not now in use. The Amadori 
adduct has been shown to be a poor immunogen, producing low titres  of low a ffin ity  
antibodies (Brownlee e ta l.  1984).
As APBA had been shown to be specific fo r glycosylated proteins (Mallia et 
al. 1981), i t  was decided to develop an ELISA system using this molecule instead of 
one of the antibody components normally used in such a system, and to immobilise 
i t  onto a solid phase. Poly-L-lysine was used as a linking agent as i t  is frequently 
used to attach other molecules to plastics and glass. I t  was also thought tha t this 
conjugation would involve the amine group of the APBA molecule, thus leaving the 
cis-diol groups free to bind to G ly-Alb. The results indicate that this did not take 
place. The Gly-Alb molecule may have in itia lly  bound to the APBA, but been 
subsequently removed during the washing steps. The N5B was high, suggesting that 
the G ly-Alb, and subsequently IgG/HRP conjugate, were binding to the walls o f the 
wells also. The addition of gelatin and bovine -globulin did not lower this NSB of 
antigen and enzyme-labelled conjugate su ffic iently .
APBA was then substituted for the antibody linked to the enzyme. This 
method in itia lly  showed more promise, as there was some response to alterations in 
conjugate and antigen concentration. However, the greater absorbance values 
obtained with lower coating concentrations indicate that the non-specific
attachment of the enzyme conjugate to the wells was greater than the specific 
attachment to albumin bound to the IgG coated on the wells. Alkaline phosphatase 
was used in itia lly , but as this system yielded no acceptable standard curve, 
horseradish peroxidase was tested instead.
Two conjugation methods were used to attach APBA to horseradish 
peroxidase. The firs t was an adaption of the method used by Bethell et al. (1978), 
to attach APBA to an agarose gel, the second was sim ilar to that o f Wilson & 
Nakane (1978) using the carbohydrate shell o f horseradish peroxidase, oxidised to 
form aldehyde groups, to react w ith the amino group of the APBA molecule 
forming a covalent coupling.
The ELISA systems utiliz ing these enzyme-labelled APBA conjugates were 
not successful, yielding very high background binding (60-90%), and no standard 
curve.
When all these variations had been tested i t  became apparent that the 
a ffin ity  o f APBA fo r G ly-Alb was weaker than tha t of the other components in the 
system for (a) the plastic well, or (b) the un-bound IgG coating the well. The 
a ffin ity  of APBA fo r G ly-Alb may be lower than that o f a specific antibody fo r an 
antigen, and as a result, the bond between APBA and Gly-Alb may be broken during 
the washing steps. These observations led to the conclusion that APBA was not a 
suitable substitute for a specific antisera to G ly-Alb.
However, specific antibodies to human albumin were freely available, and so 
an ELISA fo r albumin preceeded by a separation of G ly-Alb from non-Gly-Alb was 
considered. The original intention had been to develop a single step assay using 
APBA, but a two-step assay was fina lly attempted as the simpler method was 
unsuccessful.
2 : 8 Development o f an ELISA for Albumin
A straightforward sandwich-type ELISA (Voller et ai. 1979) was chosen as 
being the most suitable system (Mohamed et al. 1984).
PVC microplates were chosen fo r use as they are more suitable fo r binding 
antibody (Voller et ai. 1979). The diagram (Figure 2:2) illustrates the stages 
involved in the ELISA system. In itia lly , a range of concentrations fo r each 
component was tested to investigate which combination yielded the most suitable 
standard curve and lowest NSB.
2:8:1 Method
Sheep anti-human albumin IgG (as prepared in Section 2:3:2) was dissolved in 
Buffer A to give concentrations from 0.1 to lOOug/ml. The coating incubation was 
carried out overnight at 4°C or for three hours at 4°C. The wells were washed 
three times w ith Buffer C, containing gelatin to prevent non-specific binding to the 
wells (Sauer et al. 1981), and aspirated. Then human albumin was dissolved in 
Buffer C at concentrations from 0.19 to lOOOpg/ml added to the wells, and 
incubated in a moist environment at room temperature. A fte r the wells were 
washed three times w ith Buffer C. Horseradish peroxidase-labelled anti-human 
albumin IgG (as prepared in Section 2:3:2) at concentrations from 1:100 to 1:5000 in 
Buffer C was added and incubated fo r three hours at room temperature or 
overnight at 4°C. A fte r three further washes with Buffer C, 150pl o f substrate 
(Buffer E) were incubated in the wells fo r 30 minutes at 37°C in the dark. Then 
50|jl o f 2.5M were added to stop the reaction, and the absorbances read at
490nm.
Figure 2:2 Scheme to show the stages in the albumin 
ELISA method
2
-ANTI ALBUMIN 
(EXCESS) + ALBUMIN
-ANTI ALB-ALBUMIN PEROXIDASE LABELLED
ANTI ALB
-ANTI ALB-ALBUMIN-PEROXIDASE LABELLED
ANTI ALB
Albumin in the sample or standard was mixed with 
excess solid-phase albumin antibodies. After 
washing of the solid phase, peroxidase-labelled 
anti-albumin was added. After further washing, 
the label which remained bound was measured by 
the addition of substrate and measurement of the 
colour produced.
2:8:2 Results
2:8:3 Coating Concentration
The graph (Figure 2:3) shows a comparison between three concentrations of 
anti-human albumin IgG used fo r coating.
lp g /m l does not give the maximum possible absorbance values when the 
enzyme-labelled IgG was used at 1:1000 dilution. 4|jg/m l showed a plateau e ffec t, 
and could only be used w ith concentrations of antigen up to ?&\iqln\\. However, 
when 2pg/m l coating was used, changes in antigen concentration could be detected 
up to lOOpg/ml.
2:8:4 Timing of the Coating Step
2gg/m l o f anti-human albumin in Buffer A was incubated in the wells 
overnight at 4°C or for d iffe rent times at 4°C. Figure 2:4 shows the standard 
curves for these conditions. The enzyme IgG conjugate was used at a dilution of 
1:1000 throughout.
2:8:5 Timing of the Sample Incubation
Figure 2:5 shows a comparison between four d ifferent sample incubation 
times, from 30 minutes to two hours, all at 4°C. A ll other parameters were 
identical, a coating concentration of 2pg/ml IgG, fo r three hours at 4°C. The 
enzyme-labelled conjugate was used at a dilution o f 1:1000 throughout.
The incubation for two hours resulted in the most suitable standard range and 
sensitivity.
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Figure 2:3 Graph to show the effect of different coating
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Figure 2:5 Graph to illustrate the effect of
sample incubation time
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Three hours at 4°C was shown to be the most suitable incubation time for 
this system, as the standard curve shows most sensitivity over the widest range of 
antigen concentrations.
2:8:6 Timing of the Enzyme-Label Incubation
Figure 2:6 shows the effects o f time and temperature on the enzyme-label 
incubation. The overnight incubation at 4°C gave the most suitable standard 
curve, w ith the best standard range and sensitivity.
2:8:7 Summary of the Optimised ELISA for Albumin
200|jg o f anti-human albumin IgG (2jjg/m l) in Buffer A were incubated in 
each well for three hours at 4°C. Then the wells were washed three times in 
Buffer C. 200pl diluted test sample, or standard (0.19-50ug/ml) or sample added to 
wells and incubated fo r two hours at 4°C. Again, the wells were washed three 
times in Buffer C. Anti-human albumin IgG-horseradish peroxidase conjugate was 
diluted 1:1000 in Buffer C, and 200pl were added to each well and incubated 
overnight at 4°C. The wells were washed three times in Buffer C followed by the 
addition of 150|jl o f substrate (Buffer E) and the microplate incubated fo r 30 
minutes at 37°C. The reaction was stopped by the addition o f 30jj1 o f 2.5M F^SO^ 
and the absorbances were read at 490nm. Figure 2:7 shows a typical standard 
curve obtained from this assay method.
Figure 2:6 Graph to show the effect of enzyme 
conjugate incubation time on the 
albumin ELISA standard curve'
• = overnight at 4°C 
▲ = 3 hours at room temperature
0 = 2  hours at room temperature 
■ = 1 hour at room temperature
1.0
0.2
10
Albumin(mg/I)
AB
SO
RB
AN
CE
FiQure 2 : 7  Graph to show a sample s t a n d a r d .curve 
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2:9 Validation o f the Assay 
2:9:1 Loading of the Column
Plasma samples were taken and diluted before, before and a fter, or only a fter 
separation by a ffin ity  chromatography. A diabetic plasma sample was diluted 1:20 
in distilled water. 150gl o f this dilution was applied to each of two Glyco-Gel B 
a ffin ity  columns. The diluted plasma was taken and diluted further, 1:50 and 
1:2500, giving fina l dilutions of 1:1000 and 1:50000, respectively, in d istilled water. 
150pl o f each o f these dilutions was applied to two a ffin ity  columns. The a ffin ity  
separation was carried out as in Section 3:3. and further dilutions made as 
summarised in Table 2:2. The ELISA method was then used to measure albumin 
concentration, each sample being measured in trip lica te , and the percentage 
glycosylation calculated as before.
The results show that the dilution step taking place before or a fte r separation 
does not a ffec t the percentage glycosylation. I t  has been shown by Gould et al. 
(1984) that a protein load of up to 2mg per 1ml column of gel does not a ffec t the 
percentage glycosylated. Therefore, the loading used in this experiment was below 
this value.
2:9:2 Precision
'W ithin-run1 precision was estimated by measuring one sample th ir ty  times, on 
one m icro titre  plate. The 'between-run' precision was estimated measuring two 
samples in trip lica te  each time the assay was run.
The results can be seen in Table 2:3. The quality control data can be seen in 
Table 2:4.
Table 2:2
Table Showing the E ffec t o f Loading D iffe ren t Quantities 
o f Albumin onto the A ff in ity  Column on the Subsequent ELISA Results
D ilution
Before
Separation
D ilution
A fte r
Separation
Glycosylated 
Albumin % SD
1:20 1:2500
1:20 x 1:50 1:50
1:20 x 1:2500 None
6.1
6.0
6.2
0.15
0.14
0.15
Table 2:3
Table Showing ^Between-Run* and 'W ithin-Run1 Precision Data
Mean
albumin
concentration
mg/1
10.80
SD
Between run 
n = 72
0.81
CV%
7.5
Within run 
n = 30
10.65 0.47 4.5
Table 2:4 Table Showing the Quality Control Data
Mean Value SD CV%
mg albumin/1
5.5
CNjit 0.28 5.1
25.8 (n = 72) 1.62 6.3
40.5 (n=72) 1.98 6.9
Table 2:5 Table Demonstrating The Parallelism o f the ELISA Method
D ilution Value from graph Calculated
albumin/ml albumin conc. mg/1
mg/1
1:125 9.02 1.12
1:250 4.58 1.14
1:500 2.32 1.16
1:1000 1.19 1.19
Mean 1.15
SD 0.025
CV 2.17%
2:9:3 Parallelism
A urine sample was taken and diluted 1:123, 1:230, 1:500 and 1:1000. Each 
dilution was aliquoted and its albumin concentration measured in tr ip lica te . The 
results are shown in Table 2:5.
2:9:4 Sensitivity
Uncoated wells were used in the assay to estimate non-specific binding and 
were incubated w ith Buffer C, containing no albumin. The absorbance value (mean 
o f ten samples) was 0.06.
Coated wells were incubated w ith Buffer C containing no albumin, giving a 
zero standard value. The zero standard values for ten consecutive assays and the 
corresponding values fo r a concentration of 0.2 pg/m l were found to be 
significantly d iffe rent (P<0.0001).
2:9:5 Recovery of Albumin
A known concentration of albumin was measured in the ELISA method (2.5, 10 
and 20pg/ml) in trip lica te . The results are shown in Table 2:6.
2:9:6 Comparison with an Electrophoretic Method
As described in Section 3:3 albumin was measured in all the urine samples by 
an electrophoretic method. The correlation between the two methods was 0.99 
(see Figure 2:8) (P<0.0001).
Table 2:6 Table Showing the Percentage Recovery 
of Albumin in the ELISA Method
Sample
conc.
Albumin
pg/ml
2.5
10
20
Measured 
albumin 
conc. mg/1
2.6
9.5
19.2
Recovery
%
104
95
96
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Figure 2:8 Graph to show the relationship between 
the ELISA method and an electrophoretic 
method.
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2:9:7 Cross-Reactivity
A standard curve was measured and a simultaneous set of standards measured 
which had lpg /m i human IgG added to each standard. Figure 2:9 shows that no 
cross-reactivity could be detected.
2:9:8 Discussion
As human albumin is a large molecule (molecular weight = 69,000), i t  is very 
like ly that i t  has several sites at which i t  can bind to its specific antibody. This 
has been shown to be true, as a sensitive, specific assay has been developed where 
only one specific antiserum has been used. Other workers (Mohamed et al. 1984) 
also developed a comparable assay, which made use of this capacity o f the albumin 
molecule, confirming the va lid ity of the hypothesis. The sensitivity o f the assay 
was 0.2 mg/1, and the standard range 0.39 - 100 mg/1, and in te r- and intra-assay 
variation were both below 8%. The parallelism of the assay was good, and recovery 
of albumin from the samples was approximately 100%.
When the albumin ELISA had been developed and optimized, the addition o f a 
preceding step was made, to make possible the measurement o f glycosylated 
albumin. The development o f the complete assay is described in the follow ing 
section.
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Figure 2:9 Graph to show cross-reactivity with IgG
• = albumin standard curve
o = albumin standard curve with IgG (lug/ml)
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2:10 Measurement of Glycosylated Albumin Using A ffin ity  
Chromatography Followed by ELISA for Albumin
2:10:1 Method fo r Urine Samples
0.5 ml o f urine (which had been frozen, thawed and centrifuged) were applied 
to a 1 ml column of a ffin ity  gel, and the method followed as in Section 3:3. The 
wash and elution fractions were kept separately, 100 pi o f each were made up to 5 
ml w ith Buffer C (i.e., 1:50 dilution) so that the samples were in the correct buffer 
fo r the ELISA and at a suitable concentration. 200 pi aliquots, in trip lica te , o f 
both diluted wash and elution fractions were pipetted into coated wells and albumin 
concentration measured as in Section 2:7:7.
Total albumin was measured in each urine sample, diluted 1:250 and 1:500 
before use in the assay. I f  this result was out of the range of the standard curve, 
the sample was diluted further and the assay repeated.
Urine contains high concentrations o f urea, which can in te rfe re  w ith  
immunological reactions at high levels. Thus, in a urine assay, i t  was necessary to 
assess the e ffec t o f urea on the system. Figure 2:10 shows that concentrations o f 
urea up to 1M added to the antigen incubation had no e ffec t on the standard curve.
2:10:2 Method o f Plasma Samples
20 pi o f plasma were mixed w ith 400 pi o f d istilled water and mixed well. 
100 pi was taken and made up to 5 mis w ith distilled water. 150 pi of this second 
dilution was applied to a 1 ml a ffin ity  gel column and the separation carried out as 
in Section 3:3. In this case, however, the wash fraction was made up to 24 ml w ith  
wash buffer a fter separation.
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Figure 2:10 Graph to show the effect of the 
addition of urea on the albumin 
ELISA standard curve
•= albumin standard curve
a = albumin standard curve . + 0.2M urea
■ = albumin standard curve + 1.0M urea
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100 pi o f wash and elution fraction were taken and diluted 1:50 w ith Buffer 
C. 200 pi aliquots of these dilutions were pipetted, in trip lica te , into coated 
m icroplate wells, and the albumin assay carried out as in Section 2:7:7.
Nine standards, a zero standard and three quality control samples were 
measured in trip lica te  on each microplate. The absorbances were read on a 
Dynatech plate reader, and the values transferred to a BBC computer. A spline 
function programme computed a standard curve and calculated the test values.
Using these results, precentage glycosylation was calculated using the 
following equation:
Percentage = Alb E x 100%
Gly-Alb (Alb W x 8) + Alb E
where Alb E = concentration of albumin in the elution fraction 
and Alb W = concentration o f albumin in the wash fraction
2:11 Discussion
An ELISA system, preceded by the a ffin ity  chromatography separation, was 
developed to measure Gly-Alb in urine and plasma of diabetic and non-diabetic 
subjects. When this assay was developed, low concentrations of urinary albumin 
were usually measured by radioimmunoassay (Keen & Chlouverakis 1963). Other 
groups developed sim ilar radioimmunoassay methods (Miles et a l. 1970; Woo et a l. 
1978) w ith improved sensitivity. A double antibody ELISA was developed by 
Fielding and co-workers (1983) w ith greater sensitivity, but a more complex 
technique. Thus, a simple assay, suffic iently  sensitive for the measurement o f 
urinary G ly-Alb in non-diabetics was not available when this study began.
The assay system developed was simple to perform, w ith  good sensitivity and 
precision, and was specific fo r G ly-Alb w ithout the need to raise antisera to G ly- 
Alb. The addition o f the a ffin ity  separation step to the ELISA system yielded an 
ideal combination o f specific ity fo r G ly-Alb from the a ffin ity  method, and 
sensitivity from the ELISA technique.
Since the development of this technique other sensitive albumin assays have 
been developed, some using ELISA systems (Mohamed et al. 1984; Chesham et al. 
1986) or an immunoenzymometric method (Townsend 1986) or fluorimmunoassay 
and radioimmunoassay (Silver et al. 1986).
A method using the a ffin ity  separation method followed by rocket 
Immunoelectrophoresis has been developed (John & Jones 1985), but this was only 
used for plasma samples. Ghiggheri et al. (1984) have also recently published a 
method for the measurement o f G ly-Alb in urine but their technique is very
complex, using a ffin ity  purification of the albumin (on Sepharose gel) followed by 
isoelectrofocusing, staining and then bidimensional immunoelectrophoresis to check 
for purity, followed by the TBA co lorim etric assay for G ly-Alb.
In conclusion, a useful method was developed to allow the measurement of 
G ly-Alb at very low levels, such as those found in non-diabetics, to enable 
comparison between normal and raised albumin excretion.
CHAPTER 3
INVESTIGATION OF PROTEINS AND GLYCOSYLATED  
PROTEINS IN  DIABETES M ELUTUS
3:1 Introduction to the Study
I t  has been suggested that increased capillary permeability to large molecular 
weight plasma proteins is an early phenomenon in diabetes mellitus, that is 
demonstrable before tissue and organ fa ilure develop (Keen & V iberti 1981). I t  
appears to be related to the metabolic disturbance o f diabetes and associated 
haemodynamic changes and affects the microvasculature of the kidney, eye, brain 
and many peripheral tissues, such as muscle and skin. Correction o f 
hyperglycaemia and increased blood flow may reduce and normalise the excessive 
leakage (Kroc 1984).
The development o f nephropathy, w ith the detection of increased protein 
excretion in the urine as a predictor of the condition, has been studied in depth by 
groups such as V iberti et al. (1982a), the Kroc Collaborative Study Group (1984), 
Mogensen & Christensen (1984).
Keen & Chlouverakis (1963) developed a sensitive radioimmunoassay fo r 
human urinary albumin on the assumption that sequential measurement o f urinary 
albumin excretion rates would provide a sensitive detector o f the onset and rate of 
development o f diabetic kidney disease. The two main sources o f proteinuria are 
glomerular and tubular lesions (Sweny 1983). Glomerular proteinuria results from  
increased permeability o f the glomerulus, resulting in albumin being present in the 
urine at higher levels than normal. In this case the proteinuria is described as 
’selective', i f  the urine contains larger molecules, i t  is termed 'non-selective1.
Tubular proteinuria occurs in a variety o f conditions in which there is tubular 
damage or in te rs titia l inflammation. Proteins of tubular origin are predominantly 
a- and 3-globulins of low molecular weight.
Peterson et al. (1969) compared the excretion of 32-microglobulin, albumin 
and to ta l protein between healthy subjects and subjects w ith clin ica l proteinuria. 
They showed that the predominant part of plasma proteins in urine arises from a 
process o f glomerular f iltra tio n  followed by tubular reabsorption. The glomerular 
permeability of a substance is greatly dependent on its size. Arturson & Wallenius 
(1964) demonstrated that in normal subjects dextran fractions o f molecular weight 
below 10,000 - 15,000 pass across the glomerular membrane at the same rate as 
water. Larger dextran molecules are retained in increasing degrees w ith increasing 
molecular weight. Dextran of molecular weight 50,000 is practica lly excluded 
from the glomerular f iltra te . These studies using dextran, however, take no 
account o f the charge on plasma protein molecules as dextran is uncharged, or of 
the shape o f the protein, since dextran is not a globular molecule.
The findings o f Peterson et al. (1969) suggest that patients w ith glomerular 
proteinuria, i.e., increased permeability to re la tive ly large plasma proteins, had a 
normal or only slightly increased excretion of 32~micr°g l°bulin , despite a greatly 
increased excretion o f albumin and to ta l protein. A close correlation was found 
between serum levels o f 32"microgiobulin and creatinine, also found in patients 
w ith chronic renal fa ilure (Bernier et al. 1968) which suggests that $2" 
microglobulin is handled by the glomerular membrane in a sim ilar way to 
creatinine. V iberti et al. (1983) reported elevated albumin excretion in insulin- 
dependent diabetes, w ith normal levels o f 32"microgl°bulin excretion. They 
concluded that tubular function was normal in patients w ithout c lin ica l proteinuria 
(negative Aibustix < 200mg/l).
These studies suggest that albumin measurement may be of use in the early 
detection o f nephropathy in diabetes. As described earlier, a lower molecular 
weight protein measured in the urine allows more specific diagnosis of glomerular 
proteinuria.
a^-microglobulin, a low molecular weight glycoprotein, has been detected in 
human serum and urine, and found to be present in much higher concentrations in 
subjects w ith renal fa ilure (Takagi et al. 1980b). Increased serum levels were also 
found in subjects w ith a variety o f benign and malignant diseases (Takagi et al. 
1980a). a^-microglobulin has a molecular weight o f 25,000-30,000 and contains 
approximately 20% carbohydrate (Takagi et al. 1981). A comparison o f a^- 
microglobulin concentrations to the behaviour of other indicators of renal tubular 
disorders, B2‘ micro9l°b L,lin, retinol-binding protein and n-acetyl-3-D - 
glucosaminidase (all w ith a molecular weight o f <33,000) has been made by Yu et 
al. (1983). They reported elevated concentrations o f a^-microglobulin in patients 
w ith tubular dysfunction and found that this glycoprotein was also more stable at 
low pH than the other parameters. Urinary a^-microglobulin measurement has 
been used to assess nephrotoxicity in subjects exposed to substances such as 
cadmium (Nogawa et al. 1984; Kido et al. 1985) and found to be a useful indicator 
of early renal tubular damage. As plasma proteins of low molecular weight are 
elim inated mainly in the kidney by reabsorption and catabolism in the tubules, 
raised serum and urinary levels indicate tubular disorders. C lin ica lly, the levels of 
serum and urinary a^-microglobulin are elevated in patients w ith reduced GFR 
and/or tubular disorders. Kusano et al. (1985) showed that increased levels of 
serum and urinary a-^-microglobulin were found in subjects w ith a range o f renal 
diseases and confirmed that its measurement was indeed indicative of early tubular 
damage.
The measurement of this protein was therefore chosen and the assay carried 
out as in Section3:3.
A number of investigations have been made using urine collections over 24 
hours (Kroc Collaborative Study Group 1984) and overnight, (V iberti at al. 1984). 
The Steno group (Mathiesen et al. 1984) compared 1-2 hour urine collections w ith 
24-hour samples and found high correlations between the two collection 
procedures. V iberti et al. (1984) concluded that the overnight collection was the 
most convenient fo r the patients and found that the albumin excretion rates were 
reproducible. As albumin excretion increases a fte r exercise (V iberti et al. 1984) 
random urine samples taken from patients at an outpatient c lin ic may give falsely 
high levels.
A protein creatinine index, defined as m illigrams of albumin per m illim ole of 
creatinine, was suggested by Shaw et al. (1983) as a means o f allowing the 
substitution o f a random urine sample to replace the 24 hour collection. However, 
Wilkin et al. (1983) found that this index also increased a fte r exercise, and that 
there was no significant correlation between random protein creatinine index and 
24-hour albumin excretion.
I t  has been suggested that glycosylated albumin may have a role in the 
pathogenesis o f diabetic nephropathy (Ghiggeri et al. 1984), associated w ith  an 
altered renal handling of the glycosylated molecule. As a result of these findings, 
it  was decided to measure plasma and urinary glycosylated albumin levels in the 
subjects and controls.
Glomerular filtra tio n  rate has been shown to be linked w ith diabetic 
nephropathy (Mauer et al. 1983) and so GFR was estimated using creatinine 
clearance measurements (Campbell et al. 1984).
A study was set up to investigate the prevalence of microalbuminuria among 
the population of a diabetic c lin ic. A study was also made on the short and long­
term metabolic control o f the subjects, and an investigation o f the relationships 
between GHb, plasma and urinary G ly-Alb and AER. A t each clin ic attendance a 
random blood glucose measurement was made on each diabetic patient, but GHb 
was only routinely measured on those subjects who were under 33 years old. 
Urinary glucose and to ta l protein are measured at each v is it using D iastix and 
Albustix (Ames Division, Miles Laboratories L im ited, Stoke Poges, UK) 
respectively. I t  was decided that a more detailed study o f proteinuria, metabolic 
control, duration o f diabetes and prevalence of retinopathy would provide useful 
information on the diabetic population of the c lin ic.
3:2 Subjects
A ll the diabetic subjects who took part in this study regularly attended the 
diabetic c lin ic at St Luke’s Hospital, Guildford, Surrey. Names and addresses o f all 
patients due to attend the clin ic three weeks in advance were obtained, and all 
those between the ages of sixteen and s ix ty-five  were sent a le tte r w ith a reply slip 
enclosed (see Appendix 1).
Each individual who replied was contacted by telephone and the details o f the 
samples required were explained. A litre  plastic bottle for the urine sample, was 
sent w ith the covering le tte r (see Appendix 2) giving further details. The subjects 
were asked to carry out a timed overnight urine collection which they were to 
bring w ith them to their next clin ic appointment. An additional 7.5ml blood sample 
was also taken at the clin ic.
The subjects were recruited from ten consecutive clinics and the recru itm ent 
rate can be seen in Table 3:1. There was a f i f t y  percent success rate, which 
enabled a large number o f subjects to be recruited in a short time.
Age-matched controls were recruited from the University s ta ff and 
postgraduate students by personal approach. A to ta l o f th irty-n ine non-diabetic 
subjects also took part in the study.
Table 3:2 shows a complete lis t of the details obtained on all the diabetic 
individuals.
These details and the values from the assays carried out as described in 
Section 3:3:2 were all analysed using the University o f Surrey Prime computer and 
the Minitab sta tis tica l package.
Table 3:1 Recruitment of Diabetic Subjects
Number of 
Subjects
Diabetic patients sent in itia l le tte r 166
Replies received 91
Subjects recruited by le tte r 83
Subjects recruited by interview 2
Total 85
Table 3:2 Additional Information Obtained on the Diabetic Subjects 
Age
Body Weight 
Duration of Diabetes 
Type of Diabetes 
Treatment
Concomitant Drug Therapy 
Retinopathy
3:3 M aterials
Glycosylated haemoglobin quality control materials were obtained from 
Ortho Diagnostics Systems Inc, New Jersey, USA.
Glucose and creatinine standards and reagents fo r use w ith the Cobas Bio 
Centrifugal Analyser (Roche Diagnostics, Welwyn Garden C ity , Herts, UK) were 
also obtained from Roche Diagnostics. The protein reagent was obtained from  Bio- 
Rad, California, USA. The rabbit anti-a^-m icroglobulin antiserum was obtained 
from Dako Lim ited, High Wycombe, Bucks, UK. Sheep anti-human albumin 
antiserum was obtained from Guildhay Antisera, Division of C lin ical Biochemistry, 
University of Surrey, Guildford, Surrey, UK. A ll other chemicals were obtained 
from British Drug Houses L im ited, Poole, Dorset. A ll chemicals were o f the 
highest grade or purity available.
3:3:1 Methods
3:3:1:1 A ff in ity  Method for the Measurement o f GHb
Chromatography columns containing 1ml of the a ffin ity  gel were prepared. 
The gel was equilibrated by washing through w ith 5ml o f buffer I (as described in 
Section 2:2) 250mM ammonium acetate (wash) buffer at 20 - 1°C.
Erythrocytes were diluted 1:20 w ith distilled water, mixed thoroughly, and 
le ft to haemolyse fo r ten minutes.
lOOpl o f the haemoiysate, or lOOql o f the diluted quality control m ateria l 
were applied to the top of each column and allowed to soak in. 1ml o f wash buffer
was added and allowed to run into the gel. A further 7ml o f wash buffer were 
added, the eluates collected in a measuring cylinder, and the volume made up to 
15ml w ith wash buffer.
3ml o f Buffer J (as described in Section 2:2) 200mm sorbitol (elution) buffer 
at 20 -1°C were added to the gel and the eluate collected separately.
The absorbances of the two fractions were then read at 414nm in a CECIL 
292 spectrophotometer (Cecil Instruments Lim ited, M ilton, Cambridge) against the 
appropriate buffer blanks.
The percentage GHb was calculated from the following equation:
GHb% -  A elution x 100
A wash x 5 + A elution
where A elution = absorbance of the elution fraction at 414 nm 
where A w ash- absorbance o f the wash fraction at 414 nm
The between assay coeffic ient o f variation for this method was 1.8%.
3:3:1:2 Glucose Measurements in Plasma and Urine
Plasma and urinary glucose were determined using the Cobas Bio Centrifugal 
Analyser w ith the settings as described in Table 3:3. The method uses the 
hexokinase/glucose-6-phosphate dehydrogenase method (Schmidt 1961) w ith the 
production of NADPH from NADP in d irect proportion to the amount o f glucose 
present, as the end point. The glucose standards were made up in saturated 
benzoic acid and stored at 4°C. The standards were loaded onto the sample plate 
followed by the specimens, the reagent, obtained from Roche Diagnostics, was 
poured into the reagent well. Quantitation was by comparison of the absorbance 
change o f the unknowns versus the standards at 340nm, 5 minutes from the sta rt of 
the reaction.
3:3:1:3 Creatinine Measurement in Plasma
Creatinine was measured using the Jaffe reaction and based on the method of 
Varley (1969). The Cobas Bio centrifugal analyser was used w ith the settings as 
described in Table 3:4.
The reagent used was p icric acid (35mmol) and the diluent NaOH (0.32mol). 
The standards were made up in lOmM HCL.
The creatinine standards were loaded onto the sample plate followed by the 
specimens. Quantitation was by comparison of the absorbance change o f the 
unknown versus the standards at 500nm between 30 seconds and 2 minutes from  the 
start o f the reaction.
Table 3:3
L is t o f the Parameters Used for the Plasma Glucose
Assay as Carried Out on the Cobas Bio Analyser
1 Units mmol/1
2 Calculation factor 0
3 Standard 1 cone 0.5
4 Standard 2 cone 10
5 Standard 3 cone 20
6 L im it 22
7 Temperature (Deg C) 37.0
8 Type of analysis 5
9 Wavelength (nm) 340
10 Sample volume (pi) 5
11 D iluent volume (pi) 20
12 Reagent volume (pi) 150
13 Incubation time (sec) 0
14 Start reagent volume (pi) 0
15 Time of firs t reading (sec) .5
16 Time interval (sec) 300
17 Number of readings 2
18 Blanking mode 1
19 P rint-out mode 1
The standard values shown are those used fo r plasma glucose estimation. The 
following standards were used for urinary glucose estimation: 2.5, 5 and 10
mmol/1.
Table 3:4
L is t of the Parameters Used fo r the Plasma 
Creatinine Assay as Carried Out on the Cobas Bio Analyser
1 Units g/dl
2 Calculation factor 0
3 Standard 1 cone .5
4 Standard 2 cone 1.0
5 Standard 3 cone 2.0
6 L im it 15
7 Temperature (deg. C) 25.0
8 Type of analysis 4
9 Wavelength (nm) 520
10 Sample volume (pi) 20
11 Diluent volume (pi) 30
12 Reagent volume (pi) 150
13 Incubation time (secs) 10
14 Start reagent volume (pi) 0
15 Time of firs t reading (sec) 30.0
16 Time interval (sec) 120
17 Number of readings 2
18 Blanking mode 1
19 Printout mode 1
The following assays for urinary creatinine, to ta l protein, a^-m icroglobulin 
and albumin were carried out in the C linical Chemistry Department at St Luke's 
Hospital, Guildford, as part of a collaborative project. I t  was arranged to supply 
samples to both laboratories for separate research studies and also to assist in the 
validation o f the new ELISA technique.
3:3:1:4 Creatinine Measurement in Urine
The method was based on the Jaffe reaction of creatinine w ith alkaline p icric 
acid to yield a red/amber colour complex which can be read between 500nm and 
520nm. Although many compounds yield chromogenic complexes w ith  alkaline 
picrate a two-point method overcomes the interference.
P icric acid was mixed 2:1 w ith deionised water, 0.5M NaOH was mixed 1:1 
w ith diluted p icric acid to make the working solution. The sample volume was 
25pl, reagent volume, 200{jl and diluent volume 30pl. The assay was carried out 
using a C en trifi Chem 500 plus centrifugal analyser and P1000 sampler (Baker 
Instruments Lim ited, Surrey) at 30°C. Quantitation was by comparison o f the 
absorbance change o f the unknown versus the standards.
3:3:1:5 Measurement o f Urinary Total Protein
The urinary to ta l protein assay used the binding of Coomassie B rillian t Blue 
G-250 w ith protein to cause a sh ift in the absorption maximum of the dye from 
465nm to 495nm. This increase in absorbance was monitored at 495nm, The dye 
binding process was complete in approximately 2 minutes with good colour s tab ility  
fo r one hour (Bradford 1976).
Samples were diluted to contain lOpg to lOOpg protein in a volume up to 
lOOpl. 5ml Bio Rad protein reagent were added and the contents mixed thoroughly. 
The absorbance at 595nm was measured a fte r 2 minutes and before 1 hour against a 
reagent blank prepared from 0.1ml water and 5ml protein reagent. Standards, also 
supplied by Bio Rad Inc, were run in parallel and their values plotted against the 
corresponding absorbance to produce a standard curve. This was used to determine 
the protein content o f the unknown values.
3:3:1:6 Measurement o f Urinary g^-Microqlobulin
An exact volume of solution containing antigen was applied in an Agarose gel 
o f uniform thickness containing the anti-a^-m icroglobulin antiserum. An e lectric  
fie ld  induced migration o f antigen and antibody molecules, which react w ith  one 
another to form precipitation zones like ascending rockets. Unbound antigen 
w ithin the conical head migrated into the zone of antigen-antibody precipitate and 
redissolved the complexes in the front. The leading precipitate zone was displaced 
towards one of the electrodes at a rate decreasing w ith that of the disappearance 
of free antigen. The fina l position of the precipitation fron tie r o f each antigen at 
a given antibody concentration varied with the amount o f antigen applied (Laurell 
1966).
Anti-a^-m icroglobulin  antiserum was added to the agarose gel, and 10pl o f 
antigen-containing solution applied to holes cut in the gel. D ilutions o f the 
standard antigen obtained from Behringwerke (Hoechst UK L im ited, Hounslow, 
Middlesex) were used for calibration.
The electrophoresis was run with 10 volts/cm for 2-10 hours. The height of 
the various peaks formed was measured d irectly under dark-fie ld illum ination. The 
peak height corresonded to the distance found between peak and the centre of the 
application hole.
3:3:1:7 Measurement of Urinary Albumin
A sim ilar electrophoretic technique was used for measuring urinary albumin 
and was calibrated using a reference preparation of albumin (SP5-01) supplied by 
the Sheffield Protein Reference Unit.
3:3:2 Sample Collection
The subjects participating in the study brought the urine sample, which had 
been passed that morning, w ith them to the clin ic. 7.5ml of blood were taken; 5ml 
collected in lith ium  heparin tubes and 2.5ml in fluoride oxalate tubes.
The blood samples were centrifuged fo r 10 minutes at 1200 g and the plasma 
stored in four aliquots at -40°C. The red cells were stored separately at -40°C, 
and plasma from the fluoride oxalate tubes was also kept and stored at -40°C.
The volume of each urine sample was measured, and three plastic universal 
bottles were.each filled  (approximate volume 20mls), sodium azide was added as a 
preservative (0.1%), and stored at -40°C. One universal bottle was sent to St 
Luke's Hospital laboratory fo r overnight storage at 4°C prior to measurement.
3:4 Results
3:4:1 Parameters for Diabetic Subjects : Sex Differences *
Table 3:5 shows the data fo r the diabetic subjects (excluding those w ith 
proteinuria) sp lit into male and female groups. Only two of the parameters 
measured show a significant difference as calculated by the Mann-Whitney test. 
These are glomerular filtra tio n  rate (p<0.01) and body weight (p<0.001) where sex 
differences would be expected. Thus in future treatm ent o f the data, male and 
female subjects have been grouped together.
3:4:2 Age and Sex Comparison of Diabetic and Control Groups
The histogram, Figure 3:1 w ith the age distribution of diabetic and control 
groups shows that there was an age and sex matched control group fo r each group 
o f diabetic subjects.
3:4:3 Parameters fo r Diabetic Subjects : Disease Duration
The data for the diabetic subjects were sub-divided by duration o f 
diabetes, groups 1, 2 and 3 comprise, respectively, individuals diagnosed as diabetic 
less than ten, eleven to twenty and over twenty years prior to the study. The 
results can be seen in Appendix 3 and show no s ta tis tica lly  significant differences 
between the groups as measured by the Mann-Whitney test. However, non­
significant trends can be seen for the results o f urinary protein measurements, i.e. 
AER, urinary to ta l protein and urinary a^-m icroglobulin. Group 3 has the highest 
mean AER, whereas group 2 has the highest mean value for to ta l protein and group 
1 fo r a^-microglobulin. Group 3 consists entirely o f IDD subjects, whereas groups 
1 and 2 have lower proportions of IDD subjects.
Table 3:5
Diabetic Subjects : Male Compared with Female
MALE FEMALE
n 36 42
Albumin Excretion 8.9 (14.72) 5.64 (7.72)
rate pg/min
GFR (mls/min) 122.6 (66)(a) 86.8 (43.42)
Plasma Gly-Alb (%) 7.76 (4.43) 8.00(2.51)
GHb (%) 12.42 (3.85) 13.74 (3.31)
Urinary Gly-Alb (%) 9.27 (8.59) 10.19 (6.53)
Urinary a-l-M  (mg/1) 5.44 (4.88) 4.9 (7.86)
Urinary Total Protein (g/1) 84.1 (62.38) 88.8 (65.12)
Plasma Glucose (mmoi/1) 14.04 (6.52) 15.71(6.95)
Age (years) 44.1 (12.80) 40.1 (14.47)
Duration (years) 8.43 (9.12) 11.05 (9.01)
Weight (Kg) 76.8 (12.4)(b) 65.9 (15.2)
Urinary Glucose (mmol/1) 10.06 (7.88) 9.76 (9.08)
IDDM (%) 70% 66%
NIDDM (%) 30% 33%
A ll values shown are means w ith SD in parentheses
a represents p<0.01 
b represents p<0.001
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Figure 3:1 Age distribution of diabetic and control 
subjects
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3:4:4 Parameters for Diabetic Subjects : IDDM and NIDDM
The data for the diabetic subjects was divided into treatm ent groups, w ith an 
extra group comprising those IDDM patients whose duration o f diabetes fe ll w ithin 
1-13 years (mean + 2SD o f the duration of the NIDDM group). Body weight and age 
show significant differences (pCOOl) between IDDM and NIDDM groups, and the 
data can been seen in Appendix 4.
The same differences remain when the IDD group of shorter duration is 
compared w ith the NIDD group. The results for the other parameters, i.e. AER, 
urinary a^-microglobulin and to ta l protein and plasma and urinary glucose show 
differences between NIDD subjects and both the short duration and the complete 
IDD groups. Plasma and urinary GAlb and GHb show no significant differences.
Table 3:6 shows the p values fo r this data. Not a ll of the parameters show 
significant differences due to the great inter-individual variation.
3:4:3 Parameters fo r Diabetic and Control Subjects : Age Differences
The data fo r diabetic and non-diabetic subjects was divided into five ten year 
age bands. Where s ta tis tica lly  significant differences exist between diabetic and 
control groups compared as a whole as shown im Table 3:1, the difference remain 
when the groups are divided into the age ranges. AER, GHb, plasma GAlb, plasma 
and urine glucose, urinary a^-m icroglobulin and to ta l protein all show significant 
differences when the groups are sub-divided. Figures 3:2, 3:3 and 3:4 illus tra te  the 
most striking differences, fo r a-j-microglobulin, urinary to ta l protein and AER.
However, the 46-33 years old group o f both diabetic individuals show lower 
values for AER, GHb, urinary a^-m icroglobulin and to ta l protein, and plasma and 
urinary glucose levels than the age groups immediately younger and older.
3:4:6 Parameters fo r Diabetic and Control Subjects : Grouped by AER
Table 3:7 shows the data fo r the control group compared w ith the diabetic 
group sub-divided by AER. Group A, B and C comprise, respectively, subjects w ith 
an AER below lOpg/min, 10-lOOpg/min and greater than lOOug/min. When only 
the IDDM results were grouped in a sim ilar way only urinary to ta l protein showed a 
significant difference between groups A and C. These results can be seen in 
Appendix 5.
Table 3:6
Statistica l D ifference fo r Data Grouped
AER (pg/min)
Urinary al-M (mg/1)
Urinary Total Protein 
(g/l)
Plasma Glucose (mmol/1)
Duration o f Diabetes 
(years)
Body weight (Kg)
Age (years)
Urinary glucose (mmol/1)
by Type of Diabetes
Significance between 
IDDM and NIDDM
P value
0.053
0.022
0.017
0.013
0.0001
0.0003
0.0001
0.05
Significance between 
IDDMandNIDDMmatched 
Duration o f Diabetes
P value
0 o l
0 o I 
0.086
0.0086
0.1
0.0003
0.0001
0.016
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Table 3:7
Parameters for Control Subjects and Diabetic Subjects Grouped by AER
Group Control A
<10pg/min
B
10-100pg/min
C
>100pg/min
n 39 64 14 7
AER (pg/min) 3.34 (2.67) 3.14 (2.26) 25.53 (17.9) 984.6 (810)
GHb (%) 6.41 (0.51)(a) 12.71(3.54) 15.23 (3.3) 13.67 (2.56)
Plasma Gly Alb (%) 3.34 (1.35)(a) 7.76 (3.33) 8.48 (4.33) 8.12 (2.69)
Urinary Gly Alb (%) 9.18 (4.48) 8.45 (4.98) 12.35 (7.9) 15.10 (6.28)
ct^-M (mg/1) 3.31 (1.82)(c) 4.96 (6.75)(c) 6.00(6.2) 15.17 (15.7)
Total Protein (g/1) 83 (33) 73.7 (35.7)(c) 142.8 (114) 565.7 (392)
Plasma Glucose 
(mmol/1)
5.03 (1.20)(a) 14.1(6.5) 19.0(6.7) 13.4 (5.6)
Urinary Glucose 
(mmol/1)
0.20 (0.13) 9.05 (7.88) 13.75 (8.50) 8.68 (4.3)
GFR (mls/min) 115.4(5.99) 107.3 (6.04) 102.6 (6.78) 77.7(4.6)
Duration o f Diabetes 
(years)
- 8.7 (8.4) 15.8(12.4) 18.4(15.3)
Urinary Flow 
(mls/min)
0.9(0.59) 1.09 (.63) 1.07 (.99) 1.56 (.47)
a^-M /pg/m in 2.81(2.2) 5.4 (11.5) 4.36(3.1) 24.9 (26.2)
Total Protein/ 
(mg/min)
64.2 (39.1) 66.3 (31.3) 87.6 (28.8) 949 (767)
Urinary Glucose 
(mmol/min)
0.16 (.16) 9.4 (11.9) 14.1 (19.2) 16.3 (17.6)
% IDDM - 59% 86% 82%
% Retinopathy - 18% 30% 71%
All_values shown are means w ith SD in parentheses
(a)-  Significant difference from groups A, B and C
(b)“  Significant difference from groups B and C
(c) = Significant difference from group C
GHb, plasma G ly-Alb, a^-microglobulin, plasma glucose, urinary glucose and 
a^-m icroglobulin/m in show sta tis tica lly  significant differences between the control 
group and all three diabetic groups (p<.05). However, none of these parameters 
show a s ta tis tica lly  significant difference between the diabetic groups, due to the 
wide range of results w ithin each group, indicated by the high standard deviation 
values. Total protein excretion, however, shows a difference between groups A and 
C (p<0.001).
The mean GFR value fa lls across the three diabetic groups, but the change is 
not significant. Duration o f diabetes, percentage IDDM and prevalence of 
retinopathy all show an increase w ith increasing AER. Percentage w ith  IDDM and 
prevalence o f retinopathy are significantly d iffe ren t between group A and group C
(p<0.01).
As these results showed few significant differences and the numbers in the 
groups small,, groups B and C were joined as one group and compared w ith  group A. 
The results can be seen in Table 3:8.
AER, GHb, urinary Gly-Alb, urinary to ta l protein, duration, percentage w ith 
retinopathy, a^-m icroglobulin/pg/m in, to ta l protein mg/min, and urinary glucose 
mmol/min all show significant differences between group A w ith  AER <10ug/min 
and group B plus C w ith AER >10pg/min.
Table 3:9 shows the results for urinary:plasma Gly-Alb (U /PG ly-A lb) ra tio  fo r 
the groups divided by AER. The ratio  has been correlated w ith  overnight 
albuminuria (mg albumin) fo r each of the groups, and the correlation coeffic ients 
are given in the Table. Urinary Gly-Alb has also been correlated w ith albuminuria
Table 3:8
Data for all Diabetic Subjects: Divided at lQuq/min
AER (jjg/m in)
GHb (%)
Plasma Gly-Alb (%)
Urinary G ly-Alb (%)
a^-M (mg/1)
Total protein (g/1)
Plasma glucose 
(mmol/1)
Urinary glucose 
(mmol/1)
GFR (mls/min)
Duration (years)
Age (years)
% w ith retinopathy
Urinary flow (mls/min)
a^-M /m in
Total protein/m in
Urinary glucose/min
AER <10pg/min AER >10pg/
n=64 P values n=21
3.14 (2.26) <0.0001 345 (624)
12.71(3.54) <0.05 14.68 (3.08)
7.76 (3.33) NS 8.36 (3.79)
9.20 (7.37) <0.05 13.27 (7.36)
4.96 (6.75) NS 9.1(10.9)
73.8 (35.7) <0.01 284 (3.0)
14.1 (6.5) NS 17.03 (6.8)
9.05(7.88) NS 12.06 (7.59)
107.3 (6.Q4) NS 94.3 (6*13)
8.7 (8.4) <0.05 16.2(12.5)
42.4(13.6) NS 40.6 (13.9)
18% 43%
1.09 (0.63) NS 1.24 (0.87)
5.4 (11.5) <0.05 11.2 (17.6)
66.3 (31.3) <0.01 375 (592)
9.4(11.9) <0.01 14.8 (18.3)
All values are means with 5D in parentheses
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and w ith GHb. Plasma Gly-Alb has been correlated w ith GHb also, and the results 
are shown on the same table. When all the results are grouped together a 
significant correlation is found, as illustrated in Figure 3:5 (p<0.001). Blood 
glucose levels showed a significant relationship (p<0.001) w ith both GHb (Figure 
3:6) and G ly-Alb (Figure 3:7).
U/P Gly-Alb did not correlate w ith albuminuria fo r the control group, all the 
diabetic subjects, group A or group B treated separately. However, when group B 
and C or group C alone were considered, sta tis tica lly  significant correlations were 
found.
Significant correlations were found between plasma Gly-Alb and GHb fo r all 
subjects, all diabetic subjects, and group A. Groups B and C treated separately and 
together showed no correlation between these two parameters. Urinary Gly-Alb 
did not correlate w ith GHb fo r any o f the groups.
A clearance value fo r G ly-Alb was calculated which allowed fo r the d iffe ren t 
albumin concentrations in urine and plasma and for the d iffe ren t urine volumes and 
sample collection times. Using the percentage of G ly-Alb and the concentration of 
albumin in urine and plasma, the concentration of G ly-Alb in both urine and plasma 
was calculated. As the plasma albumin concentration had not been measured, the 
mean normal value was taken as 40g/l (normal range 34-48g/l) (Zilva and Pannall 
1975). The following calculation was made: U x V/P x T, where U = urinary Gly- 
Alb concentration, V = urine volume, P = plasma Gly-Alb concentration and T = 
time over which the urine sample collection was made. The clearance values were 
compared w ith AERs and a significant relationship (p<0.0001) was found, as shown 
in Figure 3:8.
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Figure 3:5 Graph to show the relationship between 
GHb and Gly-Alb values
y = 0.887 + 0.495x, r = 0.636, p<0.001 
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Figure 3:8 Graph to show the relationship between
Gly-Alb clearance and AER
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ALBUMIN EXCRETION RATE
An AER of 30|jg/min has also been considered as an upper lim it of the normal 
range, and Table 3:10 shows the data grouped in this way. AER, urinary G ly-A lb, 
urinary a^-microglobulin, urinary to ta l protein, duration and to ta l protein mg/min 
show significant differences between the two groups.
3:4:7 Parameters for Diabetic and Control Subjects: Diabetic Compared w ith 
Control Groups
Table 3:11 shows the results for the complete diabetic and non-diabetic 
groups, showing significant differences fo r a ll the parameters measured except fo r 
GFR, urinary G ly-Alb and a^-microglobulin.
Table 3:10
Data for Diabetic Subjects: Divided at 30pq/min
AER <30pg/min AER >30yg/min
n=73 n=10
AER (yg/min) 3.29 (6.07) * * 705 (800)
GHb (%) 12.96(3.48) NS 14.82 (3.58)
Plasma Gly-Alb (%) 7.93 (3.57) NS 7.75 (2.33)
Urinary G ly-Alb (%) 9.69 (7.55) * 14.07 (6.55)
a^-M (mg/1) 5.05 (6.61) * 12.9 (13.8)
Total protein (g/1) 84.0 (61.8) * 441 (380)
Plasma glucose 
(mmol/1)
14.59 (6.66) NS 16.34 (6.78)
Urinary glucose 
(mmol/1)
9.76 (7.89) NS 10.07(8.14)
GFR (mls/min) 105.8 (5.9) NS 91.2 (7.0)
Duration (years) 9.4 (8.5) * 18.8 (15.5)
Urinary flow 
(mls/min)
1.10 (.71) NS 1.31 (.61)
a -l-M /m in 5.2 (10.7) NS 18.8 (23.6)
Total protein/m in 69.6 (31.8) * 690 (752)
Urinary glucose/min 10.4 (13.7) NS 13.4 (15.3)
A ll values shown are means w ith SD in parentheses 
*  = p<0.05 
* *  = pCO.OOOl
Table 3:11
Data for all Diabetic and Control Subjects
Showing Statistical Differences
Diabetic Subjects Control Subjects
n 85 39
AER (pg/min) 88.0 (34.7) * * 3.54 (2.67)
GHb (%) 13.2 (3.52) * * * 6.41 (.52)
Plasma Gly-Alb (%) 7.91 (3.44) * * * 3.34 (1.35)
Urinary Gly-Alb (%) 10.21(7.54) NS 9.83 (6.65)
Urinary a^-M (mg/1) 5.99 (8.12) NS 3.1 (1.82)
Total protein (g/1) 127 (182) * * * 83 (33.4)
Plasma glucose (mmol/1) 14.8 (6.66) * *  * 5.03 (1.20)
Urinary glucose (mmol/1) 9.8(7.87) * * * 0.203 (0.13)
GFR (mls/min) 104.1 (6.04) NS 115.4(5.9)
Albumin/creatinine (mg/mmol) 12.2 (3.8) * * * 0.372 (0.06)
A ll vaues shown are means w ith SD in parentheses
* *  p<.001 
**■* p<.0001
3:5 Discussion
3:5:1 Comparison Between Male and Female Subjects
The results indicate that the only parameters showing a difference between 
male and female subjects are body weight and GFR. Differences would be 
expected in these two cases, but no differences have been found in the assessment 
of metabolic control or proteinuria. Male and female subjects have, therefore, 
been treated as one group. Other studies involving either IDDM (Mathiesen et al. 
1984) or NIDDM (Mogensen 1984a) have also treated male and female subjects 
sim ilarly. This study establishes that sex differences are lim ited  and not im portant 
in the study of the complications of diabetes mellitus.
3:5:2 Duration o f Diabetes
No sta tis tica lly  significant differences were observed when the data were 
considered by duration of the disease. However, AER shows a non-significant trend 
w ith increasing duration. The mean values fo r the three groups when grouped by 
disease duration indicate a considerable increase in AER, but the large variance fo r 
each group prevents the differences from showing a sta tis tica l significance.
Plasma G ly-Alb, urinary G ly-Alb, GHb, urinary to ta l protein, plasma and 
urinary glucose show the highest mean value for the intermediate duration group. 
The most important difference between the groups is the type of diabetes of the 
individuals making up the groups. Any differences that can be seen may be due to 
either differences in duration of the disease or the type o f diabetes.
Mathiesen et al. (1984) found no differences in AER between groups of 
diabetic subjects of increasing duration. However, when a long-term study was 
made of a group of diabetic subjects, the same authors found an increase of AER
afte r a six year follow-up period. V iberti et al. (1982a) also found an increase in 
AER during a 14 year study. Thus, a long-term prospective study may show the 
development of albuminuria and other complications in individuals, but a cross- 
sectional study is not adequate to demonstrate these changes w ith duration of 
diabetes.
3:5:3 Age Differences
The results suggest that age is not an important factor in the development of 
albuminuria. Age does not correlate significantly w ith any o f the parameters 
measured.
I t  is, however, surprising that the 46-55 years old group do not follow the 
trend o f increasing AER, urinary to ta l protein, urinary a^-m icroglobulin, GHb, G ly- 
Alb, or plasma and urinary glucose. This age groups appears to be in better short- 
and long-term metabolic control than the younger groups. This group is made up of 
50% IDD’s and 50% NIDD's, the same proportion as the 56-65 years old group.
There are therefore no obvious differences between the 36-45 years age
group and the 46-55 years group to explain the lower protein excretion levels found
in the older group, except fo r the lower percentage o f IDDM subjects (84% fo r 36-
45 years age group and 50% for 46-55 years age group). Duration and age appear to
be factors associated w ith  differences between the diabetic subjects. Thus far,
*
however, these factors have not been considered independently o f differences 
between IDDM and NIDDM, as i t  may be the higher proportion o f NIDDM in the 46- 
55 years age group that causes the lower AER and other results.
3:5:4 Comparison Between IDDM and NIDDM
The parameters associated w ith urinary protein excretion all show 
differences between IDDM's and NIDDM's suggesting more serious disruption o f 
kidney function in the IDDM group. When matched for duration of diabetes, these 
differences remain except fo r a^-iriicroglobulin. This suggests that both 
glomerular and tubular functions are impaired in short- and long-term IDDM 
subjects, but only glomerular function in NIDDM subjects, and to a lesser degree.
The glycosylated protein levels show very small, non-significant differences 
between the three groups, the NIDDM group having the lowest mean value fo r GHb, 
plasma and urinary G ly-Alb.
However, plasma and urinary glucose levels are significantly (p<0.05) lower in 
the NIDDM group than the other two groups. These samples were, however, 
random samples and not fasted, and as such, any significant differences must be 
treated w ith caution.
These results suggest that there is a greater differences in short-term  
giycaemic control than long-term control between the groups. Stable GHb levels 
are not affected by rapid changes in blood glucose (Svendsen et al. 1980; and 
Compagnucci et ail. 1981) providing that the GHb measurement has been carried 
out by a method that only measures the stable form. I t  has been shown tha t mean 
blood glucose levels (Svendsen et al. 1982) correlate well w ith GHb levels, but in 
this study only one random non-fasted glucose measurement was made. Thus, the 
fac t that there is a difference between the blood glucose levels o f the groups, but 
not the glycosylated protein levels, is not a contradictory finding.
3:5:5 AER and Diabetic Complications
This study was the f irs t to include the measurement of a^-m icroglobulin as 
an index of tubular function in diabetes. Table 3:7 shows the increased excretion 
of this protein in the groups w ith elevated AER. Only the group w ith an AER 
above lOOpg/min shows a significant increase in a^-microglobulin excretion when 
compared with the control group, or w ith the diabetic group w ith normal AER. 
These result suggest tha t the highly elevated albumin excretion is o f tubular as 
well as glomerular origin.
The significant relationship found between Gly-Alb clearance and AER, in 
addition to the urinary/plasma Gly-Alb ratios, show that as AER is increased, there 
is an even greater excretion of G ly-Alb, suggesting a preferential loss o f the 
glycosylated molecules.
As discussed in Chapter 1, there are several d iffe rent ways o f defining 
microalbuminuria. Groups who have used 24-hour urine collections have set two 
levels as the upper lim it o f normal; 15pg/min (Mogensen et al. 1983) and lOpg/m in 
(Ghiggeri et al. 1984). Those who have used overnight urine collections have set 
the upper lim it o f normal as 30pg/min (Viberti et al. 1982a; Gatling et al. 1985). 
When an early morning urine sample only has been taken, 30-140mg/l (Mogensen 
1984) was found to be predictive of proteinuria. Protein:creatinine ratios have also 
been used to classify levels o f protein loss. Gatling et al. (1985) found that a ra tio  
greater than 3.5mg albumin/mmol creatinine demonstrated individuals at risk o f 
future nephropathy. Gragnoli et al. (1984) compared those diabetic subjects w ith 
an AER w ithin 2 SD o f their mean normal level, w ith those above 2 SD o f the mean 
normal level. This method of grouping the diabetic subjects results in the same 
individuals fa lling into the normal and m icro-proteinuric groups as Groups A and B.
The diabetic subjects have therefore been grouped in two ways. F irs tly , w ith 
the upper lim it o f normal AER set at lOpg/min and secondly at 30pg/min.
With the upper lim it of normal AER set at 30pg/min the results are shown in 
Table 3:10. The GHb levels are not significantly d iffe ren t in this instance, 
although there is a small increase in the second group. Urinary glycosylated 
albumin ct^-microglobulin and duration show sta tis tica lly  s ignificant differences 
between the groups (p<0.05).
V iberti et al. (1982) showed that subjects w ith an AER, measured on an 
overnight sample, between 30 and 140ug/min were more like ly to suffer from 
nephropathy in la ter years. When the subjects in this study are grouped in this way, 
only three individuals fa ll into this group and so all those w ith an AER above 
30|jg/min have been treated as one group.
Gatling et al. (1983) also took 30pg/ml as the upper lim it o f normal AER on 
an overnight sample. They correlated this measurement w ith an albumin:creatinine 
ratio  and found a highly significant correlation between the two parameters 
(r=0.91). The correlation between these two parameters found in this study was 
also significant (r=0.86, p<0.001). However, as the two measurements were made 
on the same urine sample in both studies, a significant correlation would be 
expected.
AER appears to be the most informative way of grouping diabetic subjects, as 
clear differences then appear between these groups. GHb and plasma G ly-A lb show 
differences, as do duration and prevalence of retinopathy and urinary a^- 
microglobulin.
Previous studies have only considered either IDDM or NIDDM subjects, but 
not both, w ith measurements o f glycosylated proteins and urinary proteins. IDDMs 
and NIDDMs showed no differences in the levels of glycosylated proteins, but 
urinary protein loss was greater in the IDDMs than in the NIDDMs.
When the subjects are divided into three groups by AER, as in Table 3:7, only 
plasma and urinary glucose levels show significant differences between groups A 
and B, and B and C. There is also a higher incidence of retinopathy in groups B and 
C than in Group A. This la tte r group comprises only 39% IDDM subjects, compared 
w ith 86% and 82% fo r groups B and C respectively. Appendix 5 shows the data for 
IDDM subjects only, which can be compared w ith the results of Ghiggeri et al. 
(1984). The main differences between results in the two studies are that Ghiggeri's 
subjects had a much shorter duration o f diabetes (5.5 - 1.8 years, 5.3 - 1.7 years, 
and 9.8 - 1.6 years for groups A, B and C respectively) and yet were much older 
(37.4 - 5.1 years, 44.6 - 3.8 years and 51.4 - 4.1 years fo r groups A, B and C 
respectively). Thus, the two groups studied by Ghiggeri et al. who have 
microalbuminuria comprise older individuals who were diagnosed as diabetic up to 
ten years previously. However, the subjects in groups B and C in this study had 
been diabetic on average, up to 21 years out o f an average 40 years o f age. These 
workers found an increase in urinary 32"micr°g^°bulin excretion w ith  increasing 
AER, and a decrease in creatinine clearance in Group C. Their results are in 
agreement w ith the results o f this study, as a^-m icroglobulin indicates the same 
type o f kidney dysfunction as $2"mic r°g l°b L,lin.
However, Ghiggeri and co-workers found a decrease in urinary G ly-A lb 
concentration with increasing AER. This is the reverse of the results o f this study, 
which showed an increase in urinary G ly-Alb percentage w ith increasing AER. 
Groups A showed a sim ilar percentage Gly-Alb to the control group.
The difference in urinary G ly-Alb levels between the group w ith  normal AER 
and w ith elevated AER is s ta tis tica lly  significant (p<0.05). The ratio  of U/P Gly- 
Alb also shows a sta tis tica lly  significant difference between groups A and B and C.
Group A had a sim ilar mean urinary Gly-Alb level to the control group, but a 
raised mean plasma Gly-Alb level. This would cause the ratio o f U/P G ly-Alb to be 
considerably lower in group A than in the normal group, group B had an elevated 
mean urinary G ly-Alb level, but a sim ilar plasma Gly-Alb level to group A. This 
led to the U/P ratio  being higher than that o f group A, but lower than the control 
group. Group C had a higher mean urinary G ly-Alb level s till, but a sim ilar plasma 
Gly-Alb level to groups A and B, resulting in a higher U/P ratio  than groups A and 
B, but lower than the control group. A ll the diabetic groups have a lower mean 
ratio than the control group, but the ratio  increases w ith increasing AER.
Gragnoli et al. (1984) however, found that the ratio  was highest in group A 
their (AER <10pg/min), lower in the control group, decreasing to group B (AER 10- 
lOOpg/min) and lowest in group C (AER >100pg/min). Their results suggest that 
group A had elevated urinary excretion o f G ly-A lb, whereas groups B and C had 
lower urinary levels, as the serum Gly-Alb levels were sim ilar. Thus in groups B 
and C there was a progressive decrease in the excretion o f glycosylated 
proteins/mg proteinuria, in spite of the ir overlapping serum levels.
In the present study, only the groups w ith microalbuminuria or proteinuria 
demonstrated a relationship between urinary Gly-Alb and albuminuria. U/P ra tio  
also indicated a significant correlation with albuminuria in these groups. These 
results indicate that where the albumin excretion is elevated, more G ly-A lb is 
present in the urine, and the ratio  of urinary/plasma Gly-Alb is also increased.
Gragnoli and co-workers however, found negative correlations between 
urinary G ly-Alb (nmol urinary 5HMF) and levels o f 24-hour proteinuria in control 
and diabetic groups. This would appear to suggest that there was no preferential 
excretion o f glycosylated proteins in the ir patients. Gragnoli and co-workers and 
Ghiggeri and co-workers both found lower levels o f glycosylated protein in the 
urine o f diabetic subjects w ith elevated protein excretion, and yet have both 
concluded that glycosylated proteins are preferentia lly excreted, from the Gly-Alb 
clearance values that they calculated.
The raised U/P ratio  in groups B and C in this study, and the positive 
correlations between urinary G ly-Alb, the U/P ratio  and the G ly-A lb clearance 
w ith the level o f albuminuria would all seem to suggest preferentia l excretion of 
the glycosylated molecule.
Ghiggeri and co-workers have studied extensively the glycosylation process, 
particularly w ith respect to albumin (Candiano et al. 1983; Candiano et al. 1984; 
Ghiggeri et al. 1985a; Ghiggeri et al. 1985b; Candiano et al. 1985). They have 
investigated albumin and G ly-Alb from serum and urine o f diabetic subjects using 
u ltrath in-layer isoelectric focusing and silver staining (Candiano et al, 1984) and 
found Gly-Alb to be micro-heterogeneous. There were, in the case of the serum 
G ly-Alb, several more positively charged bands w ith a pi (isoelectric point, ie, the 
pH at which the molecule has no net charge) below 7. However, urinary albumin 
showed a d iffe rent result, there was a sim ilar main unmodified albumin band (pi 
4.8), but in the case o f the urinary G ly-Alb the other bands had a lower pi (4.0 -4.7) 
and were more negatively charged.
These results are the reverse o f those found by Purte ll et al. (1979) who 
prepared more positively charged (or raised pi) human albumins. When these were 
infused into rats the albumins w ith the highest pi exhibited higher clearance rates 
compared w ith unmodified albumins. The two groups of workers have, therefore, 
found opposing results. Candiano and co-workers have postulated that the more 
negatively charged albumin molecules, which they have shown w ith  the 
colorim etric assay of McFarland et al. (1979) to be glycosylated, have been 
preferentia lly excreted into the urine. When these Gly-Alb molecules have been 
studied in detail (Ghiggeri et al. 1985c) the carbohydrate moieties attached were 
found to be glucose, mannose and fructose.
The differences between the results of the two Italian groups and those 
presented here are probably due to d iffe rent methodologies being used. Both 
groups used chromatography systems fo r separating Gly-Alb from the urine and 
serum samples, based on the charge differences between glycosylated and non­
glycosylated molecules. This is a less specific separation technique than the 
a ffin ity  method used in this study, which separates samples on the basis o f cis-diol 
groups only. As a result o f these differences of methodology, i t  is not possible to 
define precisely which protein adducts have been measured by the Ita lian groups, 
making comparison of the results more d iff ic u lt. They then measured the quantity 
of glucose present in the sample attached to the protein using the co lorim etric  
method. The process involves treatm ent o f the glycosylated protein w ith  oxalic 
acid, which induces re-arrangement of the Schiff base (Gabbay et al. 1979). The 
colorim etric method is highly dependent on sample size (Klenk et al. 1982) and has 
a higher non-specific reactiv ity  (Rendell et al. 1985). As the a ffin ity  
chromatography method was used in this study the two methods do not measure 
exactly the same parameter. D irect comparisons between results are not
straightforward because o f this difference in specific ity. The level o f 
glycosylation o f a protein as estimated by a ffin ity  chromatography is expressed as 
a percentage, whereas the units quoted for the colourim etric method are nmoles 
HMF per mg protein. This also complicates comparison of the results.
The results o f these two groups o f workers d iffe r from the results of this 
study most significantly in the degree o f glycosylation o f urinary protein. 
However, they have also concluded that gly-protein is preferentia lly excreted, 
despite negative correlations between levels o f 5HMF/mg proteinuria versus 
proteinuria. In this study, however, the groups w ith raised albumin excretion have 
higher levels of urinary G ly-A lb. Also positive correlations were found between 
U/P Gly-Alb and albuminuria, between urinary Gly-Alb and albuminuria and 
between G ly-Alb clearance and AER. These findings strongly suggest that elevated 
AER is linked with increased urinary gly-alb (Taylor e ta l.  1986).
Another group (Pagano et al. 1986) have investigated the e ffec t o f exercise 
on AER and Gly-Alb excretion in six IDDM subjects. They found a positive 
correlation between urinary G ly-Alb levels and AER, but did not compare a 
urinary:plasma Gly-Alb ra tio  or clearance value w ith AER. They concluded that
i
G ly-Alb was not preferentia lly excreted, but w ithout fu rther analysis o f the data, 
this is not conclusive.
There are therefore contradictory findings on the preferentia l excretion o f 
G ly-Alb, and this complex area of the complications of diabetes w ill not be 
c larified until the mechanisms involved have been fu lly  explained.
The Italian workers separated the albumin in itia lly  on the basis of charge, and 
then measured the glucose content of the more negatively charged molecules using 
the colorim etric method. They found that there was less glucose present per mg 
protein in the group w ith higher protein excretion, and yet the ir G ly-Alb clearance 
calculations led them to conclude that G iy-A lb was preferentia lly excreted. The 
results of this study show increased Gly-Alb present in the urine o f subjects w ith
increased AER. This suggests that separation based on charge is not a suffic iently
specific technique for separating G ly-Alb and that increased negative charge is not 
the only reason for G ly-Alb being excreted in greater quantities in subjects w ith
elevated AER. Further investigations are therefore needed, w ith prospective
studies, so that the development of kidney changes, w ith  the concomitant increases 
in glycosylated and native albumin excretion can be followed.
CHAPTER 4
AN ASSESSMENT OF THE A FFIN ITY  CHROMATOGRAPHY GLYCOSYLATED  
HAEMOGLOBIN ASSAY AS A  SCREENING TEST FOR DIABETES,
AS PART OF THE ISLINGTON SURVEY
4:1 Introduction
The OGTT is s till the standard diagnostic test for diabetes, where the c lin ica l 
signs are unclear, or the blood glucose levels are borderline. The c rite ria  described 
in Table 1:2 have been based on the findings of long-term follow-up studies such as 
the Whitehall Survey (Reid et al. 1974) and the Bedford Survey (Sharp et al. 1964). 
These studies indicated the predictive ab ility  o f a 2-hour BG level in an OGTT for 
the development o f diabetic vascular disease (Keen et al. 1982). The diagnostic 
test used in these studies was a 2-hour BG level, which has resulted in this single 
measurement being given the most diagnostic weighting. However, fasting blood 
glucose has not been investigated as a diagnostic test as thoroughly as the 2-hour 
blood glucose level, and where comparisons have been made (Modan et al. 1984) the 
fasting blood glucose has been shown to be only 45% sensitive compared to the 2- 
hour blood glucose level's 95% sensitivity. I t  is only the small number o f 
unclassifiable cases that prevents the 2-hour blood glucose value from reaching 
100% sensitivity.
An effective method fo r population screening should be sensitive enough to 
identify most o f the affected population, and be re la tive ly cheap, quick and simple 
to perform. As discussed in Chapter One, GHb has been suggested as a possible 
diagnostic test fo r diabetes (Santiago et al. 1978). GHb has been thoroughly 
evaluated as a means of monitoring metabolic control and several methods have 
been compared (Mortensen et al. 1983; Boucher et al. 1983; Peterson et al. 1984). 
However, most studies which have attempted to assess the value o f GHb for 
diagnostic purposes have been incomplete, lacking large subject groups (Hall et al. 
1984) and suffic ient comparison of sensitivity and specific ity w ith the values 
obtained from the OGTT (Ferrell et al. 1984; Mortensen et al. 1983). Several
methods are available for the measurement of GHb, but as yet no one method has 
been shown to be more sensitive than the others. However, methods which 
measure only the stable GHb and are not affected by the labile form may be more 
accurate for diagnostic use (Forrest e ta l. in press, b).
The Islington Diabetes Survey was designed so that the sensitivity, specific ity  
and predictive value of a positive test for GHb could be compared w ith those of the 
2-hour blood glucose levels as screening and diagnostic tests fo r diabetes.
The survey was carried out in two phases. The firs t phase was a screening 
study to ascertain the prevalence of diabetes, hypertension and anaemia in a group 
practice population. The second phase involved the recall of a s tra tified  sample of 
these individuals, so that more detailed work could be carried out w ith a section of 
the population. A t this second, recall phase, three d iffe rent GHb assays were used, 
to compare sensitivity, specific ity and predictive value of the d iffe ren t techniques 
w ith classification based on the 2-hour blood glucose value follow ing a 75g oral 
glucose load. Electroendosmosis, iso-electric focusing and a ffin ity  chromatography 
were used to measure GHb in the recall phase.
Our involvement in this study was the measurement o f GHb, by a ffin ity  
chromatography, on the 2-hour post-glucose load blood sample of 222 subjects from 
the screening phase, and on fasting and 2-hour post load samples of a ll the recalled 
subjects. The a ffin ity  chromatography method was then assessed for specific ity, 
sensitivity and positive predictive value compared with the fasting and 2-hour 
blood glucose levels.
4:2 Subjects and Methods
The screening phase of the Islington Diabetes Survey involved 1084 subjects 
selected at random from a single group practice over the age o f 40 who took a 75g 
oral glucose load in their own homes. Two hours la ter in the hospital a finger-prick 
capillary blood sample was taken for estimation o f 2-hour, blood glucose, (BG) by 
an automated glucose oxidase method (Technicon 1, Technicon Instrument 
Company, Basingstoke, Hampshire, UK). A portion o f the sample was collected 
into an EDTA tube (Sarstedt L im ited, Leicester, UK) for analysis of GHb by 
electroendosmosis at the Whittington Hospital and by a ffin ity  chromatography at 
the University of Surrey. The a ffin ity  chromatography method was carried out as 
previously described in Chapter 3, Section 3:3. The w ithin assay coeffic ients o f 
variation for the a ffin ity  chromatography method were 2.0% and 1.5% fo r the non­
diabetic and diabetic ranges respectively. The between assay c.v. were 1.8% and 
1.5% for the same ranges.
The degree o f glucose tolerance of the subjects was assessed according to 
modified WHO crite ria  and subjects wereclassified as having normal tolerance (2- 
hour BG <8.0mmol/l), IGT (2-hour BG 8.0-10.9mmol/l) or DM (2-hour BG 
>11.0mmol). The subjects were ranked according to the ir 2-hour BG level and GHb 
level as shown in Table 4:1. A ll those w ith either level above the 90th centile, w ith 
50% of subjects w ith levels o f either or both between the 80th and 90th centiles, 
and 10% of those w ith lower levels were selected to take part in a fu rther test. 
This comprised a formal OGTT w ith measurement o f BG at each tim e point, i.e., 
fasting, 1-hour and 2-hour and measurement o f GHb fasting and at 2-hours.
Table 4:1 Centiie C u t-O ff Levels for Screening 2-Hour Post-Load
Blood Glucose (2-Hour BG) Levels and GHb Levels Measured 
by Electroendosmosis and A ff in ity  Chromatography
Centiie 2-Hour BG Electroendosmosis A ff in ity  Chromatography 
% mmol/1 % %
100 22.6 15.5 17.4
90 7.6 8.4 8.3
80 6.6 7.9 7.7
70 6.0 7.7 7.5
60 5.6 7.4 7.3
50 5.2 7.2 7.0
40 4.8 7.0 6.8
30 4.5 6.8 6.5
20 4.1 6.5 6.3
10 3.6 6.2 5.9
On this repeat test, blood glucose estimations were made on venous whole 
blood by the same method as before and samples were taken for GHb estimation by 
electroendosmosis and iso-electric focusing at the Whittington Hospital and by 
a ffin ity  chromatography at the University of Surrey.
4:3 Data Analysis
Discrim ination measures, i.e. sensitivity, specific ity and predictive value fo r 
a positive test have been calculated (Alderson 1983) for segregation o f diabetic 
from non-diabetic individuals, fo r screening 2-hour GHb values, and recall fasting 
blood glucose, fasting and 2-hour GHb levels compared with the recall 2-hour blood 
glucose level used fo r classification as defined by the WHO.
The sensitivity of a test is defined as the per cent having a test variable 
above a selected cu t-o ff point of the to ta l group w ith diabetes as shown in Table 
4:2. The specific ity o f a test is the per cent o f diabetic individuals having a test 
variable below the selected cu t-o ff point among the to ta l group of non-diabetic 
individuals. The predictive value (positive test) expresses the percentage o f true 
diabetic subjects among those w ith the test value above a selected cu t-o ff point.
Table 4:2 Definition of the Test Characteristics
Used in the Data Analysis 
Positive
Test result + True Positives
(a)
False Negatives True Negatives
(c) (d)
Sensitivity o f a test = a/a + c x 100%
Specificity o f a test = d/d + b x 100%
Predictive value (positive test) = a/a + b x 100%
Negative 
False Positives 
(b)
4:4 Results
4:4:1 Analysis of the Screening Data
2-hour post-load blood samples were received by us from 222 of the subjects 
in the screening phase for measurement o f GHb by the a ffin ity  chromatography 
method. Figure 4:1 shows the GHb levels divided by the glucose tolerance class of 
the subjects, as defined by the WHO (1980). The distribution of the GHb levels can 
be seen in Figure 4:2. Table 4:3 shows the mean GHb values in the three groups, 
demonstrating that, despite the considerable overlap of GHb levels between the 
three groups, there are sta tis tica lly  significant differences between normal 
tolerance and IGT groups (p<0.001) and between IGT and DM tolerance groups 
(p<0.001). There was a significant correlation between the GHb levels and 2-hour 
blood glucose levels (r=0.38, p<0.001, n=222) as shown in Figure 4:3.
The test characteristics (sensitivity, specific ity and positive predictive value) 
at a range of GHb cu t-o ff values of the GHb assay as a screening test fo r AGT 
(abnormal glucose tolerance; IGT + DM) and DM can be seen in Figures 4:4 and 4:5
respectively. The specific ity and predictive value (positive test) o f the 2-hour GHb
level as a screening test fo r DM and AGT at a fixed sensitivity of 90% have been 
summarised in Table 4:4.
Figure 4:1 Screening glycosylated haemoglobin 
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Table 4:3 GHb Levels in 222 Subjects in the Screening 
Phase, Showing Mean and Standard Deviations
Glucose Tolerance Class 
Normal IGT DM
n = 210 n=5 n=7
Mean % 6.9 7.9 11.2
Standard 0.9 0.8 4.2
Deviation
  0.001      0.001 ----------
Significance
(p<) 0.001
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Figure 4:3 Glycosylated haemoglobin levels plotted 
against blood glucose concentration at 
the screening phase
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Figure 4:5 Test characteristics (sensitivity, 
specificity and positive predictive 
value) at a range of cut-off levels 
for diabetes at the screening phase
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Table 4:4 Test Characteristics (Specificity and Predictive Value)
of the GHb Assay and GHb C ut-O ff Levels as a Screening 
Test fo r DM and Abnormal Glucose Tolerance •
Glucose Specificity PV+ C ut-O ff
Tolerance Level
Class % % %
DM 68.0 8.3 7.4
Abnormal Glucose 68.8 14.1 7.4
Tolerance
4:2:2 Analysis of the Recall Data
The stra tified  sample of subjects recalled from the screening study 
underwent a fu ll OGTT: 223 subjects were included, and complete data are 
available on 201 o f these individuals. They were again classified into glucose 
tolerance classes according to the WHO crite ria  and Table 4:5 shows the 
classification at recall compared w ith the classification at screening. This Table 
includes the individuals who could not be classified, most of whom were la ter 
excluded due to incomplete data, and who have been classified as IGT in subsequent 
data analysis.
The 2-hour GHb values from the recall phase of those subjects whose GHb 
levels were measured in the screening phase (n=44) have been shown as a 
percentage o f the screening value (Figure 4:6). The relationship between screening 
and recall GHb levels, both fasting and post-load samples, are significant and can 
be seen in Table 4:6.
Table 4:5 Comparison of Glucose Tolerance Class at Screening
w ith Glucose Tolerance Class at Recall Testing of 
a ll Subjects at Follow-Up (n = 223)
Classification at Screening
Classification 
at Recall
Normal IGT DM Unclassified
Normal 135 9 1 8 153
IGT 31 11 4 2 48
DM 1 3 9 0 13
Unclassified 3 4 1 1 9
T otals 170 27 15 11 223
Figure 4:6 Recall phase glycosylated haemoglobin 
values shown as a percentage of 
screening phase values. Mean 99.6%, 
mode 105%, S.D. 16.9, n = 44
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Table 4:6 Relationship of Screening GHb Levels to
Recall Fasting and 2-Hour GHb Levels
r P n
Screening GHb
with fasting recall GHb 0.41 <0.003 44
w ith 2-hour recall GHb 0.43 <0.002 44
Table 4:7 shows the results for a ll the subjects divided into three groups, 
according to their response to the 75g glucose load. No sta tis tica l difference was 
found between fasting and 2-hour GHb values for any group. There was 
considerable overlap in the GHb values for the three groups, as shown in Figure 4:7. 
The range o f fasting GHb values for the normal group was 3.16-10.02% for the IGT 
group i t  was 3.60-7.95% and for the diabetic group the range was 7.39-19.36%. 
There were however, significant differences between the IGT group and control or 
diabetic group, and highly significant differences (p<0.0001) between diabetic and 
control groups for all the measurements.
Table 4:8 shows the regression analysis of fasting and 2-hour GHb values w ith 
the area under the glucose tolerance curve (AUC). The three glucose tolerance 
groups have been treated separately and combined. When all the results were 
taken together, a significant correlation (p<0.001) was found. However, when 
normal, IGT and diabetic groups were considered separately, only the diabetic 
group demonstrated a significant relationship (p<0.05). Also shown are the
correlation coefficients for the GHb versus blood glucose levels for the fasting and 
2-hour time points fo r the normal, IGT and diabetic subjects 2-hour GHb levels 
have been plotted against the 2-hour BG levels for the whole group (r = 0.55, 
p<0.001, n = 201), showing a significant relationship (Figure 4:8). The normal group 
showed no correlation between GHb and BG levels at either fasting or 2-hour 
samples. The IGT group showed a sta tis tica lly  significant correlation (p<0.01) 
between the two parameters in the fasting state and correlation in the 2-hour 
sample (p<0.02). The results fo r the diabetic subjects demonstrate a s ign ificant 
correlation between the two parameters for both time points, w ith  greater 
significance in the fasting sample.
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Table 4:8 Relationship of Fasting and 2-Hour GHb To Area Under
the Glucose Tolerance Curve (AUC) and Blood Glucose Levels
T o t a l . N b R M A u  i ( y r
Fasting GHb
-w ith  AUC r= 0.10 0.37 (b) 0.72(b)
- w ith fasting BG r= 0.06 0.32 (c) 0.88 (a)
2-Hour GHb
-w ith  AUC r= 0.20 0.30 (c) 0.62(c)
- w ith  2-Hour BQr '  r= 0.15 0.33 (b) 0.67 (b)
Significance values fo r correlation coefficients
(a) represents p<0.001
(b) represents p<0.02
(c) represents p<0.05
0.54 (a) 
0.59 (a)
0.49 (c) 
0.54 (c)
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Figure 4:8 Glycosylated haemoglobin levels plotted
against blood glucose concentrations at
the recall phase
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The subjects were in itia lly  divided into normal, impaired and diabetic 
responses to the OGTT on the basis of the 2-hour blood glucose level, as described 
in Table 1:2. This resulted in 13 subjects (6.4%) being classified as diabetic, 48 
(23.8%) as having impaired glucose tolerance and 140 (69.6%) as having normal 
glucose tolerance.
The fasting GHb value was then compared as a screening test w ith blood 
glucose measurements. The sensitivity, specific ity and predictive value (positive 
test) o f the fasting GHb and 2-hour GHb concentrations at a range of cu t-o ff levels 
can be seen in Figures 4:9 and 4:10 respectively. The sensitivity, specific ity and 
predictive value (positive test) o f the fasting BG value at a range o f cu t-o ff levels 
have been plotted in Figure 4:11. These results are summarised in Table 4:9 
showing specific ity and predictive value at a fixed sensitivity o f 90%.
Figure 4:9 Test characteristics (sensiti­
vity, specificity and positive 
predictive value) at a range 
of fasting GHb cut-off levels 
(recall phase) for diabetes
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Figure 4: 10 Test characteristics (sensitivity, 
specificity and positive predic­
tive value) at a range of 2-hour 
GHb cut-off levels (recall phase) 
for diabetes
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Figure 4:11 Test characteristics (sensitivity, 
specificity and positive predic­
tive value) of fasting blood 
glucose as a test for diabetes at 
a range of cut-off levels
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Table 4:9 Characteristics (Specificity and Positive Predictive 
Value, PV+) of the Fasting GHb and 2-Hour GHb Value 
and Fasting Blood Glucose Level as Tests for DM at a 
Fixed Sensitivity o f 90%
Specificity PV+ C ut-O ff Levels
% %
Fasting GHb 81.3
2-hour GHb 81.4
Fasting Blood Glucose 78.7
23.5 7.7%
23.5 8.0%
23.0 5.0 mmol/1
4:5 Discussion
When the diagnosis of diabetes is not obvious from clin ical signs or 
measurement o f random and fasting blood glucose levels, a test is needed that w ill 
fa c ilita te  classification of individuals. The OGTT has become widely accepted as 
standard crite ria , but variations in dose, tim ing, type of specimen and analytical 
methods have led to d ifficu lties  in interpretation. The development of precise 
methods for measuring blood glucose and the recent recommendations of the WHO 
for the performance and interpretation of the test have led to a more uniform 
approach, but inherent variations in the OGTT remain. I t  is also an inconvenient 
and time-consuming test to carry out. For these reasons, GHb has been considered 
as an additional test fo r the diagnosis of diabetes. The test is quick and easy to 
carry out and is practical fo r use in screening large populations. GHb measures the 
cumulative e ffec t o f glycaemia over the preceding 3-4 weeks (Koenig et al. 1976) 
and so is not affected by many o f the environmental factors that make the OGTT 
so variable. In order to be o f use as a screening test, i t  must discrim inate between 
normal and diabetic glucose tolerance. The results of this study show that there is 
considerable overlap as illustrated in Figure 4:1 fo r the screening phase and Figure 
4:7 for the recall phase.
There are significant correlations between both GHb measurements and the 
blood glucose levels and area under the curve o f an OGTT when all subjects were 
considered. The relationship between 2-hour GHb levels and the corresponding 2- 
hour BG levels fo r both screening and recall samples are both significant (p<0.001) 
for the whole subject group, as illustrated in Figures 4:3 and 4:8. These results 
confirm a close relationship between GHb and the results of the OGTT. However, 
when the subjects are divided into glucose tolerance groups, in Table 4:8, the
normal tolerance group showed no correlation between area under the curve and 
fasting or 2-hour GHb levels. The IGT and diabetic groups showed significant 
correlations despite smaller numbers in the groups (n = 13 and 48 respectively). 
The highest correlation was found fo r the diabetic group. This suggests that the 
relationship found between GHb levels and area under the curve for the complete 
subject group is mainly due to the highly significant correlation found for the 
diabetic subjects.
Lester et al. (1985) found sim ilar results, w ith a highly significant correlation 
between 2-hour GHb levels and area under the glucose tolerance curve in a group 
of 47 diabetic patients. They measured HbA, using the Corning G lytrac 
electrophoretic procedure, and found a significant difference (p<0.05) between 
fasting and 2-hour HbA, levels in the diabetic group only. This difference was also 
found by Forrest et al. (in press, b) when labile GHb had not been removed by 
dialysis prior to measurement by the Corning method.
In the present study, however, using a ffin ity  chromatography no difference was 
found between fasting and 2-hour GHb values for any o f the three groups which 
suggests that the labile GHb interferes with the Corning method but not w ith the 
a ffin ity  technique. Lester ^ t  al. found that there was no correlation between GHb 
levels and area under the glucose tolerance curve fo r normal or impaired tolerance 
subjects. Our results are in agreement w ith this and the reason is probably due to 
the much narrower range of values for GHb and blood glucose values in these two 
groups than was found in the diabetic group. The significance of the relationship 
between GHb and area under the glucose tolerance curve for the diabetic group 
suggests that there is a close link between the parameters.
A t the screening stage o f the study, 24 subjects (2%) were classified as 
diabetic and 40 (4%) as having IGT, based on the two hour BG level (Forrest et al.
1984). The stra tified  sample then selected to take part in the recall phase included 
all the individuals w ith either 2-hour BG or GHb levels above the 90th centile, 
which should have included all the diabetic subjects. The sensitivity, specific ity 
and predictive value (positive test) at a cu t-o ff point of 11.0 mmol/1 of the 
screening test compared with the recall 2-hour diagnosis were 58.3%, 97.2% and 
54.2% respectively. The specific ity o f the screening 2-hour BG is excellent,w ith 
sensitivity and predictive value also good. The balance between sensitivity and 
specific ity required in a particular test depends on the purpose of the survey. In 
general, methods w ith a low specific ity are to be avoided, as the incorrect 
inclusion of large numbers of non-diabetic individuals in a population screen would 
result in falsely large numbers being diagnosed as diabetic or recalled needlessly 
for further tests.
A t a cu t-o ff point of 6.7 mmol/1 the fasting BG from the recall OGTT shows 
a sensitivity, specific ity and predictive value of 39.2%, 99.1% and 84.3% 
respectively (Figure 4:11). These figures show that fasting BG misses the m ajority 
o f diabetic individuals, but there are v irtua lly  no false positive diagnoses. A lower 
BG cu t-o ff level would improve sensitivity but lower specific ity and predictive 
value, thus including more false positives.
An assessment has been made of the value of GHb measurement as a 
screening and diagnostic test. Figures 4:4 and 4:5 show respectively the test 
characteristics for a range of GHb cu t-o ff levels as a screening test fo r DM and 
IGT, from the screening phase of the study. The graphs are very sim ilar, and Table 
4:9 confirms that there is only a small difference in predictive value at a fixed
sensitivity of 90%. A cu t-o ff level of 7.4% would yield a sensitivity of 90% and a 
specific ity of 68.8%, but an improved specific ity could be achieved (ie, fewer false 
positives) at a higher cu t-o ff level. A range of cu t-o ff points from 5.0% to 10.0% 
have been considered for both fasting and 2-hour GHb levels from the recall phase. 
The two graphs (Figures 4:9 and 4:10) showing sensitivity, specific ity and predictive 
value (positive test) indicate sim ilar results for the two GHb measurements, 
whether fasting or two hours a fte r the oral glucose load. Both graphs show that 
the best values for sensitivity and specific ity were obtained at a cu t-o ff level of 
8.0% GHb. A t this GHb level, the specific ity, sensitivity and predictive value 
values are, respectively, 84.6%, 87.2% and 31.4% for the fasting measurement and 
92.3%, 81.4% and 25.5% for the 2-hour measurement. This level does, however, 
pick out many false positives. In the normal glucose tolerance group 8.5% have a 
fasting GHb above 8.0%, and 13.5% of the subjects have a 2-hour GHb above 8.0%. 
The IGT group would yield 22.9% of its subjects w ith a fasting GHb value over 
8.0%, and 37.5% with a 2-hour GHb value over 8.0%. Raising the cu t-o ff level 
means that more diabetic subjects are missed. A t a cu t-o ff level of 8.5% GHb the 
fasting measurement gives a sensitivity, specific ity and predictive value o f 61.5%, 
93.1% and 38.1% respectively w ith corresponding values of 69.2%, 89.8% and 33.3% 
for the 2-hour measurement.
Thus the lower cu t-o ff level o f 8% GHb results in greater sensitiv ity but 
lower specific ity. Forrest et al. (in press, a) used the screening and follow-up data 
from this study and calculated sensitivity, specific ity and predictive value fo r a 
range of HbA, levels in the screening samples. The screening HbA, values were 
measured by electroendosmosis, which include labile GHb in the measurement and 
gives a higher GHb value than a ffin ity  chromatography, which we used for the 
recall samples. Fasting GHb values have also been used to calculate sensitiv ity,
specific ity and predictive value. There is l it t le  difference between fasting and two 
hour GHb levels in the recall samples. Forrest et al. (1984) conclude that 8.5% 
may be useful as an upper lim it of normal, but that a higher value such as 9.0% or 
10.5% may be more useful as a screening value. The recall data yield lower 
sensitivity and predictive value figures, but sim ilar specific ity figures to the 
screening data. This is due to the smaller number of both diabetic and non-diabetic 
individuals included in the recall than the screening calculations. In the screening 
data there were approximately tw ice as many diabetic and five times as many non­
diabetic individuals (but sim ilar numbers of false positives and negatives) than in 
the recall data. This means that specific ity, a measure of the false positive 
diagnoses, remains v irtua lly  the same, but the other two calculations are lowered 
by the reduction in numbers of true positives and negatives diagnosed.
The stra tifica tion  of the recall subjects, w ith a bias towards those w ith 
higher 2-hour BG and GHb levels, meant that a higher proportion of the reca ll 
subjects were diabetic, i.e. 6% compared w ith 2% o f the screening sample. This 
emphasis on the subjects w ith high 2-hour BG and GHb levels affects the cu t-o ff 
levels for diagnosis by GHb measurement, as the group is no longer normally 
distributed and contains few individuals w ith low GHb levels.
Santiago et al. (1978) and Koenig et al. (1976) found that the measurement o f 
H b A ^  was not su ffic iently sensitive for the screening of diabetes. Kesson et al. 
(1982) stressed the methodologic problems common to these groups of workers who 
had a ll used the ion-exchange technique. Verillo et al. (1983) classified patients 
using the WHO crite ria  and found considerable overlap in the HbA, measurements 
between the groups, as was also found in this study. Hall et al. (1984) however, 
showed good discrimination between the glucose tolerance groups and suggested
that the use of the a ffin ity  chromatography technique had overcome these 
d ifficu lties  and enabled clear distinction to be made between normal, IGT and 
diabetic responses to the OGTT. They also favoured the a ffin ity  method because i t  
avoided known interferences and had a lower c.v. than other techniques.
This study, however, indicates that using the a ffin ity  method does not 
su ffic iently  improve the diagnostic ab ility  of the measurement of GHb. The 
subjects investigated by Hall et al. had been referred for an OGTT, and so were not 
a normal sample of the population. This study comprised a much larger number of 
subjects and considerable overlap was found both in the screening and recall 
phases. This resulted in a wide range of GHb values in the normal tolerance group, 
which reflects the inter-individual differences in GHb levels between subjects w ith 
a normal response to the OGTT. The confirmation of this variation, also found by 
Verillo et al. (1983), has implications for the use o f GHb as a diagnostic tool and 
requires further study. The relationship between the screening phase and recall 
phase 2-hour GHb levels is significant (see Table 4:6) but Figure 4:6 illustrates the 
variation between the two measurements. Although a significant correlation was 
found between the screening 2-hour sample and both fasting and 2-hour recall 
samples (p<0.003 and p<0.002 respectively) the correlation coefficients were 0.41 
and 0.43 respectively, where values closer to 1.0 would have been expected due to 
the stab ility  o f GHb levels.
More recent investigation of 535 consecutive patients having an OGTT by 
A lbu tt et al. (1985) found GHb did not d iffe rentia te  clearly between glucose 
tolerance groups, and concluded that fasting blood glucose concentration, 
supplemented with information of the GHb level, might be suffic ient in most 
individuals. There would s till remain some subjects for whom the complete OGTT 
would remain necessary.
Both OGTT and GHb results must be interpreted w ith caution, especially in 
the areas where diagnosis is least clear. I t  is apparent that GHb measurement 
cannot make the OGTT redundant. Therefore GHb only has a role in the diagnosis 
of diabetes i f  i t  can be used by itse lf or w ith a screening sample (fasting or 2-hour 
blood glucose) to indicate those who are clearly normal or diabetic, and to help 
select a re la tive ly small group for the fu ll OGTT. I f  the cu t-o ff point was set, say, 
at 8.0% GHb, on a fasted or random sample, over 90% of diabetic subjects would be 
found, a fte r confirmation by the OGTT.
The sensitivity, specific ity and predictive value curves indicate that fasting 
and 2-hour GHb measurements yield sim ilar results, w ith acceptable levels o f 
specific ity  but poor predictive value. Fasting BG however, at a cu t-o ff level of 
6.7mmol/l showed excellent specific ity o f 99.1% and very good predictive value of 
83.3%, w ith lower sensitivity o f 39.4%. In other words, fasting BG measurements 
miss a number o f diabetic subjects, but pick out few false positives. GHb, 
conversely, picks out more of the diabetic subjects, but many false positive 
diagnoses are made as a result of the wide range of values encountered in the 
normal glucose tolerance group.
Thus a combination o f fasting BG and GHb measurements m ight make a 
useful prelim inary screen, to enable a high proportion of diabetic subjects to be 
identified, who could then undergo the fu ll OGTT. Forrest et al. (in press, c) 
concluded that GHb measurement did not add any extra predictive ab ility  to the 
two hour BG as a diagnostic test. However, as a population screening device i t  
may be useful to reduce the number of OGTT's required for diagnosis. Fasting BG, 
fasting and 2-hour GHb levels all gave sim ilar specificities at a fixed sensitiv ity of 
90% and a ll gave a very low predictive value (Table 4:9), confirm ing that none o f 
these measurements has any advantage over the others.
In conclusion, although GHb values have been demonstrated to correlate well 
w ith the results of an OGTT both blood glucose levels and AUC, the measurement 
o f GHb alone cannot replace the OGTT. However, used in conjunction w ith a single 
blood glucose level, i t  would be useful as a pre-screening assessment, to reduce the 
number of OGTT's required in a population.
CHAPTER 5 
GENERAL DISCUSSION
5:1 Introduction
This thesis describes, in Chapter 2, the development o f a sensitive 
immunoassay system for the measurement o f G ly-Alb. The technique fina lly  used 
was an adaption of a sandwich ELISA method, preceded by sample separation using 
the a ffin ity  chromatography method for glycosylated proteins. The method was 
used to measure albumin in the urine and Gly-Alb in the plasma and urine of 
diabetic and non-diabetic subjects.
The other major piece o f work was carried out as part o f the Islington 
Diabetes Survey. The work arose because o f a poster presented to the British 
Diabetic Association in 1983, which indicated that use o f the a ffin ity  
chromatography method to separate and quantify GHb appeared to have several 
advantages as a technique fo r screening fo r diabetes. The work described in 
Chapter 4 was done on a lim ited number o f individuals at the in itia l screen and on 
almost a ll the individuals at follow-up.
In this fina l Chapter, the usefulness of the assays for glycosylated proteins 
w ill be considered, together w ith the ir c lin ica l relevance and the role o f 
glycosylated proteins in the development o f diabetic complications.
5:2 Glycosylated Haemoglobin Measurements
As a Screening Test for Diabetes
The QGTT is the standard diagnostic test fo r diabetes, but the interpretation 
of results has been complicated in the past by lack of standardisation of the 
methodology or of the levels o f blood glucose which define normal and abnormal 
glucose tolerance. These complications have been largely removed by 
standardisation of the test and diagnostic c rite ria  (National Diabetes Data group 
1979; WHO 1980; WHO 1985), but the OGTT remains a time-consuming test to  
carry out. This is of particular relevance in large-scale screening studies where 
large numbers of tests are required. Various short-cuts to the OGTT have been 
considered (Modan et al. 1984) but no satisfactory replacement has yet been found. 
GHb measurement has been suggested as a diagnostic technique; the idea tha t a 
simple blood test using a single sample obtained at any tim e o f day could replace a 
time-consuming and unpleasant procedure, requiring dietary preparation and 
multiple blood samples, is a ttractive . However, in itia l speculation that 
measurement o f GHb could be employed as a more sensitive or specific diagnostic 
test than the OGTT has not been entirely corroborated in c lin ica l studies (Dunn et 
al. 1979; Flock et al. 1979; Dods and Bolmey 1979). The GHb level, however, 
correlates highly significantly w ith the blood glucose concentrations observed 
during the OGTT and with the area under the glucose tolerance curve in diabetic 
patients (Koenig e ta l.  1976).
The Islington Diabetes Survey was designed with the aim of assessing the 
sensitivity, specific ity and positive predictive value for three d iffe ren t GHb assays 
and 2-hour blood glucose levels as screening and diagnostic tests fo r diabetes 
(Forrest et al. In press a). Isoelectric focusing, eiectroendosmosis (w ith and
w ithout the labile fraction) and a ffin ity  chromatography were compared as a 
screening test, and the a ffin ity  chromatography showed the best specific ity and 
predictive value at a fixed sensitivity o f a ll the methods, whether the fasting or 2- 
hour post-load samples were used (Forrest et al. In press a). In the screening phase 
of the study electroendosmosis was carried out w ithout prior removal o f the labile 
fraction, and the results from this phase suggested that GHb measurements did not 
improve the predictive ab ility  of a 2-hour post-load blood glucose concentration 
(Forrest et al. In press c). However, during the recall phase, the results from the 
OGTT showed clearly that the 75g glucose load significantly increased the to ta l 
GHb level when measured by electroendosmosis w ithout prior removal o f the labile 
fraction. The isoelectric focusing and a ffin ity  methods showed no difference 
resulting from the oral glucose load (Forrest et al. In press b).
Other studies have assessed the use o f the GHb assay as a screening (Ferrel 
et al. 1984; Modan et al. 1984; Verillo et al. 1983) or diagnostic test (A lbu tt et al. 
1985; Lester et al. 1985) for diabetes. The GHb assay was shown in these studies to 
have poorer test characteristics than either fasting or 2-hour blood glucose 
concentrations. However, all o f these studies used assay methods that included the 
labile fraction, and the results from the Islington study have since shown tha t GHb 
assay methods that measure only the stable fraction are more accurate as 
screening tests for diabetes (Forrest et al. In press a).
The comparison of isoelectric focusing, electroendosmosis (stable fraction  
only) and a ffin ity  chromatography GHb assay as screening tests suggested tha t the 
a ffin ity  chromatography assay was superior to the others (Forrest et al. In press 
a), which confirms the original reason for including this method in the study (Hall 
et al. 1984). Although the method does not show complete separation o f the
glucose tolerance classes, i t  yields good test characteristics and may provide an 
acceptable screening test fo r diabetes. The use of the GHb assay to screen a 
population for the prevalence of diabetes would enable large numbers of subjects to 
be assessed quickly and then an OGTT could subsequently be carried out on a 
smaller number of subjects fo r accurate diagnosis i f  required. The a ffin ity  
chromatography assay for GHb is quick, cheap and easy to perform. Sample 
preparation to remove the labile fraction is not required, nor is rigorous 
temperature control (Klenk et al. 1982) nor control o f the haemoglobin 
concentration. Haemoglobin variants, such as HbF and HbS interfere w ith the 
results o f the ion exchange chromatography method (Bunn 1981b) but do not a ffec t 
the a ffin ity  technique (Yue et al. 1982b). These factors combined make the 
a ffin ity  chromatography method a potentially useful tool fo r screening fo r 
diabetes.
5:3 An Immunoassay for Glycosylated Albumin
The assay system that was developed was suffic iently sensitive to measure 
the very low levels of albumin and even lower levels of Gly-Alb found in the urine 
of non-diabetic individuals.
The original assay systems that were attempted using APBA to replace a 
specific antibody fo r G ly-Alb would have resulted in a simple, specific and 
convenient assay. I t  would also have been possible to use the assay to measure any 
glycosylated protein, w ithout the normal additional step in immunoassay systems of 
having to raise specific antibodies to the glycosylated portion of each protein to be 
measured. Unfortunately the a ffin ity  ligand was unsuitable for use in a solid- 
phase assay. In itia lly  APBA was attached to the walls of the wells using poly-L- 
lysine as a spacer molecule, so that the boronate moiety of the APBA molecule 
would be kept at a distance from the wall and available for binding by the cis-diol 
groups o f the G ly-Alb molecule. The well coating stage was probably successful as 
poly-L-lysine is frequently used in such circumstances, but fo r a number o f possible 
reasons the Gly-Alb did not remain bound to the APBA for the rest o f the assay 
procedure.
The other assay systems that were tested used anti-albumin IgG to coat the 
solid phase, w ith APBA conjugated to either horseradish peroxidase or alkaline 
phosphatase as the enzyme label. In the final successful system that was used 
e ffective ly, the only difference was the replacement o f APBA w ith anti-albumin 
IgG, which suggests that i t  was inadequate binding of APBA to G ly-A lb which 
prevented the assay system from functioning. The a ffin ity  o f APBA for 
glycosylated molecules is unknown, but i t  is like ly to be much lower than the very
strong a ffin ity  o f a specific antibody for its antigen. The APBA/Gly-Alb bond was 
probably broken in the subsequent washing steps of the assay which were essential 
in an attempt to lower the background binding. The later steps of the assay also 
had to be carrtM out in an environment (i.e., phosphate buffered saline at pH 7.4) 
which was required for the subsequent processes of the assay, but was unsuitable 
fo r the binding of APBA and Gly-Alb to take place (i.e., ammonium acetate buffer 
at pH 8.5).
The systems which used an APBA enzyme labelled conjugate should have been 
more like ly to be successful, as the solid phase was coated w ith anti-albumin IgG as 
is frequently used in ELISA methods (Voller et al 1979). In addition, there was only 
one washing step following the incubation of enzyme-labelled APBA w ith  the 
coated, sample-containing wells. I t  is possible, therefore, that stearic hindrance 
prevented the APBA moiety from binding w ith the Gly-Alb molecules. The enzyme 
molecule may have obstructed the boronate from  becoming attached to the Gly- 
Alb.
A combination of these potential d ifficu lties  may have prevented the adapted 
ELISA system from working e ffective ly. This was unfortunate as a lo t o f tim e and 
e ffo rt was put into trying to develop a system using APBA that would work. A 
system utilising the specific ity of APBA for the  cis-diol groups o f glycosylated 
proteins would have been simple, cheap, specific and versatile. I t  would have been 
possible to measure samples w ithout prior separation using a ffin ity  
chromatography, and so would have been more convenient than the assay system 
that was developed fina lly.
An assay method in which phenyl boronic acid was used has since been 
reported (Hayashi & Makino 1985). They made use of the spectral change 
undergone by dansylated phenyl boronic acid (N-(5-dimethyl amino-l-naphthalene 
suiphonyl)-3-aminobenzene boronic acid) which i t  reacted w ith human serum 
albumin. However, as only a one in four d ilution of serum was used in the assay, i t  
would not have had suffic ient sensitivity to measure G ly-Alb in the urine of 
diabetics or non-diabetics.
As the APBA ligand could not be used to replace a specific antibody in an 
adapted ELISA system, i t  was decided to develop an ELISA for albumin. The 
a ffin ity  chromatography method was used to separate Gly-Alb from non-Gly-Alb 
prior to measurement o f the albumin concentration o f each fraction  and 
calculation of the percentage glycosylated.
The complete method could be carried out in under 24 hours and up to 16 
urine samples could be measured at one time, which entailed measuring in 
trip lica te , two dilutions of unseparated urine, and dilutions of both the G ly-A lb and 
non-Gly-Alb fractions from the a ffin ity  separation. Each urine sample generated 
four albumin measurements, requiring twelve wells in a m icroplate. The plasma 
samples only had G ly-Alb measured by this method, as i t  was too sensitive, and 
required too high dilution factors fo r the accurate measurement o f plasma albumin.
The assay was used to measure urinary albumin, and G ly-Alb in the plasma 
and urine of all the diabetic and non-diabetic subjects who took part in the study.
5:4 The Role of Protein Glycosylation in the
Development of Diabetic Complications
Most proteins, some in tim ately involved in the complications of diabetes, 
may undergo non-enzymatic glycosylation (Kennedy & Baynes 1984). Correlative 
analyses of the extent o f glycosylation of tissue proteins are scant. This is 
unfortunate because such data would help to address the issue o f increased 
glycosylation as a contributing facto r to c lin ica l disease. A strong case exists fo r 
glycosylation as a potential source o f collagen abnormalities in diabetes, based on 
observation of non-enzymatic browning and fluorescence o f diabetic collagen 
investigated in autopsy samples (Monnier et al. 1984). Excessive non-enzymatic 
glycosylation has also been demonstrated in lens crystallins in vivo (Cerami at al. 
1979); and in in v itro  studies in peripheral and central nervous system myelin 
(Vlassara et al. 1983) and more recently, in ribonuclease A (Watkins et al. 1985) and 
DNA (Bucala et al. 1984) but the mechanisms by which these changes m ight cause 
the sequelae of diabetes have yet to be fu lly  elucidated.
The products of non-enzymatic glycosylation have been found in several 
human tissues at autopsy, including tendon, artery, nerve and glomerular basement 
membrane (Vogt et al. 1982). More recently, advanced glycosylation end-products 
(AGE) have been found in human globin and albumin (Chang et al. 1985) and the 
structure of one of the AGEs has been fu lly  described (Pongor et al. 1984). 
Exposure to raised glucose levels alters the chemistry of glomerular and other 
basement membranes. Accumulation of basement membranes, including that o f 
the glomerulus, characterises several o f the microangiopathic sequelae of diabetes, 
and is associated with increased permeability (Cohen et al. 1981). The 
glycosylation of s-amino groups on lysine and hydroxylysine residues decreases the
availability  o f these amino groups for normal collagen cross-linking. Le Pape et al. 
(1981) showed that the amount o f ketoamine-linked hexoses present, indicating an 
increased level o f glycosylation was closely related to a lowered amount o f 
collagen cross-links in the glomerular basement membrane. The AGEs form 
intramolecular cross-links and collagen w ith elevated AGEs which can be found as 
a normal consequence of ageing, has reduced solubility, which may lead to a rte ria l 
stiffening, decreased jo in t m obility and microvascular complications (Monnier et 
al. 1984).
Brownlee et al. (1984) showed that glucose-derived cross-links form  when 
reactive groups, formed as a result o f glycosylation of long-lived structura l 
proteins, trap non-glycosylated soluble proteins in the blood. These serum proteins 
(albumin and IgG) have been shown to be trapped by glycosylated collagen in the 
glomerular basement membrane, and the ir accumulation may lead to the thickening 
of the membrane. Cohen et al. (1981) suggested that the increased level o f 
glycosylation o f the glomerular basement membrane could a lte r the 
electrochemical properties o f the membrane. These changes may compromise the 
molecular or e lectrica l in tegrity  o f the filtra tio n  barrier, leading to increased 
microvascular permeability.
The exact mechanism by which the thickening of the glomerular basement 
membrane leads to elevated urinary albumin levels and preferentia l excretion o f 
Gly-Alb has not yet been explained. One theory suggests that there is an a lteration 
in charge selectiv ity of the glomerular basement membrane (Gragnoli et al. 1984). 
Their studies, however, measured Gly-Alb using a method which separated the 
albumin molecules on a charge basis, selecting the more negatively charged 
molecules, and then the carbohydrate content o f the selected fraction  was 
measured. The results of Gragnoli and co-workers and of Candiano et al. (1984) 
threfore, only takes account of the most negatively charged albumin species, 
rather than selectively separating those molecules w ith a glucose adduct.
The results o f this study show that there is an association between increased 
glycosylation of haemoglobin and presence of retinopathy and microalbuminuria. 
The increase in G ly-Alb excretion in the diabetic subjects w ith raised albumin 
excretion suggests an enhanced passage o f G ly-Alb across the glomerular filtra tio n  
barrier. The relationship between the Gly-Alb clearance values, (which are a ra tio  
of urinary to plasma levels of G ly-Alb corrected for urine volume and sample 
time), and AER, confirms the preferential excretion o f G ly-Alb at raised AER.
A reduction o f the charge se lectiv ity of the glomerular basement membrane 
would not necessarily result in an enhanced filtra tio n  of more negative molecules. 
A more like ly reason for the preferential excretion of G ly-Alb was suggested by 
Williams et al. (1981). They demonstrated that there was a preferentia l uptake of 
G ly-Alb over native albumin by endothelial m icropinocytic vesicles. Their results 
suggested that glycosylation of albumin resulted in extravasation of the molecules. 
This would explain the enhanced passage of G ly-Alb across the filtra tio n  barrier of 
the glomerulus. A lterations in the physical and e lectrica l properties o f the 
membrane may result in the overall increase in albumin excretion that occurs, 
while another mechanism, possibly a simple recognition system fo r glycosylated 
proteins causes the enhanced movement o f G ly-Alb across the glomerular basement 
membrane.
A recent report from Brownlee et al. (1986) has contributed fu rther evidence 
that AGEs are associated w ith glucose-derived cross-link formation which results 
in membrane thickening. Cross-linking of long-lived proteins such as collagen 
increases w ith age and is accelerated in diabetes (Cerami ' 1986). The AGEs 
accumulate on long-lived proteins. In collagen from diabetic subjects which has 
been exposed to elevated glucose concentrations over a long period of tim e, the
age-associated accumulation is accelerated (Monnier et al. 1984). Brownlee and 
co-workers suggested that glucose-derived protein cross-link formation could be 
prevented by pharmacologically blocking the reactive carbonyl groups on the early 
glycosylation products. They were able to show that AGE accumulation and 
glucose-derived cross-link formation could be prevented by aminoguanidine, a 
nucleophilic compound, in animal studies. The scheme for the formation o f AGEs 
and the intervention of aminoguanidine can be seen in Figure 5:1.
The contribution o f AGEs and the concomitant trapping o f serum proteins to 
the dysfunction of the glomerular basement membrane has yet to be clearly 
demonstrated in human subjects, but the evidence in animal studies is increasing. 
The theory of Gragnoli et al. (1984) that the preferential excretion of G ly-A lb is 
due to a loss of the negative charge of the glomerular filtra tio n  barrier alone, 
seems unlikely. This reduction of e lectrica l charge may be one of a number of 
factors contributing to the increased albumin excretion, but the trapping of non­
glycosylated albumin by AGEs on the membrane, enhanced vesicle uptake of Gly- 
Alb or other as yet unknown processes, may contribute to the preferentia l loss of 
the glycosylated molecule over the native one.
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5:5 Future Research
The association between glycosylation of proteins and the development of 
nephropathy s till requires much further investigation. The source of the slightly 
elevated urinary albumin in the group w ith microalbuminuria was shown to be 
glomerular and not tubular, by the measurement o f a^-microglobulin in this study 
(Nogawa et al. 1984).
Previous workers have used the presence o f raised urinary levels of 82- 
microglobulin to d iffe rentia te  between glomerular and tubular damage (V iberti et 
al. 1979; Viberti et al. 1982) but Yue et al. (1983) have shown that a^-m icroglobulin 
is more stable at low pH than 82‘ micro9l°bu lin, and should therefore be a more 
reliable index. This is the firs t study of microalbuminuria in diabetes which 
incorporates measurement o f a^-microglobulin and the results showing a 5-fo ld  
increase in a^-m icroglobulin excretion in the patients w ith the highest AER 
confirm that the highly elevated urinary albumin levels are indicative of tubular 
damage in addition to glomerular damage. Further investigation o f a^- 
microglobulin excretion w ith relation to albumin and G ly-Alb excretion over a 
period of time would be valuable.
This study, due to the very lim ited time that was available, had of necessity 
to be a cross-sectional one. A follow-up investigation o f ail the subjects would 
have yielded much useful information on the development o f early nephropathy. 
There is great variab ility  in individual AER and so further urine collections would 
have confirmed the classification of subjects according to the ir AER (Rowe et al.
1985). Causal relationships can only be suggested from a cross-sectional study; a 
prospective study, following the diabetic and control subjects over a number of 
years, would be needed to demonstrate conclusively the role o f glycosylation in the 
development of nephropathy.
Breakdown products o f the Amadori adduct, carboxymethyllysine and 
erythronic acid, have recently been reported (Ahmed et al. 1986), and the 
measurement o f these would be a useful marker for assessing the cumulative 
exposure of tissue proteins to glucose. Comparison of the excretion o f these 
markers w ith GHb and Gly-Alb levels over a period of time would give additional 
information on glycaemic control. Measurement o f AGEs would also help to 
complete this information.
This study was a random screen of a diabetic clin ic as patient selection was 
not possible in the time available. There was no computerised system fo r obtaining 
patient details, which meant that, due to the short time available, no selection of 
patients could be attempted. In a follow-up study i t  would be useful to have a 
more even distribution of patients w ith d iffe rent AERs. The small number of 
subjects w ith raised AER coupled w ith large inter-individual differences, meant 
that s ta tis tica l analysis of the data was often inconclusive, despite clear 
differences in mean values for the groups.
Therefore, larger numbers of subjects in each AER category and age range, 
studied over a period o f time w ith additional parameters measured would yield 
more information on the pathogenesis of diabetic complications. Blood pressure 
data, fo r instance, was available for so few subjects that i t  could not be included in 
the study. More detailed information on the degree of retinopathy and its 
development would also be desirable.
The role of macrophage uptake of AGEs as a possible mechanism for the 
removal of senescent molecules in normal ageing and the accelerated ageing of 
diabetes is also an area requiring further study (Vlassara et al. 1985b). AGEs may 
be involved in the development of glomerular basement membrane thickening in a 
number of ways, but the mechanisms are far from being fu lly  understood.
Non-enzymatic glycosylation of proteins not only results in accelerated 
glucose-derived cross-link formation, but also interferes w ith the normal function 
of proteins by blocking the lysine and hydroxylysine groups (Cerami et al. 1986). 
This aspect o f non-enzymatic glycosylation also requires further investigation.
This study helped to confirm an association between protein glycosylation and 
microalbuminuria. I t  also indicated that a^-rnicroglobulin m ight be a suitable 
index of glomerular/tubular function, and despite the short time available, provided 
some information on the prevalence o f retinopathy and microalbuminuria in an out­
patient diabetic c lin ic population.
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Appendix 1
SOUTH WEST SURREY HEALTH AUTHORITY
Please reply to: ST. LUKE'S HOSPITAL 
WARREN ROAD
GUILDFORD, SURREY GU1 3NT
Person dealing 
with correspondence:
Telephone:
Guildford 571122 Ext.
D e a r
I  a m  w r i t i n g  t o  y o u  t o  a s k  f o r  y o u r  h e l p  w i t h  o u r  
r e s e a r c h  i n v o l v i n g  u s i n g  s o m e  n e w  m e t h o d s  w h i c h  w i l l  g i v e  
u s ,
( 1 )  a n  i n d i c a t i o n  o f  r e c e n t  c o n t r o l  o f  d i a b e t e s
a n d  ( 2 )  a n  a d d i t i o n a l  t e s t  f o r  c h a n g e s  i n  t h e  u r i n e  
w h i c h  c a n  o c c a s i o n a l l y  b e  a s s o c i a t e d  w i t h  a  
l e a k a g e  o f  p r o t e i n  f r o m  t h e  k i d n e y .
F o r  t h i s  w o r k  t w o  s a m p l e s  a r e  r e q u i r e d /  t h e  f i r s t ,  
a  t i m e d  u r i n e  s p e c i m e n  a n d  t h e  s e c o n d ,  a  b l o o d  s a m p l e .
I f  y o u  a g r e e  t o  h e l p ,  p l e a s e  r e t u r n  t h e  e n c l o s e d  f o r m  
t o g e t h e r  w i t h  a  t e l e p h o n e  n u m b e r  w h e r e  y o u  c a n  b e  c o n t a c t e d  
d u r i n g  t h e  d a y  o r  e v e n i n g .
O n e  o f  t h e  r e s e a r c h e r s ,  M i s s  J u l i e  T a y l o r  w i l l  t h e n  
c o n t a c t  y o u  t o  a r r a n g e  f o r  t h e  u r i n e  c o l l e c t i o n .  W e  w o u l d  
s u g g e s t  t h a t  y o u  c o l l e c t  t h e  u r i n e  s a m p l e  d u r i n g  t h e  n i g h t  
p r i o r  t o  y o u r  n e x t  a p p o i n t m e n t  w h i c h  i s  o n
a n d  b r i n g  i t  w i t h  y o u  t o  t h e  c l i n i c .  A  5 m l  b l o o d  s a m p l e  w i l l  
a l s o  b e  t a k e n  a t  t h e  c l i n i c  a l o n g  w i t h  t h e  n o r m a l  B l o o d  
s u g a r .
W e  e n c l o s e  a n  e n v e l o p e  f o r  y o u r  r e p l y  w h i c h  d o e s  N O T  
r e q u i r e  a  s t a m p  a n d  i s  a l r e a d y  a d d r e s s e d .
SL10
D r  M  J  S m i t h  
D i a b e t i c  C l i n i c
Appendix 2
UNIVERSITY OF SURREY
Guildford Surrey GU2 5X H  Telcphone(0483) 571281 Telex859331
Department o f Biochemistry
Head o f Departm ent
and Professor o f  Biochemistry: Dr. D .V . Parke 
Professor o f C linical Biochemistry; Dr. V. Marks  
Professor o f H u m an  Nutrition: Dr. J .W .T . Dickerson 
Professor o f Toxicology; D r.J .W . Bridges 
Professor o f Pathology;
Dear
Thank you for agreeing to take part in the diabetic urine study. For
this study we would like an overnight urine sample to be collected in
the bottle provided.
Please perform this test the night before your next clinic visit(that 
is ).
On that evening we would like you
1) NOT to do any strenuous exercise
2) NOT to drink alcohol.
Collection of timed urine specimen.
i) Before going to bed, please empty your bladder down the toilet 
as normal AND NOTE THE TIME on the label on the bottle.
ii) Please collect ALL of the first urine passed the following 
morning (that is ) in the bottle provided and again
NOTE THE TIME on the label.
iii) Please bring the sample with you to the clinic on 
where a 5ml blood sample will also be taken.
If you have any further queries please do not hesitate to contact me 
on Guildford 571281 Extn. 857.
Thanking you for your cooperation.
Yours sincerely
Miss Julie Taylor
Appendix 3
Diabetic Subjects : Divided by Duration of Diabetes
Male n 
Female n
0-10 yrs 
26 
20
11-20 yrs 
5
15
>20 yrs
4
5
AER (pg/min) 
Plasma Giy-Alb (%) 
GHb (%)
Urinary Gly-Alb (%)
Urinary a l- 
microglobulin (mg/1)
Urinary to ta l 
protein (g/1)
Plasma glucose 
(mmol/1)
4.71 (6.26) 
7.40 (3.53) 
11.97 (3.4)
8.93 (7.87) 
5.56 (8.28)
84.67 (62.83)
14.64 (7.05)
Urinary glucose (mmol) 9.21(7.78) 
Body weight (kg) 72.88 (16.23)
Age (years) 40.6 (14.6)
% ID DM 52%
9.45 (12.75)
8.00 (2.05)
15.01 (3.13) 
10.95 (7.51) 
5.28 (3.25)
103.33 (78.67)
15.85 (6.05)
11.03 (8.40)
67.02 (13.61) 
43.8 (14.3) 
85%
14.5 (23.46)
7.52 (2.42) 
13.92 (3.32)
10.33 (6.79)
2.85 (0.88)
67.78 (29.91)
14.85 (8.34)
9.36 (8.28)
69.78 (8.44)
45.1 (8.1) 
100%
All values shown are means with SD in parentheses
Appendix 4
Diabetic Subjects Grouped by Type of Diabetes
Duration Matched 
IDDM IDDM
Duration 1-13 yrs 
56 31
AER(pg/min)
Plasma Gly-Alb(%) 
GHb (%)
Urinary G ly-Alb (%)
Urinary a l-m icro- 
globulin (mg/1)
Urinary Total Protein 
(g/D
Plasma glucose 
(mmol/1)
Urinary Glucose 
(mmol/1)
Duration of Diabetes 
(years)
Body Weight (Kg)
Age (years)
126 (422) 
7.91 (2.85) 
13.54(3.2)
10.85 (8.41)
7.04 (9.74)
154 (2.9)
16.01 (7.06)
10.79 (7.77)
13.6 (10.5)
66.0 (10.2) 
38 (14)
62 (308)
7.93 (3.24) 
12.89 (3.56)
10.02 (9.42)
7.3 (10.01)
137 (173) 
16.88 (7.04) 
12.14 (7.57)
6.4 (4.0)
65.3 (11.0) 
35(15)
All values shown are means with SD in parentheses
NIDDM
26
13.6 (47.9)
7.02 (3.34)
12.05 (3.86)
8.52 (5.42) 
3.82 (1.88)
77.6 (43.7)
12.36 (5.47)
7.13 (7.65)
4.1 (4.3)
81.0 (17.5) 
51 (8.5)
Appendix 5
All The Parameters for the IDDM Subjects Only Grouped by AER
0-10 Group A 11-100 Group B >100 Group C
pg/min pg/min pg/min
n 38 12 6
AER (pg/min) 2.86(2.2) 26.81(19.1) 1107.38 (813.2)
Plasma Gly-Alb (%) 7.9 (3.2) 7.7 (1.4) 8.4 (2.8)
GHb (%) 12.7 (3.1) 15.7 (2.7) 14.2 (2.2)
Urinary Gly-Alb (%) 9.5 (8.5) 12.4 (8.3) 16.2 (6.0)
Urinary a^-M (mg/1) 5.5 (8.6) 6.5 (6.5) 17.5(15.8)
Urinary to ta l protein (g/1) 76.4 (42.0) 154.2(119.2) (a) 616.6 (403.3)
Plasma glucose (mmol/1) 15.1 (7.0) 20.3 (6.3) 13.6(6.1)
Urinary glucose (mmol/1) 9.5 (7.8) 15.3 (6.4) 10.1(7.3)
Duration o f Diabetes (years) 11.7 (9.0) 15.7 (10.8) 21.0(15.8)
Body weight (Kg) 66.1(10.3) 65.4(9.9) 66.8 (11.9)
Age (years) 37.9 (14.1) 37.4 (14.7) 39.5 (11.7)
a significant difference between Group I and Group III
All values shown are means with SD in parentheses
